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A key feature of heart failure with reduced ejection fraction (HFrEF) is exercise 
intolerance. Correcting chronotropic incompetence using conventional age-guided 
rate-response pacemaker programming is not associated with improvements in 
exercise capacity in HFrEF. The force-frequency relationship (FFR), (increased left 
ventricular (LV) contractility as heart rate rises), is abnormal in HFrEF, and could 
explain this.  
 
This thesis comprises a series of studies with the objectives of: describing the 
reproducibility of a non-invasive, echocardiographic measure of the FFR, exploring 
whether personalised programming of the rate-response algorithm using FFR data 
acutely affects treadmill walk time, and determining whether personalised 
programming of the rate-response algorithm using FFR data is associated with longer 
term benefits. 
 
An observational study demonstrated that a reproducible, non-invasive assessment of 
the FFR, using echocardiography, is possible in patients with HFrEF and a pacemaker. 
I was able to show that critical heart rate, peak contractility, and the slope of the FFR 
were lower in patients with HFrEF compared to non-HFrEF controls. 
 
In an interventional, double-blind, randomised, cross-over trial, I compared the effects 
of tailored pacemaker rate-response programming based on the FFR data with 
ix 
 
conventional age-guided rate-response programming, on treadmill exercise time and 
oxygen consumption. This resulted in a greater improvement in exercise time and 
higher peak oxygen consumption with tailored rate-response programming. 
 
A further interventional double-blind, randomised controlled, parallel-group study 
demonstrated that six months of rate-response programming based on the FFR data, 
was associated with improved exercise time, and that conventional age-guided rate-
response programming might contribute to deteriorating left ventricular function. 
 
Based on these novel findings, I can conclude that the FFR is abnormal in HFrEF. 
Optimising pacemaker settings based on the individual’s FFR data is associated with 







‘The interval between a contraction of the heart and the preceding beat is of such 
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Figure 1.1: Nebiri 
 
Nebiri, an Egyptian dignitary, lived 3,500 years ago, under the reign of Thutmoses III 
(1479-1424 Before the Common Era (BCE); 18th Dynasty). In 1904 his tomb was 
discovered by Egyptologist Ernesto Schiaparelli (1856-1928), containing only the 
preserved head (Figure 1.1) and the four canopic jars holding the internal organs (lung, 
stomach, liver and intestines). The internal organs were removed from the body before 
mummification and embalmed separately. There was no jar for the heart because it 
was thought to be the centre of human intelligence and needed for judgement in the 
underworld; the heart was therefore left in the body. The jar inscribed for Hapi, the 
‘guardian of the lungs’ was found to be broken, and this allowed direct access to organ 




Figure 1.2: Canopic jar  
 
This first chapter will illustrate the history behind the development of the diagnostic 
knowledge and skills gained during the previous 2,000 years, that allowed Bianucci et 
al. to conclude in 2015, that Nebiri presented as the earliest reported case of chronic 
heart failure (CHF) in ancient mummies (Bianucci et al., 2016).  
 
1.1 Introduction 
Heart failure is the end stage of all diseases of the heart, and is a major cause of 
morbidity and mortality (Davis et al., 2000). It is a common clinical syndrome, typically 
characterised by symptoms such as breathlessness, fatigue and ankle swelling. These 
symptoms may be generated by a structural and/or functional cardiac abnormality, 
resulting in a reduced cardiac output and/or elevated intracardiac pressures at rest or 
during stress (Ponikowski et al., 2016).  
 
1.2 History of heart failure  
1.2.1 Greek medicine 
Prior to the advent of medicine as a science, it was religion that informed every aspect 
of medical culture, with remedies being provided by medical sorcerers and healers. 
Asclepius, son of Apollo, is said to be the creator of medical practice in Ancient 
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Greece, and his sign of a staff entwined with a snake is still the globally recognised 





Figure 1.3: Logo of the British Medical Association 
 
 
For the Ancient Greeks, an understanding of how things worked was regarded as 
fundamental to the pursuit of scientific wisdom. Consequently, the sixth century BCE 
saw the Ancient Greeks moving away from the influence of religion on medical 
practice, towards a more rational and scientific outlook. As a result, Hippocrates (460-
375 BCE) (Figure 1.4), often considered the father of Western medicine (Sallam, 
2010), adopted an approach based on treating the patient as a whole, rather than 
dealing with specific illnesses.  
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Figure 1.4: Hippocrates 
 
Hippocrates was the first physician to systematically classify diseases based on the 
similarities and differences between them. Through his observations, Hippocrates 
concluded that the human body contained four ‘humours’ (blood, phlegm, black bile, 
and yellow bile), said to be bodily fluids essential to the physiological functioning of the 
body. An imbalance in the humours, or a shift in the pattern of flow within the body, 
resulted in disease (dis-ease). Since it was believed at the time that heat was 
distributed through the body by the blood, fevers were treated by drawing blood from 
the body, thus rebalancing the humours – hence the origin and justification for blood-
letting (Thomas, 2014). Interestingly, into the 1940s venesection was regarded as 
‘very helpful’ as a treatment in cases of heart failure with a clearly raised venous 
pressure (Bourne, 1949). However, current understanding is that 
bloodletting/venesection is ineffective, if not harmful, and is no longer used in modern 
medicine, except in the prevention or treatment of the effects of iron overload as in 
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hereditary haemochromatosis, or to decrease red blood cell excess as in 
polycythaemia vera (Jhang and Schwartz, 2012). 
  
Whilst detailed descriptions of what may have been heart failure appear in the 
Hippocratic Corpus, there was little, if any, understanding of the connection between 
the clinical findings and heart disease (Katz, A.M., 1997). The belief that the primary 
function of the heart was to distribute heat by pumping air, also made it difficult to 
establish a link between cardiac function and dyspnoea (Ferrari et al., 2016). Although 
ancient writings suggest diagnoses of heart failure, the symptoms of dyspnoea and 
fatigue were also common in other diseases and so were not diagnostic. Furthermore, 
to an extent this remains in modern times, since the symptoms of heart failure are non-
specific. However, without the ability at the time to relate clinical descriptions to 
anatomic pathology, it was not possible to attribute clinical findings to heart failure. 
Hence, prior to the 19th century, the role of the heart in causing an accumulation of 





Figure 1.5: Aristotle 
 
The Ancient Greeks had no preceding knowledge of the cardiovascular system (Aird, 
2011), and there was a significant gap between clinical observation and 
pathophysiologic understanding. Aristotle (384-322 BCE) (Figure 1.5) described the 
heart as the most important organ. He considered the heart to be the seat of 
intelligence and the centre of vitality in the body; the first organ to come to life and the 
last to die. Whilst Aristotle is believed to be the first to understand that the arteries and 
veins both begin at the heart, it was not possible to clarify this until anatomy became 
a recognised discipline during the Renaissance (Ghosh, 2015).  It was Leonardo da 
Vinci (1452-1519) who first produced accurate drawings of the heart (Figure 1.6); 
describing it as being ‘made of thick muscle, vivified and nourished by artery and vein 
as are other muscles’ (Aird, 2011).  
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Figure 1.6: Leonardo da Vinci - The heart and coronary vessels c.1511-13.  




Claudius Galen (129 – circa 210 Common Era (CE)) (Figure 1.7) considered that a 
physician should be well-rounded, and familiar with other arts and scientific disciplines, 
including music, rhetoric, geometry and astronomy (Thorndike, 1922). His most 
significant contribution was to synthesise the existing knowledge, building on 
established models of physiology and disease (Aird, 2011). He also believed in 
Aristotle’s teleology: that each part of the body was designed to perform a particular 
function (Strathern, 2005). The arterial pulse was used by Galen for prognostication, 
and whilst he identified the heart as being the source of arterial pulsations, he did not 





Figure 1.7: Galen Line engraving. Wellcome Collection 
 
Although as a surgeon to the gladiators Galen would have frequently seen inside 
bodies, the dissection of humans was illegal in Rome during this time. Therefore, he 
gained experience through performing animal dissections. However, applying his 
findings from animal dissections to descriptions of human anatomy occasionally led to 




Figure 1.8: Galen's Physiological System. Wellcome Collection 
 
According to the Ancient Greeks, the cardiovascular system comprised two distinct 
networks of arteries and veins. In this open-ended system, blood and air dissipated at 
the ends of the vessels, according to tissue demand (Figure 1.8). Whilst Galen 
demonstrated that arteries contain blood (rather than air as previously thought), he 
believed that the pulse was transmitted by the arterial walls rather than by the blood 
flowing through the lumen. Venous blood was thought to be produced in the liver from 
digested food, with its prime function being to nourish each part of the body through 
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the network of veins. Some of the venous blood reached the left ventricle, where it 
combined with the pneuma (spirits taken from the air in the lungs), to produce arterial 
blood. Arterial blood gave vitality to the body through the arterial system – which was 
independent of the venous system. Venous and arterial blood were ‘used up’ as it 
passed through the organs and tissue, and therefore had to be constantly replenished 
in the liver (venous blood) and the heart (arterial blood) (De Renzi, 2004). 
Nevertheless, the medical knowledge and ideas of Galen dominated medical thinking 
until the 17th century, when the physician William Harvey (1578-1657) began to 
challenge dogma and authority (Figure 1.9).   
 
 
Figure 1.9: William Harvey demonstrating his theory of circulation of the blood 





1.2.2 Renaissance  
Harvey focussed his investigations on the heart, which, like Aristotle previously, he 
considered to be the body’s chief organ. His experiments and deductive logic caused 
him to question three particular features of Galen’s work (De Renzi, 2004): 
 
• The theory that blood was ‘used up’ and had to be constantly replenished, 
 
• The idea that arterial blood was produced in the heart through the mixing of the 
pneuma from the lungs with venous blood, 
 
• The belief that when the heart dilates, the arteries also dilate and actively suck 
in and disperse the blood. 
 
Subsequently, in 1628, Harvey was able to demonstrate that arteries and veins are 
functionally, if not structurally, connected in the lung and the peripheral tissues, and 
that blood circulates around the body (Aird, 2011). He fully described the circular blood 
flow in the body from the heart to the extremities via arteries, and from the extremities 
back to the heart via the venous system (McMullen, 1995). But of course, this could 
not be verified until it could be shown that the veins and arteries were interconnected. 
At the time, the magnifying lenses that Harvey had access to were not sufficiently 
powerful to enable the capillaries to be seen (De Renzi, 2004).  
 
Holland and Italy were the principal countries involved in the construction and use of 
the microscope during the 16th and 17th centuries. Whilst there were many zoologists 
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and botanists who were using microscopy in the 17th century, there were few 
physicians. Marcello Malpighi (1628-1694) was the first person to see the anastomosis 
between venous and arterial capillaries (Hajdu, 2002), consequently providing visual 
evidence of the circulation of the blood. 
 
Harvey’s discovery of the circulation made it possible for the physicians of the time to 
use clinical and post-mortem data to explain the haemodynamic basis for the signs, 
symptoms, and consequences of heart failure. Subsequently, it became possible to 
recognise in patients who died with stenotic and regurgitant valves, that their dyspnoea 
and oedema were the clinical consequences of a failing cardiac pump. Valve 
abnormalities were commonly found in a large number of patients dying from heart 
failure at this time because, until the mid-20th century, rheumatic heart disease was 
the major cause of heart failure (Katz, A.M., 1998). Harvey’s circulatory physiology, 
facilitated the use of anatomic pathology to draw correlations with clinical findings, 
heightening the advancement of medical discovery throughout the 17th and 18th 
centuries (Katz, A.M., 1997). However, until around 300 years later, when cardiac 
surgery made it possible to correct the structural abnormalities in these patients, there 
was little practical value in managing patients with heart failure (Katz, 2008). 
 
1.2.3 18th and 19th centuries 
Physicians began to relate various architectural changes in diseased hearts to specific 
clinical syndromes towards the end of the 18th century. The 19th century then saw 
efforts being made to understand the prognostic implications of different patterns of 
cardiac enlargement (Katz, A. and Konstam, 2009). Generally viewed as the first to 
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distinguish between dilatation and hypertrophy, Italian physician and anatomic 
pathologist Lancisi (1654-1720), noted that valvular regurgitation leads to ventricular 
dilatation because the cavities are ‘easily distended by the force of the blood that is 
regurgitated’, and suggested that dilatation weakens the heart (Wright, W.C., 1952). It 
was further noted that hypertrophy increased the energy of the heart’s contraction, 
whilst dilatation of the heart weakened its ability to contract.  
 
The various forms of cardiac enlargement, termed eccentric and concentric 
hypertrophy, acute and chronic heart failure, were subsequently described and 
evaluated at the bedside by palpation, percussion, and auscultation, with eventual 
confirmation by post-mortem.  
 
Nicolas Corvisart (1755-1821), physician to Napoleon Bonaparte, recognised that the 
left ventricular dilatation seen in aortic and mitral regurgitation, represents a response 
to increased diastolic stress, whilst concentric hypertrophy, as seen with aortic 
stenosis, represents a response to increased systolic stress. Corvisart documented 
the signs and symptoms exhibited by patients with end-stage heart failure, observing 
that death, which ‘always intervenes to terminate the painful scene which this 
combination of symptoms presents’, may occur in two ways: progressive heart failure, 
which ‘advances slowly, [until] life is insensibly extinguished,’ and sudden death, which 





In addition to the 19th century view that valvular disease was a cause of cardiac 
enlargement, it was observed that cardiac hypertrophy was common in renal disease 
(Bright, 1836). With his introduction, at the end of the 19th century, of the 
sphygmomanometer to measure brachial artery pressure, Scipione Riva-Rocci  (1863-
1937) made it possible to define the pathophysiological correlations between arterial 
hypertension, pressure overload, left ventricular hypertrophy, and heart failure 
(Mancia, 1997). 
 
During the 19th century, attempts were made to establish the prognostic implications 
of different patterns of cardiac enlargement, and to determine whether hypertrophy 
was a compensatory and adaptive response to a haemodynamic overload, or whether 
the enlargement contributed to a clinical deterioration (Katz, A. and Konstam, 2009).  
 
Amongst others, Austin Flint (1812-1886) described what is currently known as 
‘remodelling’, with hypertrophy delaying the onset of dilatation:  
 
‘The increased growth for a certain period protects against the occurrence 
of dilatation. At length, the hypertrophy reaches a point beyond which it 
cannot advance; for the muscles of the heart, like other muscles, cannot 
increase indefinitely.’ 
(Flint, 1870) p33. 
 
Osler also importantly noted that the hypertrophic response to overload, although 
initially beneficial, becomes maladaptive because the enlarged muscle slowly 





Figure 1.10: Henry Pickering Bowditch 
 
In 1871, Henry Pickering Bowditch (1840-1911) (Figure 1.10) published the results of 
a series of animal experiments that he performed, looking at the conditions under 
which the excitation processes of the heart fatigue and recover (Bowditch, 1871). His 
work recognised that the force of contraction of cardiac muscle is dependent on the 
rate and rhythm of the heartbeat. The Bowditch effect showed cardiac contraction to 




1.2.4 20th century 
James Mackenzie (1853-1925) attributed heart failure to myocardial abnormalities. He 
believed that since ‘the heart muscle supplies the force which maintains the 
circulation’, clinical manifestations of heart failure were not produced by valve 
abnormalities. Heart failure was due to the ‘exhaustion of the reserve force of the heart 
muscle’ – the reserve force being the ability to increase output in response to an 
increase in the circulatory demands (Mackenzie, 1908). As a result of Mackenzie’s 
belief that heart failure was due largely to the exhaustion of overloaded, damaged, or 
energy-starved heart muscle, recommendations in textbooks, until the end of the 20th 
century, were for heart failure patients to be treated with rest. 
 
 
Figure 1.11: Ernest Henry Starling. Photograph. Wellcome Collection 
 
 
In 1915, Ernest Henry Starling’s (1866-1927) (Figure 1.11) law of the heart refocused 
explanations of heart failure from pathophysiology and the architecture of failing 
hearts, back to haemodynamics. In the late 19th century, physicians based their views 
about the effects of increased cavity size on the pathological evidence that dilatation 
is associated with poor prognosis. Yet Starling’s demonstration that increased end-
diastolic volume increased the force of contraction, seemed to contradict the previous 
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concepts that dilatation weakens the failing heart (Mackenzie, 1908). However, 
Starling had noted that increasing diastolic volumes increased the work of the heart 
‘within physiological limits’, concluding that dilatation is one of the principle means of 
adaptation to the needs of the organism (Cowan, 1922).  
 
Katz and Konstam (2009) suggest that Starling’s law of the heart is an acute functional 
response, on a beat-to-beat basis, which allows an increased end-diastolic volume to 
increase the work of the heart, whilst the more progressive and chronic dilatation, 
resulting from pathological hypertrophy, represents a long-term architectural response 
caused by abnormal transcriptional signalling. 
 
Prior to 1785, treatment for the symptoms of heart failure was limited to bleeding, 
purgatives, blistering, garlic, ‘medicinal’ intake of wine or good ale, and the removal of 




Figure 1.12: Withering, An account of the foxglove, 1785. Wellcome Collection 
 
William Withering (1741-1799), a physician and botanist, described in his publication 
(Figure 1.12), how the use of herbal tea made from foxglove (digitalis), was effective 
in the treatment of dropsy (an old term for the swelling of soft tissues due to the 
accumulation of excess water) (Figure 1.13). After studying the effects of the foxglove 
on his patients he noted that:  
  
‘…it has a power over the motion of the heart, to a degree yet unobserved 
in any other medicine, and that this power may be converted to salutary 
ends’ 
And ‘…if the pulse be feeble or intermitting, the countenance pale, the lips 
livid, the skin cold, the swollen belly soft and fluctuating, or the anasarcous 
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limbs readily pitting under the pressure of the finger, we may expect the 
diuretic effect to follow in a kindly manner’   
(Silverman, 1989). 
 
Figure 1.13: Patient with dropsy 
 
Although he recognised the therapeutic usefulness and the toxic effects of digitalis, 
Withering did not have the physiological knowledge to understand the mechanisms of 
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its action. It was John Ferriar (1761-1815) in 1799 who was the first to recognise that 
the primary site of action for digitalis was the heart; diuresis being a secondary effect 
(van Bronswijk and Cohen, 2008). Subsequently, in 1918 Arthur Cushny (1866-1926), 
a Scottish pharmacologist, improved knowledge regarding cardiac physiology and the 
causes of arrhythmias (Cushny, 1918). Cushny’s work using animal models also led 
to a better understanding of the clinical effects of digitalis. 
 
A degree of progress was made in the 19th and early 20th centuries with fluid retention 
being treated with Southey’s tubes, which were inserted into oedematous peripheries, 
to facilitate drainage of fluid (Figure 1.14). Indeed in 1949, Geoffrey Bourne (1893-
1970) stated that Southey’s tubes could be used to drain fluid ‘in quantity’ and with 
‘great benefit’ (Bourne, 1949)p.43. However, a significant impact was made on the 
treatment of heart failure when, in 1919, Alfred Vogl (1895-1973) discovered the 
dramatic diuretic effects produced by organic mercurials (Vogl, 1950). Whilst the 
effects of the parenterally administered organic mercurials were intense, they were 
also short-lived, with the inevitable fluctuations between copious diuresis and fluid 
retention, and were therefore of little benefit in end-stage heart failure (Vogl, 1960). 
This however, prompted research into the development of powerful diuretics that could 
be administered orally. Subsequently the 1950s and 1960s saw the discovery first of 





Figure 1.14: Southey's tubes (Davis et al., 2000) 
 
The end of the 19th century saw the introduction of the use of technology, along with 
history taking and physical examination in the diagnosis of heart disease. The 
discovery of X-rays in 1895 by Wilhelm Röntgen (1845-1923), and the development 
of the electrocardiogram (ECG) in the 1890s, provided objective information about the 
structure and function of the heart, allowing important improvements in the 
investigation of heart failure (Davis et al., 2000). Whilst the first ECG from the intact 
human heart was recorded in 1887 with a mercury capillary electrometer by Augustus 
Waller, at St Mary’s Hospital, London (Barold, 2003), it was Willem Einthoven (1860-
1927), Professor of Physiology at the University of Leiden, who was the first to 
recognise the importance that the ECG would have in the diagnosis of heart disease 
(Davies, M.K. and Hollman, 1997). Einthoven advanced Waller’s work by developing 
a string galvanometer with very high sensitivity, which he used in his 
electrocardiograph.  
 
The first ECG electrodes were cylinders of electrolyte solution in which the extremities 





Figure 1.15: Early Electrocardiograph  
 
In a similar way to Galen gaining his observational knowledge of human anatomy 
through seeing injuries sustained during gladiatorial combat, advances made in the 
treatment of cardiac injuries during World War II demonstrated the possibilities of 
cardiac surgery bringing ‘the heart within the province of safe surgery’ (Harken and 
Williams, 1946). This then allowed the development of open-heart surgery, and valve 
repair and replacement – a welcome advance, since the most common cause of heart 
failure up to this point had been rheumatic valve disease.  
 
1.3 Conclusion 
Despite the above significant advances having been made in cardiovascular medicine 
and surgery, an increasing number of patients are at risk of developing subsequent 
heart failure following the myocardial damage associated with acute coronary 
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syndromes, valvular and congenital heart disease, hypertension, and many 
arrhythmias (Braunwald, 2015). As will be discussed in the next chapter, heart failure 
is the most rapidly growing cardiovascular condition globally. Consequently, the 
determination to increase understanding of the syndrome of heart failure, and to 
develop new approaches to improve the care of patients remains important.  
 
Whilst we should look to the future, we should also build on our past. Research 
surrounding heart failure is widespread, however progress in science is not an isolated 
occurrence. It builds on a foundation of knowledge. As William Harvey said ‘there is 







Chapter 2 : An introduction to heart failure and treatment 
 
This chapter will discuss the complex clinical syndrome of chronic heart failure, its 
diagnosis, management, and treatment, whilst also introducing some of the gaps in 
our knowledge to frame the interventions described in future chapters. 
 
2.1 Introduction 
Chronic heart failure (CHF) is a clinical syndrome characterised by symptoms 
including breathlessness at rest and during exertion, fatigue, and ankle swelling, and 
has been defined as: 
‘..the pathological state in which an abnormality of myocardial function is 
responsible for the failure of the heart to pump blood at a rate 
commensurate with the requirements of the metabolising tissues during 
ordinary activity’ (Braunwald et al., 1967). 
 
The key driver of the syndrome of CHF is reduced cardiac output on exertion, which 
can be the result of failure of the heart to contract effectively, or to fill effectively. In 
either setting, the primary effect is a reduction in stroke volume. The clinical syndrome, 
driven by reductions in stroke volume due to failure of cardiac contractility, is known 
as ‘heart failure with reduced ejection fraction’ (HFrEF) or ‘systolic heart failure’. On 
the other hand, CHF without a reduction in cardiac contractility is known as ‘heart 
failure with preserved ejection fraction’ (HFpEF). These two syndromes are usually 
determined by an echocardiographic assessment of ejection fraction, since the clinical 
features and symptoms are identical. A third category of CHF has also been suggested 
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of ‘heart failure with mid-range ejection fraction’ (HFmEF), where the left ventricular 
ejection fraction (LVEF) is 40-49% (Lam, C.S. and Solomon, 2014; Ponikowski et al., 
2016). 
 
The underlying pathophysiology of HFrEF on which this thesis will focus, can be the 
result of mechanical, structural, or electrical abnormalities of the myocardium. In 
developed countries, HFrEF is most often the consequence of myocardial injury due 
to ischaemia, although hypertension with chronic pressure overload or valvular 
disease remain the most common causes worldwide. Myocyte toxicity due, for 
example, to a chemotherapeutic agent, is also well recognised. The effects on the 
myocardium, be they acute or chronic insults, initiate a cycle of widespread neuro-
hormonal adaptation. In the myocardium, these influences lead to a gradual change 
in the size, shape and function of the cells and the cardiac chambers, known as 
remodelling, which initially, through the lengthening and hypertrophy of 
cardiomyocytes, preserves stroke volume. However, this remodelling, and the 
influences that drive it, is associated with ongoing progressive myocyte hypertrophy, 
apoptosis, and necrosis, with accompanying fibroblast proliferation and interstitial 
fibrosis. Eventually, not only the muscle but also the fibrous structures of the heart are 
affected, leading to sphericity, and loss of competence of the atrio-ventricular valves 
which accelerates the process further due to volume overload (McMurray, J.J. and 




The neuro-hormonal activation, and the impaired haemodynamics, particularly 
impaired perfusion, has widespread effects, most notably on the kidneys, skeletal 
muscles, lung function, and immune system.  
 
Overall, the syndrome of HFrEF is associated with shortened life expectancy, 
recurrent hospitalisations and significantly reduced quality of life (Dickstein et al., 
2008) and despite great therapeutic advances, the mortality rate remains high at 
around 50% at 5 years (Hobbs, F.D.R. et al., 2007; Taylor et al., 2019).   
 
2.2 Epidemiology 
HFrEF is the most rapidly growing cardiovascular condition globally and is the 
common final end point for most forms of cardiovascular disease. Around 2% of the 
adult population in developed countries is affected by HFrEF, rising to approximately 
10% of over 70-year-olds (Ponikowski et al., 2016). Whilst the incidence has remained 
stable over the last two decades, the prevalence of HFrEF is increasing due to: an 
ageing population, the improved survival from ischaemic heart disease (IHD), and also 
the development of modern treatments for HFrEF (Pazos-Lopez et al., 2011). The 
average age at diagnosis is 77 years, but is significantly lower in areas of economic 
deprivation (Sutherland, 2010). Since age is an important risk factor for HFrEF, the 
burden on healthcare systems in developed countries increases as these populations 
age (Bleumink et al., 2004). Societal burden is also increased by lifestyle choices, with 
more people than ever living alone. A high level of perceived societal isolation is 
associated with an increased risk of death, hospitalisations, and outpatient 
appointments (Manemann et al., 2018).  Furthermore, improved treatment of heart 
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disease and an increase in such cardiovascular risk factors as type 2 diabetes mellitus 
and obesity, in the context of healthy lifestyles continuing to decline in countries with 
emerging economies, means that a new increase in global incidence of HFrEF is 
underway.   
 
2.3 Economics 
Whilst therapeutic advancements have improved the treatment of HFrEF, morbidity 
and mortality remain high. HFrEF is the most common cause for hospital admission in 
those over 65 years old (Roger, 2013), and causes or complicates 5% of all hospital 
admissions in the United Kingdom (UK) (NICE, 2014; NICOR, 2019). 
 
Although heart failure accounts for approximately 2% of the entire National Health 
Service (NHS) budget, this does not include costs related to nursing home care and 
hospitalisations where heart failure is coded as a secondary diagnosis, which have 
been estimated to account for a further 2% of expenditure. Indeed, heart failure is 
thought to cost the NHS around £905 million per year (Stewart et al., 2002).  
 
2.4 Aetiology and pathophysiology of heart failure 
CHF, and particularly HFrEF, is the consequence of an acute or chronic insult to the 
cardiomyocytes from which the cardiac syncytium never fully recovers. 
 
The leading cause of HFrEF in developed countries is IHD (Ziaeian and Fonarow, 
2016). However, overall, hypertension is thought to be the greatest aetiological factor 
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(Vasan and Levy, 1996; Cleland et al., 2001; Lüscher, 2015). Not only does 
hypertension contribute to the development of chronic left ventricular (LV) dysfunction 
directly, it is also the most common driver of coronary artery disease (CAD) and 
thereby IHD. Moreover, the epidemic of the metabolic syndrome in the developed 
world where hypertension is a key player, but also compounds the atherosclerotic 
effects of type 2 diabetes mellitus (Drozd and Kearney, 2017), means that despite 
effective blood-pressure-lowering therapies, hypertension remains the most important 
global risk factor for LV dysfunction (Kuznetsova et al., 2010). 
 
Given the high contribution of IHD to HFrEF, and the modest but key differences in 
treatment of HFrEF due to IHD, patients with HFrEF are often classified as having the 
syndrome due to IHD or not. ‘Non-ischaemic cardiomyopathy’ or ‘non-ischaemic heart 
failure’ can therefore be due to valvular heart disease, infiltration (amyloid, 
sarcoidosis), viral infection, idiopathic dilated cardiomyopathy, and can be induced by 
tachyarrhythmia. Indeed, a failure to adequately control ventricular rate in the long-
term may also cause a progressive decline in LV function (Khand et al., 2000). 
Paradoxically, although a great contributor to HFrEF due to IHD, hypertension is also 
a common cause of non-ischaemic cardiomyopathy. 
 
Chronic and acute IHD and particularly myocardial infarction (MI), lead to the death of 
cardiomyocytes which are then replaced by scar, leading to impaired cardiac 
contraction. Aneurysm formation can further worsen cardiac function, as can 
dyssynchronous motion within the infarcted region. Ventricular structure and geometry 
may be subsequently distorted by remodelling, further impairing cardiac function. 
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Indeed the progressive dilatation post MI plays an important role in the development 
of HFrEF (Gaudron et al., 1993). Whilst coronary occlusion may also lead to a 
persistent, but not permanent, loss of cardiac contraction without permanent cell death 
(hibernation), recurrent ischaemia can lead to a more short-term loss of cardiac 
contractility (stunning) (Cleland et al., 2001). However, less severe, or transient 
coronary occlusion with entirely reversible ischaemia, which may or may not provoke 
angina, does not usually lead to ventricular dysfunction.  
 
Although the above conditions initiate myocardial dysfunction, the basic 
pathophysiological process is driven, accentuated and persists due to compensatory 
mechanisms that although initially successful, eventually fail to preserve cardiac 
output and ultimately contribute to the progression of the condition (Triposkiadis et al., 
2009). 
 
Many patients may have asymptomatic cardiac dysfunction for years before they 
experience symptoms. The compensatory mechanisms of increased stroke volume 
through LV remodelling, along with peripheral vasoconstriction because of increased 
renin-angiotensin-aldosterone system (RAAS) activation, increased heart rate and 
cardiac contractility via sympathetic nervous system activity, can maintain filling 
pressures and cardiac output. 
 
Stroke volume and ventricular function depend on a combination of preload, 
myocardial contractility, and afterload. Hypertension contributes significantly to the 
development of HFrEF, both directly (through increased afterload) and indirectly 
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(through its role in IHD). The higher afterload, through elevated resistance of the 
peripheral vasculature results in a compensatory increase in myocardial mass in order 
to maintain normal cardiac output (Pazos-Lopez et al., 2011). Left ventricular 
hypertrophy is characterised by a higher myocardial stiffness and a decreased ability 
to relax and fill (Gaasch et al., 1982; Smith et al., 1985). 
 
However, these compensatory mechanisms eventually fail, and rather than further 
dilatation of the LV causing an increase in stroke volume, it causes the end-diastolic 
pressure to increase, and contraction becomes mechanically inefficient. High levels of 
angiotensin II and adrenergic hormones stimulate continued peripheral 
vasoconstriction, increasing afterload further, and cause salt and water retention, 
leading to an increase in the circulating volume. These hormones also increase 
myocyte apoptosis leading to worsening LV function and an over-activation of 
compensatory mechanisms (Hilfiker-Kleiner et al., 2006). Furthermore, as the LV 
dilates, there is a concomitant widening of the mitral orifice, with resultant functional 
mitral regurgitation.  
 
2.5 Signs and symptoms  
Whilst the characteristic diagnostic feature of HFrEF is impaired cardiac pumping 
function, defining HFrEF from a clinical perspective is challenging because the signs 
and symptoms are non-specific (Table 2.1), and can be seen with normal ageing. For 
example, fatigue (Falk et al., 2009) and dyspnoea (Ekman et al., 2005) are often 
dismissed as a consequence of ageing and deconditioning, and therefore not 
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adequately explored as symptoms of HFrEF. Nevertheless, defining HFrEF into 
different types is critical due to the widely differing approaches to treatment. 
 
The most common symptoms are breathlessness and fatigue, resulting in exercise 
intolerance  (Watson et al., 2000).   
Table 2.1: Signs and symptoms in heart failure  
Signs Symptoms 
Cachexia and muscle wasting Exertional breathlessness 
Tachycardia Ankle swelling 
Pulsus alternans Orthopnoea 
Elevated jugular venous pressure 
Laterally displaced apex beat 
Right ventricular heave 
Bi-basal fine crackles 
Third heart sound 




Paroxysmal nocturnal dyspnoea 






Although these signs and symptoms have poor sensitivity and poor specificity, they 
can alert the healthcare practitioner to the possibility of underlying disease. On the 
other hand, the absence of symptoms does not exclude underlying disease. 
Consequently, accurate diagnosis of HFrEF requires thorough clinical assessment, in 
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combination with relevant investigations, to demonstrate signs, symptoms, underlying 
aetiology, and to provide objective measurements of severity (Figure 2.1). There are 
however limitations in a physical examination, since patients (particularly those with 
less severe HFrEF) may have few abnormal signs. Furthermore, many patients with 
significant cardiac disease and without apparent symptoms, may deteriorate slowly, 
assume this is a normal part of ageing and consequently do not seek help. Conversely, 
many patients presenting with the common and non-specific heart failure symptoms 
of shortness of breath on exertion, exercise intolerance, and ankle swelling, do not in 
fact have heart failure (Davie et al., 1997). Hence investigation must include people 
with seemingly mild symptoms and few signs, but who are at elevated risk of 
underlying HFrEF; such assessment must combine physical examination and clinical 
investigations. 
 
The progressive nature of the syndrome contributes to a low quality of life score in the 
HFrEF patient population. Indeed, patients with HFrEF suffer a poor quality of life, 
worse than that of patients with other chronic conditions (chronic obstructive 
pulmonary disease and many cancers), not only due to the high probability of 
readmission (Stewart et al., 2001), but also due to frequent visits to their general 
practitioner (GP), and persistent reduced physical capacity because of the typical 
symptoms of breathlessness and fatigue (Hobbs, F.D. et al., 2002).   
 
2.5.1 Assessing clinical severity 
The functional classification developed by the New York Heart Association (NYHA) is 
most commonly used to provide a subjective assessment of symptoms and an 
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estimate of physical limitation (NYHA, 1994) (Table 2.2). Despite the somewhat lack 
of sensitivity to change and being subjective, the NYHA classification does give a 
guide to prognosis, is a criterion for additional medical management, and acts as an 
indication for implantation of a pacemaker device. Moreover, in an individual and a 
population, changing NYHA classification can provide a reflection of improvement or 
deterioration in clinical state, and aid in the evaluation of response to therapy. 
 
Table 2.2: NYHA Classification 
NYHA Classification Level of symptoms 
 
Class I Symptoms of HFrEF only at levels that 
would limit normal individuals 
Class II Symptoms of HFrEF with ordinary 
exertion 
Class III Symptoms of HFrEF with less than 
ordinary exertion 





Multimorbidity is defined as the coexistence of two or more chronic conditions (Tinetti 
et al., 2012), and has been shown to be increasingly common in heart failure (Conrad 
et al., 2018). This is of particular concern in HFrEF since comorbidities may precipitate 
acute decompensation, increase hospitalisations and complications (Page and 
Lindenfeld, 2012), therefore impacting on the prognosis (Chamberlain et al., 2015). In 
an observational cohort study of 1,794 patients with HFrEF, comorbidity accounted for 




HFrEF may be exacerbated by anaemia, renal dysfunction, cachexia, and 
arrhythmias. Atrial fibrillation (AF) in particular, may contribute directly to an abrupt 
decline in function.  
 
2.6 Diagnosis 
Demonstration of underlying cardiac dysfunction is a fundamental component in the 
diagnosis of HFrEF, since precise pathology determines the specific treatment used 
(Ponikowski et al., 2016). Furthermore, accurate and early diagnosis is key in the 
reduction of mortality, morbidity, and cost of HFrEF. However, cardiac dysfunction 
results from many different disease processes, which may be related to causes other 
than HFrEF. Therefore, the clinical suspicion of HFrEF should be confirmed with 
objective investigations and the demonstration of cardiac dysfunction at rest (Watson 
et al., 2000) (Figure 2.1). 
 
The routine use of an electrocardiogram (ECG) is mainly recommended to rule out 
heart failure, since a diagnosis of HFrEF is unlikely in the presence of a completely 
normal ECG (sensitivity 89%) (Ponikowski et al., 2016). An ECG may also identify the 
presence of any coexisting arrhythmias or evidence of IHD and may additionally 






Figure 2.1: HFrEF diagnosis algorithm (adapted from Ponikowski et al., 2016) 
 
UK and European guidance suggest that the plasma concentration of natriuretic 
peptides should be used as an initial diagnostic test and guide to further investigation 
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if HFrEF is suspected, particularly in the non-acute setting. Elevated natriuretic 
peptides can help identify those patients who require further cardiac investigations, 
whilst those with normal plasma natriuretic peptide concentrations are unlikely to have 
HFrEF (Ponikowski et al., 2016; NICE, 2018).  
 
Natriuretic peptides may also be elevated because of several cardiovascular and non-
cardiovascular reasons, which may reduce their effectiveness in diagnosing HFrEF. 
Most important amongst those reasons are AF, age and renal failure (Maisel et al., 
2008). Natriuretic peptides have high negative predictive values (0.94-0.98) in acute 
and non-acute settings, and low positive predictive values in the acute (0.66-0.67) and 
non-acute (0.44-0.57) settings (Cowie et al., 1997; Yamamoto et al., 2000; 
Krishnaswamy et al., 2001; Zaphiriou et al., 2005; Fuat et al., 2006; Roberts et al., 
2015). Therefore, the use of natriuretic peptides is recommended for ruling out, rather 
than confirming, a diagnosis of HFrEF (Ponikowski et al., 2016). As such, an elevated 




Echocardiography (or cardiac ultrasound) is a well-established and recognised 
imaging modality, and as such performs a central role in not only the diagnosis of 
HFrEF, but also in determining appropriate treatment, assessment, and monitoring. It 
provides immediate, non-invasive diagnostic information about chamber volumes, 
ventricular systolic and diastolic function, wall thickness, valve function, and 
pulmonary hypertension, reducing the necessity of invasive investigations in many 
37 
 
patients. Furthermore, echocardiography is a portable and relatively inexpensive 
imaging method. Since echocardiography forms a central outcome in the studies 
carried out for this thesis, a full review of the use of echocardiography in the context 
of HFrEF forms chapter 4. 
 
2.6.2 Cardiopulmonary exercise testing 
Over the past decade, acknowledgement of the importance and value of 
cardiopulmonary exercise testing (CPET) within healthcare settings has grown (Faghy 
et al., 2020). CPET is recommended in the assessment of patients with HFrEF to 
measure response to physical exertion, since impaired exercise tolerance is a key 
component in the diagnosis of HFrEF.  
 
During a CPET, patients perform physical exertion whilst breathing room air. Workload 
is measured and controlled through an ergometer. This is usually a treadmill or a 
stationary cycle, or alternatively an arm-crank cycle or a rowing ergometer. Accurate 
assessment of workload is achieved through use of a standard protocol. The volume 
and concentration of inspired and expired oxygen (O2) and carbon dioxide (CO2), and 
respiratory rates and volumes, are collected via a mouthpiece or facemask. Metabolic 
gas exchange is analysed on a breath-by-breath basis by O2 and CO2 analysers.  
 
Measurement of ventilatory and O2 uptake patterns in HFrEF can quantify disease 
severity and prognosis (Malhotra et al., 2016). Exertional fatigue can be objectively 
measured as a reduction in peak oxygen consumption (VO2) and an increase in 
ventilatory response to exercise (VE/VCO2 slope) during incremental exercise testing 
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with metabolic gas exchange analysis, suggesting that patients with HFrEF ventilate 
more for a given workload and given carbon dioxide output than controls (Buller and 
Poole-Wilson, 1990; Davies, S.W. et al., 1991).   
 
2.7 Management  
The objectives of treating patients with HFrEF are to improve symptoms, quality of life 
and functional capacity, to prevent hospitalisation, and extend longevity which is often 
described by a reduction in mortality over a finite time (Ponikowski et al., 2016). 
Multiple pharmacological therapies have been shown to improve mortality in 
prospective, randomised controlled trials (Hunt et al., 2009; Cubbon et al., 2011). 
Pacemaker devices have been shown to reduce mortality rates in selected patients 
(Bristow et al., 2004; Bardy et al., 2005; Cleland et al., 2005). However, the best way 
to integrate medical and device therapy, education and general approaches, is within 
a multidisciplinary team approach to delivery of care (Morton et al., 2018).  
 
2.7.1 General management 
Much of the advice provided to patients on lifestyle and general management, 
following a diagnosis of HFrEF is not evidence based. I have used the guidelines 
published by the European Society of Cardiology (ESC) working group on heart failure 
(Ponikowski et al., 2016). 
 
Patient education on the aetiology, importance of adherence to treatment plans, 
benefits of medication dosage optimisation, and the prompt reporting of a deterioration 
in symptoms, can improve outcomes (Koelling et al., 2005), although this is not a 
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consistent finding (Jaarsma et al., 2008). Nevertheless, patient education may allow 
the patient to feel more in control and involved in management decisions. 
 
Modification of risk factors may prevent or delay the development of HFrEF. Control 




Patients should eat a healthy, well-balanced diet. The most important element of diet 
management in patients with HFrEF is salt restriction. Fluid retention is the most 
prevalent cause for clinical worsening and hospitalisations in HFrEF. Since dietary salt 
intake directly contradicts the action of diuretics, reinforcement of the need to restrict 
salt intake is necessary (Katz, A. and Konstam, 2009). Alcohol consumption should 
not be excessive. Those taking warfarin should be warned that changes in their diet 
may result in loss of anti-coagulant control.  
 
2.7.1.2 Exercise 
Exercise-based cardiac rehabilitation can improve symptoms and reduce the risk of 
heart failure hospitalisations in patients with HFrEF, however access greatly varies 
(Sagar et al., 2015). The Quality and Outcomes Framework (QOF), under the 
guidance of the National Institute for Health and Care Excellence (NICE), developed 
‘indicators’ for managing patients with HFrEF; these indicators are financially 
incentivised targets for GPs. Whilst the HFrEF guidelines of both the ESC and NICE 
recommend referral to an exercise-based cardiac rehabilitation programme, the 2019-
40 
 
20 QOF indicators no longer reward GPs for referral (Ponikowski et al., 2016; NICE, 
2018). Patients should nevertheless be encouraged to take regular exercise and be 
reassured that far from being something they should avoid, they should take exercise 
as their symptoms allow, rest and repeat. 
 
2.7.1.3 Smoking 
Cigarette smoking is a major contributor to all forms of cardiovascular disease. It 
increases risk factors for heart failure such as: raised blood pressure, increased heart 
rate, diabetes, and atherosclerosis. Gopal et al. found that current smokers exhibited 
a significantly increased risk of incident heart failure compared to non-smokers, after 
controlling for other clinical heart failure risk factors and incident coronary events 
(Gopal et al., 2012).  
 
Although there has been a suggestion of a ‘smoker’s paradox’, where smokers who 
were hospitalised with heart failure had lower risk adjusted in-hospital mortality and 
similar early post-discharge mortality compared with non-smokers, this was not fully 
explained by measured covariates (Fonarow et al., 2008).  
 
A meta-analysis of nine articles (n=70,461) reported that 16% of smokers continued 
to smoke after a heart failure diagnosis (Son and Lee, 2020). Persistent smoking 
increased the hazard ratio (HR) of mortality by 38.4% (HR=1.384; 95% confidence 
interval (CI): 1.139-1.681) and readmission by 44.8% (HR=1.448; 95% CI: 1.086-
1.930). Persistent smoking was found to be associated with poor health status, 




Since smoking continues to be a leading cause of preventable morbidity and mortality, 
continued attempts at smoking cessation aimed at both individual and population 
levels are appropriate. 
 
2.7.2 Pharmacological treatment 
The mainstay of HFrEF treatment is pharmacological therapy, with the key targets 
being symptomatic relief, slowing of disease progression and increasing survival. The 
treatment of HFrEF up until the 1980s focused primarily on symptom control using 
diuretics and digoxin. Contemporary pharmacological treatments are directed at the 
inhibition of the two major neuro-hormonal pathophysiological mechanisms that 
underlie the development and progression of HFrEF, namely the RAAS and the 
sympathetic nervous system. In the short-term, these systems are beneficial and 
adaptive, maintaining organ perfusion and cardiac output. But in the long-term, cardio-
myocyte hypertrophy, apoptosis, and fibrotic proliferation result in adverse remodelling 
and pump dysfunction (Pazos-Lopez et al., 2011). 
 
Neuro-hormonal antagonists (angiotensin-converting enzyme (ACE) inhibitors, 
mineralocorticoid/aldosterone receptor antagonists (MRAs) and beta-adrenoceptor 
antagonists (β-blockers)), have been shown to improve survival in heart failure, and 
are recommended for all patients with HFrEF, unless contra-indicated or not tolerated 




2.7.2.1 Loop and thiazide diuretics 
Diuretics are recommended to manage the symptoms of HFrEF that are associated 
with fluid and salt retention, such as shortness of breath, and peripheral and 
pulmonary oedema. Whilst no randomised controlled trials have demonstrated long 
term effects on mortality or morbidity (Ponikowski et al., 2016), they provide rapid and 
effective symptomatic relief (Faris et al., 2002) by blocking sodium reabsorption in the 
renal tubules, resulting in increased urinary sodium and water excretion. The aim is to 
use the lowest dose to achieve and maintain euvolaemia. 
 
Diuretics are divided by mode and site of action. Spironolactone and eplerenone, both 
of which have a diuretic effect, are discussed below. The other two major groups are 
loop diuretics and thiazide diuretics. Loop diuretics (furosemide and bumetanide) are 
used most commonly in HFrEF, and work by inhibiting sodium and chlorine 
reabsorption from the ascending limb of the loop of Henle in the renal tubules. Loop 
diuretics are more potent and their effect is generally preserved in the presence of 
modest renal impairment (Pazos-Lopez et al., 2011). Thiazide diuretics inhibit sodium 
reabsorption at the beginning of the distal convoluted tubules and are often used in 
the later stages of the disease process when there is resistance to the effects of loop 
diuretics with persistent oedema. Loop and thiazide diuretics can be used in 
combination, but adverse effects such as dehydration and renal dysfunction are more 






2.7.2.2 Angiotensin-converting enzyme inhibitors  
With a reduction in cardiac output due to LV dysfunction, there is a fall in renal 
perfusion which leads to a compensatory rise in renin excretion. Renin converts 
angiotensinogen to angiotensin I, which through angiotensin converting enzyme is 
converted to angiotensin II. This agent has powerful vasoconstrictive, salt-retentive, 
and hypertrophic properties. ACE inhibitors impede the conversion of inactive 
angiotensin I to the active angiotensin II, and also inhibit the kininase enzyme which 
is involved in bradykinin degradation (Brown and Vaughan, 1998). Blockade of these 
systems has favourable effects on cardiac and vascular remodelling. As a result, there 
is arterial and venous dilatation, a slight drop in arterial blood pressure, and improved 
renal blood flow. 
 
In patients with HFrEF, ACE inhibitors significantly improve survival, reduce 
hospitalisations, relieve symptoms and slow the progression of the disease (Swedberg 
and Kjekshus, 1988; Cohn et al., 1991; Yusuf et al., 1991). Additionally, randomised 
controlled trials have demonstrated increased survival with ACE inhibitors in patients 
who develop systolic dysfunction following an MI (Pfeffer et al., 1992; Julian et al., 
1993; Kober et al., 1995). 
 
The benefits of ACE inhibitors have been demonstrated in HFrEF and LV systolic 
dysfunction (LVSD) without symptoms. Consequently all patients with any grade of 
LVSD should be initiated on low dose ACE inhibitor therapy and up-titrated to the 
maximum tolerated dose to achieve inhibition of the RAAS (NICE, 2018). Possible side 




2.7.2.3 Adrenergic receptor antagonists (β-blockers) 
The sympathetic nervous system is chronically overactive in HFrEF, which leads to 
increased heart rate and energy demands, adverse remodelling, interstitial fibrosis, 
arrhythmia provocation and stimulation of RAAS activation. Inhibition of adrenergic 
activity with the use of β-blockers is associated with reduction of all these effects. 
Chronic β-blocker therapy improves LV remodelling, reduces risk of hospitalisation, 
and improves survival (Triposkiadis et al., 2009; Bristow, 2011; Chatterjee, S. et al., 
2013). 
 
In patients with symptomatic HFrEF due to LVSD, β-blockers reduce mortality and 
morbidity, in addition to ACE inhibitors and diuretic therapy (Hjalmarson et al., 2000; 
Packer et al., 2002). 
 
β-blockers should be introduced at a low dose and gradually up-titrated to the 
maximum tolerated dose, with regular monitoring of both heart rate and blood pressure 
for hypotension and bradycardia (NICE, 2018). Adverse effects of β-blocker use 
include symptomatic hypotension, bradycardia, and fatigue. 
 
2.7.2.4 Mineralocorticoid/aldosterone receptor antagonists  
Spironolactone and eplerenone are MRAs that block the receptors binding aldosterone 
and other steroid hormone receptors.  Resulting in reduced salt and water retention, 
MRAs are recommended in all symptomatic patients with HFrEF and LVEF ≤35%. In 
conjunction with ACE inhibitors and β-blockers, MRAs reduce mortality and HFrEF 
45 
 
hospitalisation (Pitt et al., 1999; Pitt et al., 2003; Zannad et al., 2011). Treatment 
should be initiated at low doses with careful monitoring of serum potassium and renal 
function. The main side effects related to aldosterone antagonists are hyperkalaemia 
and gynaecomastia (Pazos-Lopez et al., 2011). 
 
2.7.2.5 Angiotensin II type I receptor blockers  
Despite treatment with currently recommended drugs, the actions of angiotensin II 
may contribute to the progression of HFrEF through increased impedance of LV 
emptying, adverse long term structural effects on the cardiovascular system, and the 
adverse effects of activation of other neuro-hormonal agonists (Cohn and Tognoni, 
2001). Angiotensin II type I receptor blockers (ARBs) are recommended as an 
alternative therapy in those HFrEF patients who are intolerant of an ACE inhibitor, due, 
for example to cough or angio-neurotic oedema (Maggioni et al., 2002). Candesartan 
has been shown to reduce cardiovascular mortality in a randomised controlled trial 
(Granger et al., 2003), and valsartan showed a reduction in HFrEF hospitalisations in 
heart failure patients with LVSD and taking an ACE inhibitor (Cohn and Tognoni, 
2001). However, combined ACE inhibitor/ARB therapy in HFrEF, which can lead to 
marked hyperkalaemia, is only recommended where other therapies are contra-
indicated or not tolerated. Combined ACE inhibitor/ARB should only be considered in 
patients with symptomatic HFrEF, receiving a β-blocker and intolerant of an MRA, and 
must be used under strict supervision because of the risk of serious side effects 





2.7.2.6 Angiotensin receptor neprilysin inhibitor  
Angiotensin receptor neprilysin inhibitors (ARNi) are a new class of therapeutic agents 
that have been developed to act on the RAAS and the neutral endopeptidase system. 
Sacubitril valsartan, a combination of valsartan (an angiotensin receptor blocker) and 
sacubitril (a neprilysin inhibitor), results in increasing levels of natriuretic peptides that 
counterbalance high circulating levels of neuro-hormones in HFrEF. Increased levels 
of A-type natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) enhances 
diuresis, natriuresis, and myocardial relaxation, while reducing myocardial 
hypertrophy. Renin and aldosterone secretion are also inhibited by ANP and BNP. 
Selective AT1-receptor blockade reduces vasoconstriction, sodium and water 
retention, and cardiac hypertrophy (King et al., 2015). 
 
Sacubitril valsartan has been found to be superior to ACE inhibition alone in reducing 
the risks of death and of hospitalisation for HFrEF (McMurray, J. et al., 2014). 
 
2.7.2.7 If-channel inhibitor 
Ivabradine specifically inhibits the If current in the sinoatrial node and slows the heart 
rate without altering: myocardial contractility, the cardiac conduction system or 
coronary vascular resistance (Fox, 2006). Because of its specific action on the sinus 
node it is only effective in patients in sinus rhythm (Ponikowski et al., 2016). Ivabradine 
reduced the combined endpoint of mortality or hospitalisation for patients with 
symptomatic heart failure and LVEF ≤35%, with a heart rate of ≥70 beats per minute 
(bpm) in sinus rhythm, hospitalised for heart failure within the previous 12 months, and 
already on maximally tolerated doses of β-blocker, and ACE inhibitor (or ARB) and an 
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MRA (Swedberg et al., 2010). Ivabradine is approved for use in patients with HFrEF, 
LVEF ≤35%, in sinus rhythm with a resting heart rate ≥75 bpm, because of the survival 
benefit based on a subgroup analysis (Bohm et al., 2013; Ponikowski et al., 2016). 
 
2.7.2.8 Digoxin 
As noted in 1.2.4, digoxin (digitalis) has been used for over 200 years in the treatment 
of heart failure. With its mild inotropic and diuretic properties, digoxin moderates 
neuro-endocrine function and slows atrio-ventricular conduction (Pazos-Lopez et al., 
2011). It is predominantly used in HFrEF to modulate ventricular rate in patients in AF, 
but only when other available treatments are not an option (Ponikowski et al., 2016). 
However, a recent meta-analysis confirmed that digoxin use is associated with an 
increased mortality risk in AF, and in heart failure patients treated according to 
contemporary guidelines, and suggests that until results of randomised placebo 
controlled trials become available, digoxin should be used with great caution (Vamos 
et al., 2019). 
 
2.7.2.9 Anti-arrhythmic agents 
Heart failure patients, particularly with an ischaemic aetiology, are at increased risk of 
ventricular tachyarrhythmia and sudden cardiac death (Cleland et al., 2002). However, 
anti-arrhythmic agents, other than β-blockers, do not improve survival in HFrEF 
(Ponikowski et al., 2016). This is probably because a ventricular arrhythmia most 
frequently represents a serious HFrEF problem that is not reversed by treatments 




2.7.3 Cardiac implantable electronic devices 
Cardiac implantable electronic devices (CIEDs) have become a central feature of the 
management of HFrEF over the last 20 years. Beyond treatment of bradycardia, there 
are two main approaches to pacemaker therapy with considerable overlap of 
indications. Despite widespread acceptance of their benefits and excellent trials 
supporting their use, pacemaker devices remain underused in the HFrEF population 
(Lund et al., 2017).  
 
2.7.3.1 Implantable cardioverter-defibrillator 
Around 40% of patients with heart failure suffer sudden or unexplained death (Poole-
Wilson et al., 2003b). This may be as a result of bradyarrhythmia or tachyarrhythmia, 
but may also be due to coronary, vascular or cerebrovascular episodes (Gatzoulis et 
al., 2017). Treatments to improve, or delay the progression of cardiovascular disease, 
can reduce the incidence of sudden cardiac death, but will not treat arrhythmic events 
as they occur. Anti-arrhythmic medications can reduce the frequency and burden of 
tachyarrhythmia, but as mentioned above, can worsen overall mortality (Ponikowski 
et al., 2016). However, implantable cardioverter-defibrillators (ICD) may reduce the 
risk of sudden cardiac death due to severe ventricular arrhythmias, either by anti-
tachycardia pacing or delivering a shock to terminate ventricular tachycardia or 
ventricular fibrillation.  
 
2.7.3.2 Cardiac resynchronisation therapy 
Around one third of patients with HFrEF have some degree of intraventricular 
conduction delay, which may worsen LVSD (Cazeau et al., 2001). Cardiac 
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resynchronisation therapy (CRT) is a form of pacemaker therapy that aims to improve 
the coordination of cardiac contraction. A ventricular electrode is placed in the right 
ventricular (RV) apex, or on the RV septum, and a further electrode is positioned to 
stimulate the LV free wall (Kirk and Kass, 2013). By pacing through both electrodes 
simultaneously, it is possible to improve conduction timing, which can reduce 
dyssynchrony and improve cardiac output (Cleland et al., 2005). Current ESC 
guidelines (Table 2.3) recommend consideration of CRT in patients with LVEF <35% 
and QRS duration ≥150 milliseconds (msec) (Ponikowski et al., 2016). 
 
CRT has been shown to improve symptoms and quality of life, and to reduce 
hospitalisation rates, morbidity and mortality in HFrEF (Cazeau et al., 2001; Abraham 
et al., 2002; Bristow et al., 2004; Cleland et al., 2005). However, implantation of CRT 














Table 2.3 Current ESC guidelines for CRT implantation 
Recommendations Classa Levelb 
CRT is recommended for symptomatic HFrEF patients in SR with a QRS duration 
≥150 msec and LBBB QRS morphology with LVEF ≤35% despite OMT to improve 
symptoms and reduce morbidity and mortality. 
I A 
CRT should be considered for symptomatic HFrEF patients in SR with a QRS duration 
≥150 msec and non-LBBB QRS morphology with LVEF ≤35% despite OMT to improve 
symptoms and reduce morbidity and mortality. 
IIa B 
CRT is recommended for symptomatic HFrEF patients in SR with a QRS duration of 
130-149 msec and LBBB QRS morphology with LVEF ≤35% despite OMT to improve 
symptoms and reduce morbidity and mortality. 
I B 
CRT may be considered for symptomatic HFrEF patients in SR with a QRS duration of 
130-149 msec and non-LBBB QRS morphology with LVEF ≤35% despite OMT to 
improve symptoms and reduce morbidity and mortality. 
IIb B 
CRT rather than RV pacing is recommended for patients with HFrEF regardless of 
NYHA Class, in SR or AF, with an indication for ventricular pacing and high degree AV 
block to reduce morbidity. 
I A 
CRT should be considered for patients with LVEF ≤35% in NYHA Class III-IV despite 
OMT to improve symptoms and reduce morbidity and mortality if they are in AF and 
have a QRS duration ≥130 msec and good rate control to ensure bi-ventricular capture 
is in place or the patient is expected to return to SR. 
IIa B 
Patients with HFrEF who have received an RV pacemaker or ICD and develop 
worsening HF despite OMT with a high proportion of RV pacing may be considered for 
upgrade to CRT. This does not apply to patients with stable HFrEF. 
IIb B 
CRT is contra-indicated in patients with a QRS duration <130 msec. III A 
AF = atrial fibrillation; AV = atrio-ventricular; CRT = cardiac resynchronisation therapy; HFrEF = heart failure 
with reduced ejection fraction; ICD = implantable cardioverter-defibrillator; LBBB = left bundle branch block; 
LVEF = left ventricular ejection fraction; msec = millisecond; NYHA = New York Heart Association; OMT = 
optimal medical therapy; RV = right ventricular; SR = sinus rhythm. 
aClass of recommendation 
bLevel of evidence 
 
2.7.3.3 Remote monitoring 
Remote monitoring of pacemaker devices offers an opportunity to improve device 
follow-up efficiency. The ability to monitor technical function and disease-specific 
parameters allows the potential to modify disease progression in HFrEF patients 
(Braunschweig et al., 2019), and the possibility of detecting decompensation earlier. 
Wireless, automated remote monitoring systems download patient data from the 
device using radio transmissions to communicate with a base station located in the 
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patient’s home. The system can be programmed to transmit data at regular intervals, 
which has the advantage of reducing in-person device follow-up appointments. 
Additionally, the system can be set to transmit if specifically programmed triggers are 
activated.  
 
Remote monitoring is standard in many cardiac centres for device function and safety 
reasons. The potential of remote monitoring, whilst thought to be significant 
(Brahmbhatt and Cowie, 2019), has not been shown to be consistent in large scale 
randomised controlled trials (Morgan et al., 2017). However, during the coronavirus 
disease 2019 pandemic, in-person follow-up of pacemaker devices was significantly 
affected. This has resulted in widespread increase in the use of remote monitoring for 
pacemaker devices (Varma et al., 2020). 
 
2.7.4 Surgical treatment 
Surgical treatment options for end-stage heart failure are limited. Heart transplantation 
is considered the gold standard treatment for eligible symptomatic patients with end-
stage HFrEF (Patel et al., 2016). However, with a limited donor pool of hearts for the 
increasing number of patients requiring cardiac transplantation, other methods have 
been investigated. 
 
Left ventricular assist devices can improve myocardial contractility and reverse 
remodelling. These devices are used for short term survival benefits, either as a bridge 
to transplant or as a destination therapy, where transplantation is contraindicated and 
prognosis is poor (Marinescu et al., 2017). 
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2.8 Acute heart failure 
Acute heart failure refers to a rapid onset or a worsening of symptoms and/or signs of 
heart failure (Braunwald, 2013). It is a life-threatening medical condition requiring 
urgent evaluation and treatment, typically leading to urgent hospitalisation (Ponikowski 
et al., 2016). It may present as new onset of HFrEF, but most admissions with heart 
failure are acute decompensations of HFrEF. Whilst decompensation of HFrEF can 
occur without precipitant factors, it usually presents due to one or more factors, for 
example: infection, anaemia, uncontrolled hypertension, rhythm disturbances or non-
adherence with medication or diet.  
 
2.9 Right heart failure 
Since the circulation is a closed system, the failure of one ventricle deleteriously 
affects the performance of the other. Right heart failure is a clinical syndrome with 
signs and symptoms of heart failure resulting from RV dysfunction, and is caused by 
the inability of the RV to support optimal circulation in the presence of adequate 
preload (Konstam et al., 2018).  
 
Acute right heart failure can occur as a result of abruptly increased RV afterload, due 
to, for example, pulmonary embolus, hypoxia, or acidaemia, or to the decreased RV 
contractility that might occur with RV ischemia, myocarditis, or post-cardiotomy shock. 
On the other hand, chronic right heart failure most commonly occurs as a result of the 
gradual increases in RV afterload caused by pulmonary hypertension, which in turn, 






Since it is only in patients with HFrEF that therapies have been shown to reduce both 
morbidity and mortality (Ponikowski et al., 2016), for pragmatic reasons my thesis will 
focus on those patients with symptoms that are predominantly due to HFrEF, and with 
objective evidence of LVSD.  
 
Despite improvements in patient outcomes due to advances in the treatment and 
management of HFrEF, the prognosis of patients with HFrEF remains poor. The 





Chapter 3 : Heart rate in heart failure 
 
Heart rate is the primary assessment in almost all interactions between healthcare 
providers and their patients, especially those patients with cardiovascular disease. Far 
from being simply a measure of the effect of diseases and drugs on the heart, it is 
appreciated that heart rate itself is a critical contributor to both symptoms and 
progression of cardiovascular disease.  
 
In the 1870s, Henry Pickering Bowditch recognised that the force of contraction of 
cardiac muscle is dependent on the rate and rhythm of the heartbeat (Noble, 1992). 
Initially known as the Treppe (staircase) effect, and more recently described as the 
force-frequency relationship, chapter 3 will explore this critical mechanism, how it 
could be influenced by cardiovascular disease, and how it might be relevant in 
contemporary patients.  
 
3.1 Introduction 
Exercise requires an increase in delivery of oxygen and heightened removal of carbon 
dioxide and other waste products, therefore demanding greater cardiac output. In 
health, cardiac output increases during exercise through rises in both stroke volume 
(the amount of blood ejected with each heart beat) and heart rate (the number of times 
per minute that the heart beats) (Camm and Fei, 1996). The key feature of heart failure 
with reduced ejection fraction (HFrEF) is reduced exercise tolerance, one of the main 
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contributors to this is thought to be reduced cardiac output during activity (Camm and 
Fei, 1996; Stahlberg et al., 2011; MacIver and Dayer, 2012). However, resting left 
ventricular (LV) function is poorly related to exercise capacity (Clark et al., 1996). 
Since exercise intolerance experienced by patients with HFrEF leads to significant and 
persistent impairment of quality of life, this is an important area to address. 
 
3.2 Cardiac output 
Cardiac output is an important indicator of cardiac function, and is the product of heart 
rate and stroke volume according to the simple yet important equation: 
 
                             Heart Rate x Stroke Volume = Cardiac Output  
 
Normally, during exercise, cardiac output increases to meet the requirements of 
metabolic demand. This increase is brought about through changes in both heart rate 
and stroke volume (Cooper and Storer, 2001). 
 
Since cardiac output is a function of heart rate and stroke volume, it is possible that 
poor heart rate rise during exercise could contribute to reduced exercise capacity. 
However, the relationship between heart rate rise on exercise, cardiac output, and 
exercise capacity, in addition to how their interaction changes with age, sex, fitness 
and disease, is poorly understood. Furthermore, after over 80 years of research there 




3.3 Stroke volume 
Stroke volume is the quantity of blood ejected from the LV into the aorta with each 
heartbeat, and is dependent on preload, contractile force, and afterload. Preload is 
determined by LV cavity pressure and volume at the end of diastole, such that 
increasing end-diastolic volume results in an increased stroke volume. Afterload is 
determined by the LV cavity pressure and volume during systole, and is the resistance 
to ejection during each ventricular contraction. Increased resistance results in a 
decreased stroke volume. 
 
3.3.1 Stroke volume enhancement 
As the heart rate rises during exercise, enhancement in the LV stroke volume results 
from increased LV filling, and from decreased LV systolic volume due to greater LV 
contractility. The increased LV contractility comes largely from three mechanisms. The 
most appreciated are the enhancement of contractility through adrenergic 
mechanisms and the cardiac contractility regulation known as the length-tension 
relationship, or Frank-Starling mechanism (Noble, 1992) through increased LV 
diastolic volume (representing stretch of the cardiomyocytes fibres) (Higginbotham et 
al., 1986; Vella and Robergs, 2005). 
 
On the other hand, despite its crucial importance during exercise, the intrinsic capacity 
of the heart to increase the strength of contraction in response to an increase in 
contraction frequency (or heart rate), variably known as the force-frequency 
relationship, Bowditch effect, Treppe phenomenon or staircase phenomenon, has 
been paid little attention relative to the other fundamental physiological mechanisms. 
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3.4  Heart rate 
3.4.1 Resting heart rate 
As HFrEF progresses, the resting heart rate becomes increasingly elevated, which is 
associated with reduced cardiac efficiency, increased myocardial oxygen demands, 
and furthermore, represents a risk-marker (Nikolovska Vukadinović et al., 2017). In a 
sub-analysis of a randomised controlled trial, investigators tested the hypothesis that 
elevated resting heart rate at baseline, is a marker for subsequent cardiovascular 
death and morbidity. The investigators found a 34% increased risk of cardiovascular 
death in patients with impaired LV function following myocardial infarction, and a 53% 
increase in hospitalisation at a heart rate of >70 beats per minute (bpm) compared 
with those with a lower heart rate. Each 5 bpm increase in heart rate was associated 
with increased cardiovascular death by 8%, and increased HFrEF hospitalisation by 
16% (Fox et al., 2008). Böhm et al. reported that in HFrEF, cardiovascular death is 
higher at rates >75 bpm, and HFrEF hospitalisation risk is elevated at rates >70 bpm 
(Böhm et al., 2010). DeVore et al. reported that despite broad use of beta-
adrenoceptor antagonists (-blocker), a heart rate ≥ 70 bpm was observed in 73% of 
HFrEF patients and was associated with worse 1-year outcomes, although the authors 
were not able to provide information about the actual dose of β-blocker (DeVore et al., 
2016). 
 
Large randomised trials have shown that -blockers improve morbidity and mortality 
in patients with HFrEF (CIBIS-II, 1999; MERIT-HF, 1999; Poole-Wilson et al., 2003a). 
However, despite the burden of evidence showing that pharmacological treatment to 
lower the resting heart rate may improve both mortality and morbidity (Flannery et al., 
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2008; Fiuzat et al., 2012), and that heart rate reduction should be a pivotal treatment 
target in HFrEF (Hori and Okamoto, 2012), there is a failure to achieve recommended 
doses in a large proportion of patients (Maggioni et al., 2010). This may be due to 
contraindications or intolerance, however, there is also a concern that lowering the 
resting heart rate could induce exercise intolerance and symptomatic bradycardia, 
thereby increasing symptoms of breathlessness and fatigue.  
 
3.4.2 Heart rate during exercise 
In adults with normal heart function, the heart rate rises steadily with increasing work, 
to a peak that is generally accepted to be inversely related to age. Key features of 
HFrEF thought to contribute to exercise intolerance are reductions in peak heart rate, 
LV contractility and cardiac output, during activity. 
 
The relevance of peak heart rate on exercise has become particularly challenging 
since the advent of heart rate limitation as a key target of HFrEF therapy. The belief 
that limited heart rate rise during exercise, known as chronotropic incompetence, is a 
contributor to exercise intolerance in HFrEF (Al-Najjar et al., 2012; Brubaker and 
Kitzman, 2013) has been countered by observational and interventional data (Jamil et 
al., 2016; Chatterjee, N.A. and Heist, 2018).  
 
3.4.3 Chronotropic incompetence 
The ‘Åstrand formula’ of 220 bpm minus age, is the most frequently used benchmark 
to determine target peak heart rate (Robergs and Landwehr, 2002). The inability of the 
heart rate to increase in proportion to the level of physical exertion or metabolic 
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demand, known as chronotropic incompetence, is commonly found in HFrEF patients. 
Chronotropic incompetence is defined as either an inability of the peak heart rate to 
reach an arbitrary percentage (usually 80%) of the age-predicted maximum, or a 
reduction in the ratio of heart rate reserve to metabolic reserve, where a ratio <0.8 
indicates chronotropic incompetence, irrespective of age, fitness, or functional 
capacity. However, these cut-offs are based upon small-scale observational studies 
of generally healthy people performing symptom-limited exercise tests. 
 
The heart rate-response, or rate-adaptive, pacemaker function was developed in an 
attempt to optimise exercise tolerance in patients with chronotropic incompetence (Alt 
et al., 1995). Currently, no guidelines exist that offer advice on the programming of 
peak heart rate; generally, the formula of 220 bpm minus age is used. However, this 
does not consider the condition of the patient. Whilst heart rate-response pacing in 
people without HFrEF is associated with an increase in cardiac output during exercise 
(McMeekin et al., 1990), and better quality of life (Oto et al., 1991), using pacemakers 
to increase the peak heart rate in HFrEF has been shown to worsen both prognosis 
and cardiac function (Nägele, H. et al., 2008). 
 
3.4.4 Heart rate and exercise capacity in HFrEF 
Heart rate contributes to cardiac output, which plays a key role in determining exercise 
capacity (Clark et al., 1996). Although no conclusive evidence exists in the literature, 
of benefit to exercise time or quality of life in HFrEF through either increasing the mean 
and peak heart rate with rate-response pacing, or programming the rate-response 
function off  (Jamil et al., 2016), the standard age-related rate-response algorithm of 
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220 bpm minus age is the only guidance currently available. How this guidance is used 
in clinical practice remains unknown. 
 
Thus, the paradox, where medical therapy to reduce heart rate is proven and applied, 
but where pacemaker patients with HFrEF may be subjected to higher mean heart 
rates by the use of an unproven rate-response algorithm, suggests that a therapeutic 
opportunity is being missed, or perhaps even that harm is being done. Furthermore, 
this inconsistency potentially contributes to poorly defined heart rate targets in 
guidelines (Ponikowski et al., 2016), and low rates of achievement of optimal -blocker 
doses in those with and without pacemaker devices (Fowler et al., 2007; Greene et 
al., 2019).  
 
Moreover, there has been conflicting evidence as to whether chronotropic 
incompetence contributes to, or is the result of, the reduced exercise capacity that is 
characteristic of worsening HFrEF (Witte, K. K. and Clark, 2009).   
 
In a study of 278 patients with stable HFrEF, on optimal medical therapy, a significant 
proportion of participants had chronotropic incompetence, which was associated with 
lower exercise capacity (Jorde et al., 2008). In a further study, looking at the 
relationship between the presence of chronotropic incompetence and mortality in an 
unselected cohort of 411 patients with HFrEF who underwent cardiopulmonary 
exercise testing, chronotropic incompetence was present in 42% of the study 
population. This was associated with significantly lower exercise time and peak 
oxygen consumption (millilitres per kilogram per minute (ml/kg/min)). There was 
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however no association between chronotropic incompetence and mortality (Al-Najjar 
et al., 2012). 
 
Conversely, in a study looking at heart rate response to exercise in HFrEF, no 
significant difference in resting heart rate, age, maximal oxygen consumption 
achieved, or LV ejection fraction (LVEF) was demonstrated between those patients 
with and without chronotropic incompetence (Roche et al., 2001). Using a treadmill-
based symptom-limited exercise protocol and gas exchange analysis, Clark et al. 
studied 57 participants with HFrEF (mean LVEF 30%) and 14 controls. In the HFrEF 
group, peak oxygen consumption was significantly reduced (19.6 (standard deviation 
(SD) ±7.6) versus (vs) 35.0 (±9.9) ml/kg/min; p <0.001), additionally there was a 
correlation between peak heart rate and heart rate rise with peak oxygen consumption 
(r=0.47, 0.59; p <0.001). However no difference was seen in peak oxygen 
consumption or exercise time between those with chronotropic incompetence (defined 
as peak heart rate <80% age predicted maximum; n=16) and those without 
chronotropic incompetence (Clark and Coats, 1995).  
 
This was further investigated by Witte et al. in a study comprising controls (n=9) and 
patients with HFrEF (n=11) undertaking submaximal exercise testing at set 
proportions of maximal previously identified workloads (15%, 25%, 50%). The 
workload/heart rate ratio during the peak tests was found to be lower in patients than 
control subjects. In addition, although a relationship between heart rate and workload 
for control subjects was found (r = 0.85; p <0.0001), no such relationship was found in 
patients with HFrEF (r= 0.003; p = 0.98). Despite a lower peak heart rate, patients with 
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HFrEF have a greater heart rate for a given workload during submaximal testing. The 
authors suggested that heart rate limitation is unlikely to be the cause of exercise 
intolerance in HFrEF patients (Witte, K. K. and Clark, 2009).  
 
Heart rate response to exercise was investigated in 237 HFrEF patients and 118 
controls, to establish the prevalence of chronotropic incompetence in patients with 
HFrEF and the effects of intrinsic or β-blocker induced chronotropic incompetence on 
exercise capacity (Witte, K. K. et al., 2006). The data demonstrated that patients taking 
-blockers had significantly lower peak heart rates and more chronotropic 
incompetence than those not taking -blockers, but that there was no overall 
difference in peak oxygen consumption despite a longer exercise time (498 vs 435 
seconds; p=0.02). This higher exercise time despite lower heart rate is especially 
interesting, since it implies either an improvement in metabolic efficiency with -







Figure 3.1: The relationship between heart rate rise and exercise capacity 
(Jamil et al., 2016) 
 
 
In a series of randomised, placebo-controlled, double-blind studies, seeking to clarify 
the role of heart rate on exercise capacity in HFrEF, Jamil et al. reported a weaker 
association between exercise capacity and heart rate rise in severe HFrEF compared 
to controls; increasing heart rate rise using rate-response pacing (versus fixed-rate 
pacing) in unselected patients with HFrEF did not improve peak exercise capacity; 
furthermore, acutely lowering resting heart rate and peak heart rate using ivabradine 
did not result in worsening exercise capacity (Figure 3.1) (Jamil et al., 2016). These 
studies set the scene for an exploration of the mechanisms of a failure of patients with 
HFrEF to benefit from higher heart rates. 
 
3.5 Force-frequency relationship 
The depolarisation-rate dependent mechanism, where increases in heart rate lead to 
increases in the force of contraction, is variably known as the Bowditch effect, Treppe 
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phenomenon, or the force-frequency relationship (Bowditch, 1871). This frequency-
dependent up-regulation of cardiac contractility is rapid and intrinsic to the myocardial 
cell, with no external involvement from neuronal or hormonal controls.  
 
Cardiac contractility is the intrinsic capacity of cardiomyocytes to generate contractile 
force at a specific heart rate, independent of preload and afterload. Whilst the force-
frequency relationship in the assessment of contractility has been used in studies of 
isolated strips of failing myocardium, and widely in animal models of heart failure, there 
has been no translation of the approach to clinical practice. To assess the cardiac 
contractility in vivo presents challenges that I shall outline, and although clinical 
research studies have to some extent overcome these technical issues (Bombardini, 
T et al., 2013), the lack of clinical utility has been a key limitation to moving the 
assessment to the clinical arena.  
 
Formative work on the force-frequency relationship was descriptive. It was not until 
the latter decades of the 20th century that data on the cellular physiology of the force-
frequency relationship arose to enhance our understanding of this important, intrinsic 
biological mechanism.    
 
3.5.1 Discovery of the force-frequency relationship 
The first account of the force-frequency relationship, was made in 1871 by Henry 
Pickering Bowditch (1840-1911), an American soldier, physician, physiologist, and 
dean of the Harvard Medical School (Bowditch, 1871; Bruce Fye, 1994). Known for 
his research on cardiac contractility and nerve conduction, Bowditch’s work on the 
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force-frequency relationship and the ‘all or nothing’ principle of cardiac muscle 
contraction, are his most recognised within cardiovascular physiology.  
 
Bowditch described that the contractile force of the frog heart increases as the heart 
rate rises (Janssen and Periasamy, 2007). Pioneering experiments were designed to 
study how the excitation process of the heart fatigues and recovers. By filling the 
isolated ventricle of an excised frog heart with fluids of variable composition, the 
strength of contraction could be determined by the degree of fluid movement in a 
manometer following ventricular contraction induced by external electrical stimulation.  
 
Using this laboratory arrangement, Bowditch discovered that: a sufficient degree of 
stimulus strength is required to elicit a cardiac contraction, a prolonged period of 
stimulation and subsequent cardiac contraction reduces cardiac contractility (which 
Bowditch described as fatigue), and that pressure increased as the interval between 
stimuli decreased, but that at the shortest intervals pressure again declined. It was this 
last discovery that Bowditch named the ‘staircase’ or ‘Treppe’ phenomenon, writing:   
 
‘The interval between a contraction of the heart and the preceding beat is 
of such importance for the strength of contractility that the study of this 
effect is a prime necessity’  (Bowditch, 1871). 
 
In the early 1900s, Robert S. Woodworth (1869-1962), was able to identify that the 
Treppe phenomenon existed in mammalian as well as amphibian hearts. Woodworth 
also explored the force of cardiac contraction following different stimulation periods. 
He was able to demonstrate that the force of contraction diminished following a 
66 
 
shortened interval after the previous contraction (simulating an extra-systole), and that 
the force of the contraction following this was increased (post-extra-systolic 
potentiation). Subsequently, many investigations using isolated strips of myocardium 
have been published, but with no real understanding of the cellular physiology 
underpinning the force-frequency relationship (Cattell and Gold, 1938; Koch-Weser 
and Blinks, 1963). 
 
The first half of the 20th century saw cardiovascular research being dominated by 
Starling’s law of the heart. However, the realisation that cardiac rhythm and cardiac 
contraction influence each other through electro-mechanical coupling allowed 
Bowditch’s findings to be re-discovered. Prompted, in part, by the development of 
cardiac pacemaker systems to alter heart rhythms in the treatment of cardiac 
arrhythmias, renewed interest was shown in the relationship between interval and 
developed force (Noble, 1992). 
 
3.5.2 Development of the assessment of cardiac contractility 
Efforts have been made to transfer the experimental methods of assessing contractility 
in isolated strips of myocardium, to the intact beating heart by measuring 
pressure/volume loops in animal models (Suga et al., 1973; Suga and Sagawa, 1974). 
The results of a study carried out in humans were found to be consistent with animal 
studies, and supported the potential usefulness of the end-systolic pressure/volume 
relationship as an index of myocardial contractile state in man (Grossman, W et al., 
1977). This highlighted the need for further research, especially investigating non-
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invasive methods to assess cardiac contractility using the force-frequency 
relationship.  
 
In animal models, it has been shown that LV contractility could be indexed by end-
systolic elastance (Kono et al., 1984; Chantler et al., 2008). End-systolic elastance is 
the slope of the end-systolic pressure volume relationship (ESPVR) and has also been 
measured in humans from pressure-volume loops acquired during cardiac 
catheterisation, as an index for assessing cardiac contractility at rest in the intact 
circulation (Shishido et al., 2000; Bombardini, T., 2005a). However, the invasive nature 
and the technical difficulties involved in measuring this index prevent its widespread 
clinical acceptance (Shishido et al., 2000) (Chantler et al., 2008).   
 
A more practical non-invasive evaluation of the LV end-systolic pressure/volume ratio 
was first proposed by Sagawa and Suga, who reported that LV dimensions measured 
via ultrasound could be substituted for LV volume. They also suggested that peak 
carotid pressure could be substituted for end-systolic LV pressure (Sagawa et al., 
1977). Further work has demonstrated that systolic blood pressure obtained using a 
manual sphygmomanometer and a standard stethoscope can be used as a surrogate 
for LV end-systolic pressure, due to their close approximation (Slutsky et al., 1980; 
Ginzton et al., 1984; Bombardini, T. et al., 2003)  
 
Assessment of LV contractility requires: the measurement of left ventricular end-
systolic pressure (LVESP), a measure of LV end-systolic volume (LVESV) indexed for 
body surface area (LVESVi), and a method by which to increase the heart rate in a 
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stepwise manner. Dividing LVESP by LVESVi gives a surrogate of LV contractility, 
which has been validated against invasive methods (Bombardini, T. et al., 2003; 
Bombardini, T., 2005a). 
 
The force-frequency relationship is defined as: up-sloping (or positive) when peak end-
systolic pressure volume ratio is higher than the baseline and intermediate values, 
biphasic when there is an initial up-sloping followed by a down-sloping and peak end-
systolic pressure volume ratio is lower than the intermediate values, and flat or 
negative when peak end-systolic pressure volume ratio is equal to or lower than the 












Whilst the molecular processes responsible for the regulation of cardiac force with an 
increase in heart rate are not completely understood, it is generally accepted that 
changes in calcium handling play a crucial role in the force-frequency relationship 
(Janssen and Periasamy, 2007; Balcazar et al., 2018).  
 
In the 1960s it became apparent that movement of calcium ions (Ca2+) on a cellular 
level was related to the change in force of cardiac contraction produced by varying 
contraction intervals, and that it was possible that the amount of Ca2+ released to 
activate contraction may relate to the degree of contraction (Noble, 1992). Evidence 
for this hypothesis was made available through work on radioactive Ca2+ myocardial 
cellular entry and exit, which demonstrated a rise in Ca2+ entry and exit during 
episodes of increased inotropy, such as an increase in stimulus frequency (Winegrad 
and Shanes, 1962; Langer and Brady, 1963; Noble, 1992). The importance of Ca2+ in 
the force of cardiac contraction was confirmed by the work of Allen and Blinks in 1978 
with the first measurements of intracellular Ca2+ concentration. Allen and Blinks were 
able to show that the main inotropic interventions of: increased stimulation frequency, 
cardiac glycosides, catecholamines, and raised extra-cellular calcium concentration, 
all lead to an increase in systolic Ca2+ (Allen and Blinks, 1978). 
 
Hence increased cardiac contractility depends upon increased concentrations of Ca2+ 
in cardiomyocytes (Eisner et al., 2017). In HFrEF there are several abnormalities of 
Ca2+ handling which lead, especially at higher heart rates, to: decreased Ca2+ 
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sensitivity, depletion of Ca2+ stores, and delayed diastolic Ca2+ removal, which 
contribute to the attenuated force-frequency relationship (Mulieri et al., 1992; Mishra 
et al., 2002). 
 
Consequently, cardiomyocytes from HFrEF patients display a flatter slope in response 
to more rapid stimulation, and the peak of the curve (optimal cardiac contractility) 
occurs at lower frequencies than in non-HFrEF patients. This may contribute to 
functional limitation, and moreover has the potential to lead to further progression of 
LV systolic dysfunction, and consequently further progression of HFrEF.  
 
3.5.4 Clinical relevance in HFrEF 
In the normal heart, cardiac output is positively coupled to the power of LV contractility 
by the force-frequency relationship (Bowditch, 1871), such that, as heart rate 
increases (and diastolic filling time shortens), cardiac output and LV contractility 
increase. Thus, a positive force-frequency relationship prevents a reduction in stroke 
volume due to reduced filling at higher heart rates, which would significantly impair 
cardiac efficiency. In health, the force-frequency relationship can contribute up to 40% 
of the increase in cardiac output experienced during exercise (Higginbotham et al., 
1986).  
 
However, in HFrEF, this critical physiological response is attenuated (Cotton et al., 
2001). It has been suggested that the degree of abnormality of the force-frequency 
relationship may be a biomarker of progression or regression of HFrEF (Cotton et al., 
2001; Palomeque et al., 2004; Bondke et al., 2010). Furthermore, there is a decrease 
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in LV contractility above a certain heart rate, known as the critical heart rate. Whilst 
the heart rate might increase beyond the critical heart rate, cardiac contractility beyond 
this point decreases (Figure 3.3).  
 
 
Figure 3.3: Force-frequency curve showing peak contractility, FFR slope, and 
critical heart rate 
 
Therefore, the critical heart rate, as derived from the force-frequency relationship 
assessment, determines the heart rate at which cardiac contractility is optimal. 
  
Subsequently, a fundamental feature in patients with HFrEF is an impaired force-
frequency relationship, such that ‘maximal’ heart rate is not synonymous with ‘optimal’ 
heart rate. If the critical heart rate at which LV contractility begins to decline is at the 
level of resting heart rates, the response to increases in heart rate may be ‘negative’ 




Furthermore, any step over this ‘critical heart rate’ may contribute to functional 
limitation, and moreover has the potential to lead to further progression of the clinical 
syndrome of HFrEF. 
 
3.6 Summary  
Exercise intolerance is a key finding in patients with HFrEF. This is considered to be 
due to reduced cardiac output at rest, and impaired increase in cardiac output with 
exercise, resulting in lower oxygen consumption, exercise intolerance and fatigue. 
Cardiac output is dependent on heart rate and stroke volume. In patients with HFrEF, 
the heart rate rise during exercise is less than in controls doing the same proportion 
of peak exercise, known as chronotropic incompetence. Rate-response cardiac pacing 
was developed with the aim of improving exercise tolerance in patients with 
chronotropic incompetence. However, the use of rate-response pacing to increase 
peak heart rate in patients with HFrEF is associated with a worse prognosis and 
cardiac function (Nägele, H et al., 2008). Furthermore, heart rate limiting agents 
improve prognosis in HFrEF (Lechat et al., 2001; Poole-Wilson et al., 2003a).  
 
The literature therefore highlights a critical conflict. A higher heart rate in HFrEF is 
associated with reduced cardiac efficiency and increased myocardial oxygen demand. 
Lowering the resting heart rate to improve mortality worsens heart rate rise and 
reduces the peak heart rate achieved. On the other hand, whilst using a pacemaker 
to treat chronotropic incompetence or reducing the dose of heart rate lowering 
medications will improve heart rate rise, this however, has a detrimental effect on 
overall survival and mortality. Moreover, although chronotropic incompetence in 
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HFrEF is associated with reduced functional capacity, correcting this in patients with 
HFrEF does not result in an improvement in oxygen consumption, symptoms, or 
exercise time.  
 
Finally, the force-frequency relationship in HFrEF, linking heart rate, cardiac output, 
and cardiac contractility, is attenuated, such that cardiac contractility does not increase 
normally with increases in heart rate.  
 
These observations lead to the conclusion that chronotropic incompetence does not 
cause the characteristic exercise intolerance seen in HFrEF, and the contrary concept 
that chronotropic incompetence could be a cardio-protective ‘chronotropic adaptation’. 
Hence the question as to what the target heart rate should be, remains. 
 
3.7 Conclusion 
The focus of this thesis is to explore the relationship between heart rate and cardiac 
contractility, and the influence of HFrEF on this relationship. It will investigate the 
hypothesis that conventional rate-response, or rate-adaptive, algorithms do not take 
into account the altered force-frequency relationship in HFrEF, and that there may be 
a lower optimal heart rate range for cardiac contractility in HFrEF patients than in 
controls, and will present a personalised method of assessing this, and the clinical 




Chapter 4 : Echocardiography 
 
The heart, a dynamic cyclic pump, can respond to different loading conditions. Since 
it can respond and adapt to varying blood volumes and varying degrees of flow 
resistance, the ability to measure the changing characteristics and functional 
parameters of cardiac muscle is clinically relevant for assessing heart failure. 
Considered the most important advance in diagnostic cardiology since the discovery 
of X-rays by Röntgen (Roelandt, 2000), this chapter will explore the cardiovascular 
imaging modality of cardiac ultrasound. 
 
4.1 Introduction 
Transthoracic echocardiography, also known as cardiac ultrasound, has become an 
integral part of modern cardiology, providing information about the anatomy and 
physiology of the heart and great vessels, and is the most frequently used method for 
cardiac functional and structural assessment in patients with heart failure (Ponikowski 
et al., 2016; Omar et al., 2016). Echocardiography variables (for example, dimensions 
and ejection fraction) are incorporated into international guidelines as components of 
decision making in the management of heart failure, valve disease and arrhythmias. 
The critical benefits of echocardiography are that it is non-invasive, reproducible, 






4.2 History of echocardiography 
The origin of ultrasound technology dates back to the discovery of the piezoelectric 
effect by Pierre and Jacque Curie in 1880. The use of ultrasound in medicine began 
in the 1940s, and specifically in cardiology, in the 1950s (Meyer, 2004). 
 
In 1953, Hellmuth Hertz and Inge Edler modified a sonar device that they had 
borrowed from a local shipyard (Fraser, 2001) (Figure 4.1).  
 
 





They used their modified device to record images from Hertz’s own heart, 
demonstrating the potential for ultrasound applications in cardiology. However, it was 
not until the early 1960s that this potential became more widely recognised (Houghton, 
2013).   
 
Work by Harvey Feigenbaum stimulated an interest in using ultrasound to examine 
the left ventricle (LV). This prompted the development of techniques for measuring LV 
wall thickness, LV internal dimension, and LV stroke volume (Edler and Lindström, 
2004). Importantly, Feigenbaum recognised the relevance of training people 
(Feigenbaum, 2008), including non-physicians, in echocardiography (Figure 4.2). 
Indeed, the widespread use of echocardiography highlighted and reinforced the 
necessity for professional regulation, along with the use of published national and 
international guidelines to support evidence-based practice, and provide clear 
standards for performing echocardiograms (Wharton et al., 2015; Galderisi et al., 





Figure 4.2: Harvey Feigenbaum (right) with an early M-Mode echocardiographic 
system, during his first training course  
(Meyer, 2004) 
 
Collaborations between engineers and physicians in the 1970s, resulted in the 
development of two‐dimensional (2D) echocardiography (Feigenbaum, 1972), 
Doppler echocardiography (Goldberg, 1985), colour flow Doppler echocardiography 
(Kisslo, 1988) (although this was not widely used until the 1980s), and trans-
oesophageal echocardiography (Meyer, 2004). 
 
4.3 The cardiac cycle 
The cardiac cycle describes the events that occur during each heartbeat, and 
echocardiography allows a visualisation of those events, allowing correlation of 
anatomic structures with their physiological functions (Brunner et al., 1995). A cardiac 
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cycle comprises four phases (Figure 4.3). Whilst the phases apply to both left and right 
heart, this brief review will concentrate on the left heart. Phases one and two 




Figure 4.3: The Wiggers diagram 
 
4.3.1 Isovolumic contraction 
Isovolumic contraction begins with the closure of the mitral valve as the LV pressure 
rises at the start of ventricular systole. After mitral valve closure, the LV pressure 





4.3.2 Ventricular ejection 
The aortic valve opens when LV pressure exceeds aortic pressure, and blood is 
ejected through the aortic valve into the aorta. LV volume falls as the blood is ejected 
from the LV, but the pressure continues to increase until it peaks and then starts to 
decrease. 
 
4.3.3 Isovolumic relaxation 
The aortic valve closes due to falling LV pressure and initially the LV volume remains 
the same, until LV pressure falls below the left atrial (LA) pressure. Once pressure in 
the LV is lower than that in the LA, the mitral valve opens. 
 
4.3.4 Ventricular filling 
Ventricular filling occurs whilst the mitral valve is open and LA pressure remains higher 
than LV pressure, due to LA contraction and continuing LV relaxation. This phase ends 
when the mitral valve closes at the start of ventricular systole (when LV pressure rises 
above that of the LA). 
 
4.4 Principles of echocardiography 
Echocardiography provides tomographic moving images of cardiac structures and can 
also interrogate blood flow. Multiple imaging planes enable a comprehensive 




The term ultrasound describes a mechanical wave, similar in character to audible 
sound, but at frequencies greater than 20 kilohertz (kHz) (Duck, 2000). Ultrasound 
used for echocardiography is usually within the frequency range 1.5-7 megahertz 
(MHz). The velocity at which sound travels through a medium depends on the density 
and elastic properties of that medium. The average propagation velocity for the heart 
is 1,540 metres per second (m/s). Ultrasound pulses emitted from the transducer travel 
through body tissues and as the beam reaches a boundary between tissues with 
different acoustic impedances, a proportion of energy is reflected back towards the 
transducer. Complex analyses of the ultrasound waves that are reflected and 
backscattered from the patient’s body, generate a display of cardiac images and flow 
data on the echocardiogram monitor. 
 
4.4.1 Echocardiography imaging modalities 
4.4.1.1 A-mode imaging 
Early echocardiographic recordings were made using amplitude mode (A-mode), 
which recorded the amplitude of the reflected ultrasound (Figure 4.4). The amplitude 
of the spike is determined by the intensity of the reflected signal, the distance between 









4.4.1.2 B-mode imaging 
Brightness mode (B-mode) represents the amplitude of the reflected signal by the 
brightness of a dot, with the distance between dots corresponding with the distance of 
the reflected signal from the transducer. 
 
4.4.1.3 M-mode imaging 
The introduction of time as a second dimension to B-mode imaging, created motion 
mode (M-mode) imaging which records motion, transmitted and received along just 
one scan line, by positioning an on-screen cursor across the region of interest. This 
produces a highly sensitive display of movement along the vertical axis of the display 
screen, against time along the horizontal axis (Figure 4.5). Therefore this mode of 
scanning, with its high sampling rate, is very useful for assessing the rapid movement 
of valve leaflets, measuring cardiac dimensions, and allows accurate timing of events 





Figure 4.5: M-mode imaging, showing the aortic valve 
 
4.4.1.4 Two-dimensional echocardiography 
The data obtained from electronically scanning the ultrasound beam through an arc, 
generates a real-time 2D echocardiographic image (Figure 4.6). This allows more 
information than that produced by M-mode, about the geometry of the heart, and 





Figure 4.6: 2D imaging, showing apical 4-chamber view 
 
Although standard ultrasound imaging is based on reflection of the fundamental 
transmitted frequency from tissue interfaces, tissue harmonic imaging is based on the 
harmonic frequency energy. The properties of harmonic frequencies (including 
increased signal strength with depth of propagation), result in improved LV endocardial 
definition, and thus more accurate endocardial border tracing for measurement of LV 
volumes (Otto, 2013). However, because lateral resolution is reduced through 
harmonic imaging, objects may appear thicker than with fundamental frequency 
imaging. 
 
4.4.1.5 Doppler echocardiography 
The Doppler effect was first described by the Austrian physicist Christian Döppler 
(1803-1853) in 1842 (Roguin, 2002) (Figure 4.7). It describes the apparent change in 
frequency of a wave when there is relative motion between the wave source and the 
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observer. The perceived frequency is higher, in comparison to the emitted frequency, 
when the wave source is moving towards the observer, and lower when moving away 
from the observer. The perceived change in frequency is referred to as a frequency 
shift. When applied to the heart, a frequency shift is induced when a sound wave 
strikes moving red blood cells. The transmitted frequency (transducer frequency) is 
compared with the frequencies within the returning signal to quantify the frequency 
shifts produced by the moving red blood cells. The velocity and direction of blood flow 
can be calculated by determining the frequency shifts. 
 
 
Figure 4.7: Photographic portrait of Christian Döppler 
 
 
Colour flow Doppler imaging is a method of estimating and displaying a ‘map’ of the 
mean velocity of blood flow. The velocities are assigned a colour (by convention blood 
flow towards the transducer = red; blood flow away from the transducer = blue), which 
is determined by the direction of blood flow in relation to the ultrasound transducer and 
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the relative velocity of flow. The colour map is superimposed on the 2D image, 
producing a real-time representation of the spatial extent of blood flow, generating a 
2D image of intracardiac blood flow (Figure 4.8). The relative velocities of blood flow 
are displayed as differing hues. 
 
 
Figure 4.8: Colour Doppler imaging, showing mitral regurgitation 
 
In addition to measuring the motion of blood cells, the Doppler principle can also be 
applied to myocardial tissue motion in the form of tissue Doppler, providing information 
on myocardial mechanics. It can be displayed as colour Doppler images to show 
myocardial tissue motion, or as spectral pulsed-wave Doppler traces when assessing 




Figure 4.9: Pulsed-wave trace of lateral mitral annulus obtained with tissue 
Doppler imaging 
 
4.4.1.6 Three-dimensional echocardiography 
Three-dimensional (3D) echocardiographic imaging is based on the same principles 
as 2D imaging but uses a more complex full volume acquisition and display of data. 
Whilst a 2D transducer typically contains 128 elements arranged in a linear fashion 
and creates a tomographic slice of the heart, a 3D matrix array transducer contains 
almost 3,000 elements arranged in a rectangular grid which produces a pyramidal 
volume dataset (Houghton, 2013).  Imaging in 3D offers several important advantages 
over 2D imaging. It measures in a third dimension, it does not rely on plane positioning, 
and does not require geometric modelling or assumptions about chamber shape. 
However, 3D echocardiography still depends on good image quality, and has lower 





4.5 Measurement of the variables used in this thesis 
The decrease in cardiac contractility associated with heart failure with reduced ejection 
fraction (HFrEF) results in a decrease in stroke volume and an increase in LV volumes. 
According to the law of Laplace, the increase in radius of the dilated, failing heart, 
reduces the pressure generated by a given contractile force. Thus, an important 
therapeutic aim in HFrEF management is to reduce cardiac distention and improve 
cardiac contractility. Therefore, measuring LV dimensions and volumes, using 
echocardiography, before and after interventions, such as those explored within this 
thesis, can be used in determining the efficacy of those interventions. 
 
LV ejection fraction (LVEF) is a function of stroke volume (SV) and LV end-diastolic 
volume (LVEDV): 
 
LVEF = SV/LVEDV x 100 
 
The role of stroke volume in the force-frequency relationship thus makes LVEF a 
relevant variable to measure in the studies presented within this thesis. LV volumes 
are also relevant parameters to measure since the end-systolic volume is required to 
calculate LV contractility, and end-diastolic volume is a measure of the size of the LV. 
 
LVEF is the most validated and commonly used echocardiographic measure of 
systolic function. Playing a key role in the management of heart failure, LVEF helps to 
identify patients who are likely to respond to therapy for HFrEF, in addition to 
88 
 
identifying those who will benefit from cardiac implantable electronic device therapy 
(Marwick, 2015).   
 
Although the terminology used to define HFrEF is centred on the measurements of 
LVEF, it should be remembered that the degree of cardiac dysfunction relates poorly 
to symptoms (Coats, 1996; Witte, K. K. et al., 2004).  
 
Furthermore, the strict application of cut-offs in individual patients can potentially lead 
to misclassification (Lam, C.S.P. et al., 2020). However, since clinical trials forming 
the basis of evidence-based treatment recommendations are predicted on LVEF cut-
offs, LVEF remains a key factor in guiding treatment decisions in clinical practice 
(Klaeboe and Edvardsen, 2019). Moreover, since other methods of definition currently 
lack clarity, and effective proven therapies are only available for the treatment of 
systolic heart failure, the classification of heart failure based upon LV function remains 
(Ponikowski et al., 2016). 
 
Internal dimensions and volumes are the most frequently used variables to quantify 
LV cavity size (Ciampi and Villari, 2007). Measurements are taken at specific points 
during the cardiac cycle, usually end-diastole and end-systole, determined by the 
electrocardiogram (ECG). The measured dimensions can then be used in equations 
to derive parameters of LV function (Harkness et al., 2020).  
 
LV internal cavity and wall thickness dimensions should be measured in the 
parasternal long-axis view, with measurements taken just distal to the mitral valve 
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leaflet tips (Wharton et al., 2015). This can be achieved using 2D guided M-mode 
(Figure 4.10), or using digital callipers in 2D imaging (Figure 4.11).  
 
 





Figure 4.11: LV end-diastolic dimension using digital callipers 
 
Volumetric measurements require optimal endocardial definition, and are made by 
manually tracing the endocardial border of the LV, excluding the papillary muscles 
(Lang et al., 2006). The most common and robust method for assessing LV volumes 
is the modified Simpson’s biplane method of discs, which combines two orthogonal 
views from the apical two chamber view and the apical four chamber view (Lang et al., 
2006) (Figure 4.12). The LV cavity is divided into a number of slices, or discs, of known 
thickness. Volume is then calculated by adding together the volumes of the individual 
slices. This process makes fewer assumptions about LV geometry, allowing an 





               
               
Figure 4.12: Simpson’s biplane method of measuring LV volumes and LV 
ejection fraction 
(A) Apical four-chamber LV end-diastolic volume; (B) Apical four-chamber LV 
end-systolic volume; (C) Apical two-chamber LV end-diastolic volume; (D) 
Apical two-chamber LV end-systolic volume. 
 
 
4.6 Other non-invasive cardiac imaging modalities 
4.6.1 Cardiac magnetic resonance imaging 
Magnetic resonance imaging (MRI) uses a powerful magnetic field, radio waves and 
computer technology to non-invasively produce high resolution images. An application 
of MRI is to image the structures within and around the heart (cardiac magnetic 
resonance imaging (CMR)). Like ultrasound, it does not use ionising radiation and is 




CMR is considered as the gold standard for measuring LV volumes and ejection 
fraction (Hundley et al., 2010), because it is able to image the whole heart in multiple 
planes and provides good endocardial definition. The important differences in the 
accuracy of CMR when compared with 2D echocardiographic measurements of LV 
volume and ejection fraction, are based on the fact that CMR is a volumetric technique 
with high contrast and spatial resolution (Hudsmith et al., 2005).  
 
Although it has been shown that CMR offers a complementary role to 
echocardiography in evaluating the underlying aetiology, and is considered the gold 
standard for assessment of LV volumes and ejection fraction (Peterzan et al., 2016), 
there are some restrictions. The strength of the magnet may affect devices or implants, 
for example pacemaker devices. Many devices are now MRI conditional, but there 
may be problems with older devices. Quickly changing magnetic fields may generate 
electrical currents in electrically conductive devices with the potential risk of inducing 
arrhythmia, or inhibiting therapy, in patients with pacemaker electrodes in place. 
Furthermore, metallic devices, such as pacemaker systems, may induce excessive 
local tissue heating, which in the case of cardiac devices could lead to temporary or 
permanent loss of capture (Levine et al., 2007). 
 
Claustrophobia may also be a limiting factor in a patient undergoing a CMR, as may 
extreme obesity such that the patient cannot fit into the scanner. A limiting factor more 
pertinent to HFrEF is the inability to perform a CMR on a patient who is too breathless 




Additionally, the gadolinium contrast medium used in some CMR investigations is 
contraindicated in people with estimated creatinine clearances <30 millilitres per 
minute (ml/min). Gadolinium contrast agent may cause nephrogenic systemic fibrosis, 
a rare but serious reaction, in patients with a history of kidney disease; renal 
dysfunction is relatively common in patients with heart failure (Peterzan et al., 2016). 
There is a very small risk of an allergic reaction in all patients who receive a contrast 
medium. 
 
The cost, limited availability, and its incompatibility with metallic devices, for example 
pacemakers, make CMR impractical for widespread clinical use, and even as a 
research tool its application is limited due to cost, contraindications, generalisability, 
and patient acceptance of repeated scans. 
 
4.6.2 Radionuclide imaging 
The main clinical application for radionuclide imaging in heart failure is myocardial 
perfusion imaging for the assessment of ischaemia and viability for the diagnostic and 
prognostic workup of patients with coronary artery disease and heart failure (Boogers 
et al., 2011). A disadvantage of radionuclide imaging is the exposure to radiation. The 
radiation exposure varies between 10-18 milliSievert (mSv) depending on the 
radioactive tracer used. 10 mSvs is equivalent to 5 years of natural background 
radiation (Underwood et al., 2004). Furthermore, this method of imaging cannot 
perform real-time imaging at the rate required for the study protocols within this thesis, 




4.6.3 Computed tomography 
Whilst cardiac computed tomography (CT) is not considered a technique of choice for 
the evaluation of cardiac function, it is capable of measuring LV volumes and function 
for specific indications (Aziz et al., 2019). This is particularly so when for example, 
suboptimal echocardiographic windows or issues with CMR (claustrophobia, non-MRI 
conditional pacemaker device), mean that an alternative imaging modality is required 
to obtain the relevant information.  
 
4.7 Study related echo strengths and limitations 
Transthoracic echocardiography is widely accepted as being able to assess cardiac 
structure and function (Pastore et al., 2020), and furthermore is recognised as the first 
line imaging modality in heart failure (Aziz et al., 2019).  
 
Although echocardiography can be used with a high degree of accuracy for clinical 
decision making, knowledge of the strengths and limitations of this modality is critical 
for correct clinical diagnosis and patient management (Otto, 2013).  
 
4.7.1 Strengths 
The strengths of echocardiography include that it is widely available, portable, allows 
a comprehensive and immediate non-invasive assessment of cardiac anatomy and 
function, is relatively inexpensive, and does not use ionising radiation (Modin et al., 
2018). Furthermore, when carried out by appropriately trained and accredited staff, 
echocardiography is safe. Although echocardiography depends on interactions 
between ultrasonic energy and living tissues, with current ultrasound technology, 
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biological effects are unlikely to be caused directly by tissue heating (Duck, 2008). 
Moreover, there is no evidence of significant health risk from exposure to medical 
ultrasound for patients or clinical staff (Knuuti et al., 2014). 
 
4.7.2 Limitations 
Although it is generally accepted that echocardiography is able to assess cardiac 
structure and function (Pastore et al., 2020), there is evidence that it may be less 
accurate than other modalities (McGowan and Cleland, 2003), with the estimate of 
LVEF as a sequential test within individuals being constrained by limited test-retest 
(Marwick, 2003).  
 
Limitations in the accuracy of the measurements made during echocardiographic 
imaging may include suboptimal images, with body habitus influencing the technical 
ability to acquire good quality images (thus affecting reproducibility), insufficient 
training, and lack of operator experience.  
 
Bellenger et al., compared 2D echocardiography, radionuclide scanning and CMR, 
performed within four weeks, in patients with chronic stable heart failure. They 
reported mean LVEFs of 31 ± 5% with 2D echocardiography using modified Simpson’s 
biplane method; 24 ± 21% with radionuclide scanning; and 30 ± 9% with CMR. All 
mean LVEFs were significantly different from all other techniques (p <0.001), except 
for 2D echocardiography Simpson’s biplane method and CMR (p = 0.23). Wide levels 
of agreement were revealed with end-diastolic volume and end-systolic volume 
assessed by 2D echocardiography Simpson’s biplane method and CMR (52 ml to 216 
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and 11 ml to 188 respectively), despite good correlation (Bellenger et al., 2000). This 
suggests that, where available, CMR is the preferred option for volume and LVEF 
estimation in heart failure patients, because of its accuracy, reproducibility, and 
superior image quality.  
 
4.7.2.1 Reproducibility 
Good reproducibility, repeatability and reliability are essential in cardiac imaging. 
Reproducibility is defined as the variation in the same measurement made on the 
same subject in changing conditions, for example a different operator or time frame. 
Repeatability is the variation in repeat measurements made on the same subject in 
identical conditions, and reliability is the size of error between measurements (Bunting 
et al., 2019). 
 
Whilst 3D echocardiography has been shown to be more reproducible than 2D 
echocardiography (Omar et al., 2016), this modality was not available during the series 
of investigations within this thesis. However, to reduce, as far as possible, any under 
or overestimations in volumetric measurements, all images were acquired and 
reported by an experienced, accredited clinical scientist. Furthermore, intra-, and inter-
observer variability were assessed.  
 
The intraclass correlation coefficient (ICC) is used to determine the reliability and 
reproducibility of numeric measurements, reflecting the degree of correlation and 
agreement between measurements. Values between 0.75 and 1.00 suggesting 
excellent correlation (Cicchetti, 1994). ICC was used in this series of investigations to 
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assess variability within a single operator (intra-observer) and between different 
operators (inter-observer), for LVEF and volume measurements.  
 
4.7.2.2 Competency 
The accurate acquisition of good quality images is dependent upon the operator’s skill 
in firstly acquiring the images, and secondly making the correct measurements. This 
relies on good quality, on-axis imaging, with accurate endocardial border detection 
and tracing (Rösner et al., 2015). Appropriate training, accreditation and subsequent 
maintenance of skills and continuing professional development, play an essential role 
in the ability to accurately acquire and measure high quality echocardiographic 
images. Furthermore, the inter-observer variability of clinical echocardiographic 
measurements has been shown to improve with formalised training, (Donner et al., 
2018). 
 
Estimations of LVEF based on linear measurements of LV dimensions from M-mode 
and 2D imaging are not recommended, because of the likelihood of inaccurate 
geometric assumptions. It is recommended that assessment of LVEF and LV volumes 
should be made in 2D, by the modified Simpson’s method of discs, or alternatively, 
when available and feasible, by 3D based full volume acquisition (Lang et al., 2006; 
Wharton et al., 2015). However, this method can also be subject to errors due to 
foreshortening, poor endocardial definition, and assumptions about LV geometry, 
leading to underestimations in LV volumes. In order to acquire high quality images, 
acquisition should use optimal gain settings and breath-hold techniques to clearly 
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delineate endocardial borders, and to avoid artefact related to excess noise, rib or lung 
movements and translational motion of the heart (Rösner et al., 2015). 
 
4.8 Conclusion 
2D echocardiography was the imaging modality of choice for the investigations 
reported in this thesis because it is safe, easily accessible, repeatable, patient-friendly, 
and cost-effective. Whilst it is acknowledged that CMR provides high resolution 
images and reproducible estimates of LV volumes and ejection fraction, the 
participants recruited to the studies necessarily had pacemaker devices. Although 
many pacemaker devices are now MRI conditional, some of the older pacemaker 
generators, or their pacing electrodes are not MRI conditional. I have described the 
steps I took to ensure that image quality and reproducibility of estimates of LV volume 





Chapter 5 : Methodology 
 
My studies have all been designed in collaboration with patients; the primary outcomes 
of the interventional studies have therefore been patient-orientated, specifically walk 
distance, with secondary and exploratory outcomes of symptoms and quality of life. 
However, due to their mechanistic and prognostic relevance, I also included other 
more physiologically relevant endpoints from the cardiopulmonary exercise tests 
(CPET). Each study has included left ventricular (LV) function as a secondary 
outcome. The techniques employed for the echocardiographic outcomes of relevance 
have been outlined in chapter 4. This chapter will therefore focus on the exercise 
outcomes, their relevance to the syndrome of heart failure with reduced ejection 
fraction (HFrEF), and their assessment. 
 
5.1 Measuring exercise capacity 
The patient advisors in the Patient and Public Involvement and Engagement group at 
the Cardiovascular Clinical Research Facility (CVCRF) at Leeds Teaching Hospitals 
National Health Service (NHS) Trust (LTHT), have described that exercise capacity is 
the principle variable for patients. It is the primary reason for presentation, drives 
quality of life, and is a key marker of prognosis. Its value as an endpoint probably 
derives from the fact that it combines pulmonary gas exchange and cardiovascular 
performance in delivering oxygen (O2) to exercising skeletal muscle, and the 
exercising muscle to extract O2 from the blood (Krikler, 1992), and skeletal metabolism 




Exercise capacity is routinely assessed by measuring peak symptom-limited oxygen 
consumption during an incremental treadmill or cycle-based CPET. Considered as a 
gold standard, non-invasive, objective assessment of exercise capacity (Tran, 2018), 
CPET plays an important role in the diagnosis, quantification of symptoms, prognosis 
and assessment of therapeutic interventions in patients with HFrEF (Wright, D.J. and 
Tan, 1999). Beyond simply assessing maximal workload and exercise time, CPET 
allows the routine assessment of other variables, many of which are derived from the 
difference in O2 and carbon dioxide (CO2) concentration between inspired and expired 
air, ventilation, body weight and heart rate. The key derived variables include peak 
oxygen consumption, oxygen uptake at anaerobic threshold, and the slope relating 
ventilation rate to carbon dioxide production (VE/VCO2 slope). 
 
During a CPET, all gas exchange is measured breath-by-breath. During exercise, 
oxygen consumption (VO2) and carbon dioxide production (VCO2) at the mouth 
represent O2 utilisation and CO2 production at the musculoskeletal level.    
 
5.1.1 Exercise protocols 
Exercise is performed either on a powered treadmill or a stationary cycle. There are 
various incremental exercise protocols for both modes. Workload is increased on a 
treadmill by increasing the speed and slope, and on a cycle by increasing the 
resistance to wheel rotations. In both settings, the increases in workload can be 
gradual or stepwise, with the aim of a steady but consistent increase to allow adequate 
metabolic gas kinetic response, whilst maintaining an exercise time of between six 
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and twelve minutes, to maximize the accuracy of peak oxygen consumption 
measurements (Buchfuhrer et al., 1983). 
 
5.1.1.1 Familiarity with the protocol 
As many participants will be unfamiliar with the exercise modes and the equipment, a 
familiarisation test is recommended, especially when exploring the effect of an 
intervention in a longitudinal study. Although some have recommended several 
familiarisation tests to obtain reproducible results (Pinsky et al., 1990), performing 
multiple familiarisation tests is not practical. Furthermore, the greatest difference 
seems to occur between the first and second tests (ESC, 2001). Previous data have 
described that a familiarisation test or repeated CPET studies are not a training 
stimulus (Witte, K. K.  et al., 2003; Bensimhon et al., 2008). Hence this provided 
reassurance that one familiarisation test was sufficient for the studies within this thesis, 
and also that following this, any changes would be a consequence of the intervention. 
Moreover, the intervention studies described are placebo-controlled and double-blind. 
 
5.1.2 Measuring oxygen consumption 
‘Peak oxygen consumption’, or more appropriately ‘oxygen consumption at peak 
exercise’, describes the highest oxygen consumption achieved in patients with HFrEF 
(Albouaini et al., 2007). In this thesis I shall use the traditional term of peak oxygen 
consumption. Even this is a compromise to pragmatism of clinical practice. The true 
definition of ‘maximal oxygen uptake’ is represented as a plateauing of oxygen 
consumption measurements despite additional increases in workload. This 
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physiological maximum is rarely achieved in patients with HFrEF during a symptom-
limited test, due to symptoms and motivation. 
 
Peak oxygen consumption is a well-established measure of aerobic capacity and 
exercise tolerance, and is frequently used to assess HFrEF (Mancini et al., 1991; 
Bensimhon et al., 2008). The value is directly related to cardiac output and muscle 
blood flow at peak exercise based on the Fick equation (peak oxygen consumption = 
cardiac output x arteriovenous O2 concentration difference at the respiring skeletal 
muscles during sustained maximal effort). Total oxygen consumption is usually 
normalised to weight, to allow a  comparison between individuals of differing body 
mass, i.e. millilitres per kilogram per minute (ml/kg/min) (Wasserman et al., 2005).  
 
Patients with HFrEF typically have lower than age-predicted peak oxygen 
consumption, and an increase in the ventilatory response to exercise (VE/VCO2 slope), 
during incremental exercise testing with metabolic gas exchange analysis (Solal et al., 
1990; Clark et al., 1996; Wasserman et al., 1997). 
 
Importantly, peak oxygen consumption is poorly correlated with resting 
haemodynamic parameters such as left ventricular ejection fraction (LVEF), because 
haemodynamic parameters measured at rest do not accurately reflect cardiac 
pumping function during exercise (ESC, 2001). However, cardiac output is governed 
by heart rate and stroke volume, and during exertion, peak oxygen consumption 
correlates with maximal cardiac output (Miyamura and Honda, 1972). An insufficient 
cardiac output is the chief determinant of reduced aerobic capacity and reduced 
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exercise tolerance in asymptomatic and mildly symptomatic HFrEF patients 
(Harrington and Coats, 1997; ESC, 2001). On the other hand, those with moderate or 
severe HFrEF are limited by a combination of impaired cardiac output reserve, and 
abnormal peripheral mechanisms (ESC, 2001).  
 
5.1.3 Respiratory exchange ratio 
The respiratory exchange ratio (RER) is the ratio of VCO2 production to VO2 
consumption. It relates to a similar ratio of cellular respiration known as ‘RQ’. As 
exercise intensity increases, the ability of the skeletal muscles to respire 
predominantly aerobically is exceeded, and anaerobic metabolism becomes more 
dominant. The resultant increase in lactate production results in increasing VCO2 
production, in an attempt at buffering a reducing blood pH. Peak RER is used to 
determine adequate effort during a test, with ≥1.10 used as an indication of good 
volitional effort, and indicates that anaerobic threshold has been surpassed 
(Wasserman et al., 2005; Keteyian et al., 2016), rather than the test being terminated 
due to other limiting factors such as poor motivation or musculoskeletal pain.  
 
5.1.4 VE/VCO2 slope 
A key prognostic measure in HFrEF is the relationship between minute ventilation and 
carbon dioxide production (VE/VCO2 slope). HFrEF is associated with a greater amount 
of ventilation for a given carbon dioxide output, and therefore a degree of 
hyperventilation, for a given workload (Wasserman et al., 2005). The elevated VE/VCO2 
is inversely related to cardiac output at peak exercise (Reindl et al., 1998), and a 
steeper VE/VCO2 slope being related to adverse prognosis (Sun et al., 2002; Ingle et 
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al., 2007). The origin of the increased ventilation is unknown, and although it has been 
proposed to be due to a mismatch of ventilation to perfusion (Mezzani, 2017), it is 
much more likely to be due to a combination of inputs including heightened signals 
from exercising muscle (Clark et al., 1996). 
 
5.1.5 Anaerobic threshold 
The anaerobic threshold is the point at which the body’s capacity for exercise driven 
by aerobic metabolism is surpassed. Further increases in work are therefore largely 
facilitated by anaerobic metabolism, leading to a steeper increase in CO2 output for a 
given O2 consumption. The inflection point is frequently given the term ‘anaerobic 
threshold’. From this point onwards, exercise can no longer continue in a steady state 
and, will eventually, have to cease.   
 
From a clinical perspective, the anaerobic threshold is a recognised measure for 
submaximal exercise capacity and can be used to assess the functional benefits of a 
given therapy based on its correlation to activities of daily living (Wilmore et al., 1998). 
In HFrEF patients, anaerobic threshold tends to occur at around 70% of peak oxygen 
consumption, which is lower than in those without HFrEF (Shimizu et al., 1991; ESC, 
2001). Increasing the anaerobic threshold to allow reasonable exercise to continue 
without accumulation of lactic acid or other products of anaerobic metabolism, is a key 
outcome of exercise interventions, since it determines symptoms, repeatability of 





5.2 Measuring left ventricular contractility 
Cardiac contractility is the intrinsic capacity of cardiomyocytes to generate contractile 
force at a specific heart rate, independent of preload and afterload. Therefore, 
assessment of the force-frequency relationship in vivo should ideally occur 
independently of loading. 
 
5.2.1 Assessing the force-frequency relationship 
To be of relevance to clinical care, the force-frequency relationship must be examined 
in a reproducible way in vivo, requiring a means to adjust heart rate without affecting 
other haemodynamic variables, and a method of measuring LV contractility.  
 
Assessment of LV contractility requires: the measurement of LV end-systolic pressure 
(LVESP), a measure of LV end-systolic volume (LVESV) indexed for body surface 
area (LVESVi), and a method by which to increase the heart rate in a stepwise manner. 
Dividing LVESP by LVESVi gives a surrogate of LV contractility, which has been 
validated against invasive methods (Bombardini, T. et al., 2003; Bombardini, T., 
2005a). 
 
Most of the investigations into the force-frequency relationship have been carried out 
ex vivo in myocardial strips, either from explanted hearts during transplantation or from 
biopsy material.  (Mulieri et al., 1992; Bondke et al., 2010). Moreover, many have been 
conducted at room temperature, such that the results do not necessarily reflect the 





5.2.2 Invasive assessment of the force-frequency relationship 
Although used widely in animal studies, measuring end-systolic elastance for 
increasing heart rates is not practical in the clinical setting due to the complexities of 
using a temporary pacing electrode to increase the heart rate, alongside the catheters 
for measuring the pressure volume relationship. Conductance catheters have been 
used for in vivo measurements of pressure-volume loops to assess cardiac 
contractility. Whilst this approach may be accurate and robust, and can be useful to 
confirm the findings of non-invasive testing (Cotton et al., 2001), it is invasive, complex 
and technically demanding, and furthermore exposes the patient to contrast, radiation 
and infection (Bombardini, T. et al., 2003), and therefore rarely used in clinical practice. 
 
5.2.3 Non-invasive assessment of force-frequency relationship 
Scintigraphy has been proposed as a non-invasive method, offering a photographic 
(rest-peak stress) assessment of LV contractility. However, only assessing the rest 
and peak sections of the force-frequency relationship means that the dynamic 
variation at the intermediate frequencies is not measured, such that peak cardiac 
contractility and peak heart rate may not be correctly recorded. Furthermore, 
scintigraphy exposes the patient to ionising radiation. 
 
Echocardiography is an appropriate and repeatable method of non-invasively 
measuring LV contractility in vivo. Via this modality, LV contractility can be estimated 




The LV systolic volume is measured using 2D images, with cuff systolic blood pressure 
(SBP) used as a surrogate for end-systolic pressure. This measure of LV contractility 
(SBP/LVESVi) has been validated against invasive methods (Bombardini, T. et al., 
2003).   
 
A limitation of this method is in the use of the systolic cuff pressure as a surrogate for 
end-systolic pressure in the LV contractility equation. Non-invasive measurement of 
pressure may lead to an overestimation of LV pressure since the brachial arterial 
pressure reflects an amplified LV pressure wave secondary to the rheological 
properties of the arterial tree (Bombardini, T. et al., 2007). However, it has been shown 
that there is a tight relationship between peak and end-systolic pressure, such that 
any error would be systematically distributed along the whole force-frequency 
relationship curve, as long as the heart rate rise is not due to an agent with 
vasoconstrictive properties (Slutsky et al., 1980). Furthermore, the peak systolic 
pressure / end-systolic volume ratio is a reproducible method of assessing LV 
performance during exercise (Mehmel et al., 1981). 
 
Bombardini and colleagues have demonstrated the feasibility of a non-invasive 
estimation of the force-frequency relationship during stress echocardiography, using 
the patient’s permanent pacemaker to increase the heart rate. Their work has allowed 
them to conclude that, theoretically, assessing global contractility in this way could be 
of use in the identification of limited contractile reserve and latent global LV dysfunction 




Cardiac contractility can also be estimated using tissue Doppler velocities to measure 
myocardial acceleration during isovolumic contraction (Vogel et al., 2003). This 
method also relates to invasive data and appears independent of preload and afterload 
(Dalsgaard et al., 2007).  
 
Cardiac contractility has also been assessed using temporary pacing and tissue 
Doppler imaging, in a study comprising 11 children undergoing cardiac surgery. The 
aim was to investigate changes in the force-frequency relationship in the early post-
operative period in selected groups of children undergoing cardio-pulmonary bypass 
and surgical repair of congenital heart defects. A marked variability in response was 
noted, ranging from no effect in patients undergoing atrial septal defect closure, to a 
significant reduction in cardiac contractility response following neonatal arterial switch. 
The authors concluded that this application of the force-frequency relationship might 
allow a refinement of myocardial protection and postoperative support (Cheung et al., 
2006). However, the tissue Doppler approach to an assessment of the force-frequency 
relationship provides information that is limited to regional myocardial velocities and 
so, does not reflect the overall contractile performance of the LV (Dini et al., 2013). 
 
Advantages of the echocardiography approach include that it is non-invasive, and 
does not present ionising radiation or biohazard risk to either the patient or the operator 
(Picano, 2003).  
 
The force-frequency relationship has also been reliably assessed using a Doppler-
derived method where LV ejection force was calculated according to the law of 
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conservation of momentum, at rest and during exercise (Dini et al., 2013). However, 
this method of assessment is limited to regional myocardial velocities and does not 
reflect the overall contractility of the LV. Further limitations to this method include 
transducer angulation, correct measurement of the LV outflow tract, and the 
assumption that the LV outflow tract diameter does not alter during exercise. However, 
this method could be useful in patients with poor endocardial definition. 
 
A further non-invasive method of measuring LV contractility in vivo has been reported, 
demonstrating that it is feasible to record the force-frequency relationship using a non-
invasive transcutaneous force sensor, attached to the mid-sternal precordial region by 
a solid gel electrocardiogram (ECG) electrode (Bombardini, T. et al., 2007). Using an 
accelerometer, the sensor measures the vibrations that result in the first heart sound, 
generated by isovolumic myocardium contractions (Sakamoto et al., 1965). Whilst it 
was found that the sensor-built force-frequency relationship was related to the 
standard stress echo-built force-frequency relationship, further studies are needed to 
compare the non-invasive sensor method with LV pressure-volume loops in humans. 
 
Although cardiac contractility can also be estimated by intracardiac impedance around 
a permanently implanted pacing lead, only one company currently manufactures 
pacemakers capable of making these measurements (Bondke et al., 2010). However, 
the use of the right ventricle (RV) for pressure or impedance measurements, rather 
than the LV, limits the clinical use of this pacemaker in an NHS setting, since it is 
unclear in any one individual how the impedance measure in the RV relates to LV 




5.2.4 Increasing the heart rate 
Various methods of increasing the heart rate during force-frequency relationship 
assessment have been reported in the literature, including inotropes (Bombardini, T. 
et al., 2007), graded bicycle exercise (Bombardini, T. et al., 2003), and incremental 
pacing (Bombardini, T. et al., 2005b).  
 
Whilst using an infusion of a cardiac stimulant is a convenient method to increase the 
heart rate in patients who do not have a pacemaker, these agents have an 
unpredictable effect on preload and afterload. For example, the most frequently used 
agent, dobutamine, leads to a decrease in LV end-diastolic pressure in HFrEF 
suggesting reduced LV filling pressures, which leads to a reduction in cardiac 
sympathetic activity (Azevedo et al., 2000; Al-Hesayen et al., 2002). This is unlikely to 
have a neutral effect upon LV contractility. 
 
LV contractility measured during exercise is likely to be the most relevant method of 
increasing heart rate to patients. Stress echocardiography is an established clinical 
tool (Rodgers et al., 2000). Bicycle stress echocardiography, with blood pressure, 
electrocardiogram, and LV volumes obtained at each step of increased heart rate, has 
been used to build a force-frequency relationship over a wide range of frequencies. 
The advantage of this approach is that all the basic parameters are routinely acquired 
during exercise stress echocardiography (Bombardini, T. et al., 2003). A disadvantage 
is that echocardiography during exercise stress can be technically demanding for the 
sonographer. Furthermore, exercise stress evaluates the effect of heart rate increase 
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and the effect of inotropic stimulation, rather than pure heart rate effect (Bombardini, 
T. et al., 2005b). 
 
Using a permanently implanted pacemaker, rather than exercise or inotropic 
stimulation, to increase the heart rate, has been shown to be feasible (Picano et al., 
2002). Since this method does not involve peripheral muscle contraction, intrinsic 
catecholamine release, or intravenous inotropes, it has been suggested that pacing 
allows a ‘pure’ index of LV contractility (Bombardini, T. et al., 2005b). Patients with 
cardiac resynchronisation devices are the sickest HFrEF cohort in whom controlling 
heart rates might be most beneficial. Furthermore, optimisation of heart rate ranges 
can be carefully controlled and monitored in pacemaker patients, making this group a 
useful first step in developing an understanding of the force-frequency relationship in 
HFrEF. 
 
5.3 Study protocols  
5.3.1 Baseline visit 
I collected information on comorbidities, past medical history, medication types and 
doses, pacemaker device settings, and New York Heart Association (NYHA) functional 
classification. Height and weight were measured at the start of each visit to enable 
oxygen consumption measures and echocardiographic parameters to be adjusted for 
body weight and body surface area, respectively. 
 
All participants gave informed written consent, underwent a full echocardiographic 
assessment, and performed a peak, symptom-limited treadmill-based familiarisation 
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cardiopulmonary exercise test with breath-by-breath metabolic gas analysis. The 
results from the familiarisation tests were not included in the final analysis. 
 
5.3.2 Blinding protocol 
The interventional studies had a double-blind design, such that both the participant 
and I were blinded to the pacemaker settings and exercise time. An un-blinded clinical 
scientist programmed the pacemaker device according to the randomisation, including 
sham reprogramming where appropriate to avoid the risk of un-blinding (Hauptman 
and Gottlieb, 2014). The same un-blinded clinical scientist also monitored the ECG 
during the CPET. A screen prevented the participant and me from seeing the monitor. 
The resting, peak and recovery blood pressures were measured using a standard 
manual cuff sphygmomanometer.  
 
5.3.3 Exercise testing protocol  
CPETs were performed using the Ultima CardiO2 CPET system (Medical Graphics UK 
Limited, Gloucester, UK). The equipment was calibrated using manufacturer-
recommended volume and gas calibration techniques before each test. 
 
5.3.3.1 Preparation of the participant 
The procedure was explained in full to each participant, and it was made clear, before 
the test started, that since the aim was to assess peak exercise capacity, they would 
be encouraged to exercise to their limit. The participant was informed that their heart 
would be monitored using an ECG, and their blood pressure would be recorded every 
three minutes. The importance of not talking was impressed upon each individual. 
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Participants could try the mouthpiece or mask on before starting the test, and they 
were reassured that the treadmill would start very slowly. To stop the test, participants 
were instructed to raise their right hand.  
 
Exercise-ECG electrodes were placed in standard positions, a blood pressure cuff was 
placed around the participant’s left arm, and the participant was then asked to sit on a 
chair on the treadmill. The mouthpiece and nose-clip (or mask) were then fitted to the 
participant, and baseline ECG and blood pressure recordings were taken. Resting 
metabolic gas and ventilation readings were recorded for a period of six minutes to 
ensure steady-state conditions were achieved. Further reassurance was provided 
where necessary to ensure stable baseline readings. 
 
5.3.3.2 Exercise protocol 
Participants were exercised using the ramping treadmill protocol which is 
characterised by a gradual increase in work rate (Porszasz et al., 2003). An advantage 
of the ramping protocol is the lack of the abrupt increase in work rate typical of the 
step protocols. The participant was encouraged to use the treadmill handrails only as 
a guide and for balance, since dependence on handrails reduces the work being 
performed and the reliability of the oxygen uptake data (Berling et al., 2006). A 12-
lead, real-time ECG was displayed throughout the rest, test, and recovery phases. My 
view of the ECG monitor was obscured by a screen, to maintain blinding. 12-lead 
ECGs were printed at baseline, end of every three-minutes during exercise, at peak 
exercise and during recovery. Inspired and expired air was collected using a 




Participants were encouraged prior to the test, to perform a maximal test, and asked 
to exercise to exhaustion or to the onset of symptoms. No motivation or instructions 
were given during the exercise phase. Procedures were in place to ensure that the 
test would be terminated in the event of symptoms or ECG abnormalities. A recovery 
time of at least six minutes was observed, or until heart rate and any ECG changes 
returned to normal. All the study CPETs took place in the same exercise laboratory. 
The CPET and ECG data were all anonymised, recorded and stored securely for 
subsequent analysis. For safety reasons, participants were asked to remain in the 
department for 30 minutes following their CPET. 
 
5.3.4 Echocardiography protocol 
Full baseline transthoracic echocardiography was carried out by me in accordance 
with British Society of Echocardiography guidelines (Wharton et al., 2015). All 
echocardiographic images were acquired using a commercially available ultrasound 
system (GE Vivid E95, GE Healthcare, Milwaukee, Wisconsin). Subsequent images 
were recorded at each 15-beat frequency increase during the incremental pacing 
protocol. 
 
Images were stored as a raw digital imaging and communications in medicine 
(DICOM) format and exported to an offline workstation (EchoPAC, GE Healthcare) for 




Echocardiogram analysis was performed by me in random order. I was blinded to 
patient and study visit. Analysis included calculation of LV end-diastolic volume, LV 
end-systolic volume and LVEF, using 2D imaging from the apical four and two 
chamber windows, using the modified Simpson’s biplane summation of discs method 
by tracing the endocardial border in diastole and in systole, excluding the papillary 
muscles (Lang et al., 2006). Care was taken to ensure that the apical four and two 
chamber windows were separated by 60º, and that the LV was not foreshortened 
(Wharton et al., 2015; Harkness et al., 2020). The frame at the R-wave was taken as 
end-diastole, and the frame with the smallest LV cavity was taken to represent end-
systole (Otto, 2013). Since chamber size can be influenced by body size, structural 
indices were indexed to body surface area (BSA). The LVESVi was calculated at each 
stage as LVESV divided by BSA, where BSA was calculated using the Mosteller 
equation (Mosteller, 1987). An average of three measurements in sinus rhythm or five 
measurements in atrial fibrillation, from representative cycles, was used in the final 
analysis.  
 
5.3.4.1 Force-frequency relationship assessment protocol 
Echocardiographic images were recorded at rest. Pacing was then initiated at the 
lowest multiple of 10 beats per minute (bpm) above baseline heart rate. After four 
minutes a further set of echocardiographic images was taken, along with a blood 
pressure measurement. Subsequently the pacing rate was increased in stepwise 
intervals of 15 bpm with echocardiographic images and blood pressure recorded after 
every four-minute stage, until the maximum predicted heart rate, as predicted by 
Åstrand (220 bpm minus age) was reached, or the onset of symptoms or other 
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contraindications to continuing. At this stage peak data were collected and the 




I re-reported each echocardiographic image set for intra-operator reproducibility. For 
inter-operator reproducibility another clinical scientist also reported each image set. 
Calculating LV volumes using the modified Simpson’s biplane method of discs is 
widely used and accepted (Marwick, 2003; Harkness et al., 2020). In addition, end-
systolic volume evaluation from echocardiographic images has a higher reproducibility 
than end-diastolic volume, and only the former was used in the calculation 
(Bombardini, T. et al., 2005b). 
 
5.3.5 Blood pressure protocol 
Calculation of the end-systolic pressure-volume relationship requires a measurement 
of the LV pressure at end-systole (Grossman, W. et al., 1977; Mehmel et al., 1981). 
Manual SBP recordings made using a sphygmomanometer and a standard 
stethoscope, were used as a surrogate for end-systolic pressure. SBP was recorded 
at the point at which the first tapping sound (phase 1 Korotkoff) occurred for two 
consecutive beats (Nutter, 1978). 
  
5.3.6 Left ventricular contractility calculation 
LV contractility at each heart rate was calculated by dividing SBP by LVESVi. 
Contractility was plotted against heart rate to produce the force-frequency relationship 
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curve. From this it was possible to determine the peak LV contractility, the slope of the 
force-frequency relationship, and the optimal heart rate for LV contractility (the critical 
heart rate (CHR)).  
 
The force-frequency relationship was defined as up-sloping (or positive) when peak 
exercise SBP/LVESVi (end-systolic pressure volume ratio (ESPVR)) is higher than the 
baseline and intermediate values; biphasic when there is an initial up-sloping followed 
by a down sloping and peak ESPVR is lower than the intermediate values; and flat or 
negative when peak ESPVR is equal to or lower than the baseline values (Figure 3.2). 
 
5.4 Assessing quality of life in HFrEF 
The term ‘quality of life’ tends to be used to characterise an individual patient’s quality 
of life from his or her own perspective (Katschnig, 2006). Patients with HFrEF have 
lower quality of life compared to healthy individuals and other patients with chronic 
illnesses. Physical and mental complications, such as fatigue, depression, anxiety, 
oedema, shortness of breath, and therapeutic processes, have a serious and negative 
impact on the quality of life of HFrEF patients (Moradi et al., 2020). The aim of 
assessing quality of life in research is to have an appraisal of how the physical and 
emotional effects of a condition affect an individual’s life (Guyatt, 1993; Katschnig, 
2006), and also to assess the effect on quality of life of interventions that do not extend 
life or delay time to next hospitalisation. Moreover, quality of life scores are a surrogate 




Improving health-related quality of life is acknowledged as a key goal in the 
management of patients with HFrEF (Ponikowski et al., 2016), although individual 
patients may differ in their priorities with some regarding quality of life, and others 
longevity and a compromise to their quality of life, as their main objectives (Lewis et 
al., 2001). 
 
Numerous quality of life assessment tools have been presented, although not all have 
been validated or are in routine use in heart failure (Koshy et al., 2020). The most 
frequently used are the Minnesota Living with Heart Failure Questionnaire and the 
Kansas City Cardiomyopathy Questionnaire (Coelho et al., 2005). In general, these 
quality of life tools have not been assessed in relation to each other and are usually 
used independently. 
 
The quality of life measures used for the studies in this thesis are the Minnesota Living 
with Heart Failure Questionnaire, and the generic EuroQOL 5D-3L (EQ-5D) 
questionnaire and visual analogue score. 
 
The Minnesota Living with Heart Failure Questionnaire (Figure 5.1) is a 21-item patient 
self-assessment that measures patients’ perceptions regarding the effect of HFrEF on 
their daily lives, and evaluates the response to heart failure treatment (Rector, 1987). 
Questions are answered using a Likert scale of 0-5, where 0 = the question has no 
impact on the patient’s quality of life or is not applicable, and 5 = the greatest adverse 
effect. The overall quality of life score ranges from 0-105, with a higher score 








The EQ-5D is a generic health questionnaire comprising two parts. The first part 
(Figure 5.2) assesses the patient’s ability to mobilise, self-care and perform their usual 
activities, and also scores their pain/discomfort and anxiety/depression levels. The 
second part (Figure 5.3), a visual analogue score, allows the patient to rate their 
current overall health state on a scale of 0-100, with 0 being the lowest and 100 being 
the best possible health. The scores can then be converted into a country-specific 















Chapter 6 : Can the force-frequency relationship be reliably 
described in patients with chronic heart failure and a pacemaker 
device?  
 
Hypothesis: The force-frequency relationship can be reliably described in patients 
with chronic heart failure and a pacemaker. 
 
6.1 Introduction 
Chronic heart failure secondary to left ventricular systolic dysfunction, also known as 
heart failure with reduced ejection fraction (HFrEF), is a common syndrome 
characterised by symptoms of breathlessness and fatigue in the presence of left 
ventricular systolic dysfunction (LVSD). This limits the ability to perform even minor 
levels of exercise and activities of normal daily life, and may also contribute to long 
term deterioration in cardiac function. 
 
In the normal heart, heart rate increases with increasing work to a peak that reduces 
with ageing. Patients with HFrEF have a lower peak heart rate than matched controls, 
and this has been considered as one reason for the reduced exercise tolerance in 
HFrEF (Colucci et al., 1989; White et al., 1995). 
 
Cardiac output, heart rate and stroke volume are interdependent; continuously 
increasing the heart rate will affect stroke volume by reducing left ventricular (LV) filling 
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time and hence the LV end-diastolic volume (LVEDV) (Mattera et al., 2011). Increasing 
the force of contraction during exercise ensures that cardiac output matches venous 
return. 
 
Increases in cardiac contractility during exercise are under two major influences: 
depolarisation-rate dependent (heart rate dependent; force-frequency relationship), 
and catecholamine-dependent. Increasing LV contractility through the force-frequency 
relationship compensates for reductions in diastolic filling time and avoids a 
paradoxical fall in cardiac output. It is therefore reasonable to assume that each heart 
has its own individual force-frequency relationship with a unique LV contractility rise 
with increasing heart rate, a unique heart rate at which LV contractility peaks, and its 
own unique downward slope following this peak, where LV contractility worsens with 
increasing heart rate. It is also recognised that the force-frequency relationship is 
abnormal in patients with HFrEF, with a lower contractile rise in response to an 
increase in heart rate, a lower peak LV contractility and a lower heart rate at which this 
occurs (Cotton et al., 2001; Kayhan et al., 2002). Whether the slope of deterioration is 
greater following this critical heart rate is unknown. This therefore leads to the 
hypothesis that patients with HFrEF might benefit from a lower heart rate to remain on 
the upward part of the force-frequency relationship slope. 
 
Consequently, the aim of this observational study was to describe, using 
echocardiography, the contractile response to an increase in heart rate, in patients 





6.2.1 Study design 
This investigation was an observational cohort study, designed to examine LV 
contractility in response to increases in heart rate, in patients with HFrEF and a 
pacemaker. All participants were approached at routine outpatient clinic appointments 
(either the heart failure clinic or pacemaker follow-up clinic) and given patient 
information sheets.  
 
Ethical approval1 was granted by the Health Research Authority (National Research 
Ethics Service Centre: Yorkshire and the Humber Research Ethics Committee 
reference: 12/YH/0097). National Health Service (NHS) permission2 for this research 
was granted at Leeds Teaching Hospitals NHS Trust (LTHT) Research and 
Development Department (R&D) (LTHT R&D reference: CD12/10115). 
 
6.2.2 Study population 
Patients with HFrEF, persistent symptoms on exertion, and a pacemaker device, were 
recruited from the heart failure clinic. Each patient was invited to the Cardiovascular 
Clinical Research Facility (CVCRF) at LTHT. An unselected consecutive group of 
patients with a standard pacemaker, normal atrioventricular conduction, and no 
evidence of HFrEF, was also recruited from the pacemaker follow-up clinic, as a 
control group. Within this cohort of 105 participants, 90 had HFrEF (HFrEF group), 
 
1 See Appendix A 
2 See Appendix B 
126 
 
and 15 had pacing devices, with no symptomatic or structural evidence of heart failure 
(control group). All participants had a pacemaker device in situ for a clinical indication, 
with stable pacemaker device and lead variables for at least the previous three 
months.  
 
6.2.3 Inclusion and exclusion criteria 
Inclusion criteria for the test patients were: HFrEF with a left ventricular ejection 
fraction (LVEF) ≤ 50% and symptoms of breathlessness or fatigue on exertion, on 
optimally tolerated medical therapy, with no change in medication over the previous 
three months, and stable symptoms. The pacemaker must have been implanted for at 
least three months and have stable lead variables. No other invasive cardiac 
procedures should have been undergone for at least the previous three months. All 
participants were capable of performing a peak cardiopulmonary exercise test on a 
treadmill and provided informed written consent. 
 
Participants who were pacing dependent in the atrium, such that no heart rate rise 
during activity would be exhibited, were excluded. Other exclusion criteria consisted 
of the inability to provide informed written consent, and the presence of comorbidities 
that would limit exercise capacity, such as: uncontrolled angina, peripheral vascular 
disease, severe valvular dysfunction, severe obstructive or restrictive respiratory 
conditions, oxygen dependence, and any musculoskeletal abnormalities or disorders 
that could restrict walking on a treadmill. People with poor echocardiographic imaging 





6.2.4 Study procedures 
Each participant attended the CVCRF for a single visit. I collected information on 
comorbidities, past medical history, medication, pacemaker settings, and New York 
Heart Association (NYHA) functional class.  
 
Echocardiographic images were collected at baseline, as described in chapter 5. Atrial 
pacing was then initiated in DDD mode3 (or VVI in patients with atrial fibrillation (AF)) 
for patients with a cardiac resynchronisation therapy (CRT) pacing device, or in AAI 
mode (or DDD with long atrioventricular delays to avoid right ventricular pacing, or VVI 
for patients in AF) for subjects without CRT, at the lowest multiple of 10 beats per 
minute (bpm) above baseline heart rate. The heart rate was then increased in stepwise 
15 bpm intervals every four minutes, with echocardiographic images recorded at each 
stage. This was repeated until: the maximum predicted heart rate of 220 bpm minus 
age was reached, the patient complained of any discomfort, or significant 
electrocardiogram (ECG) changes were detected. LV contractility was calculated non-
invasively using the systolic blood pressure and the LV end-systolic volume index, as 
described previously in chapter 5, to enable the force-frequency relationship curve to 
be plotted. The patient was not made aware of the heart rate, blood pressure or 
echocardiographic measures at any stage of the testing process. All pacemaker 
settings were returned to pre-test settings following the test. 
 
 




6.2.4.1 Sample size calculation 
Previous studies investigating LV contractility in patients with heart failure were able 
to demonstrate significance using heart failure cohorts of 11 ± 4 patients and control 
cohorts of 8 ± 3 subjects (Bombardini, T., 2005a). Therefore, the aim was to recruit at 
least 12 control participants. We expanded the HFrEF cohort to allow for a greater 
standard deviation and lower reproducibility of non-invasive assessment of LV 
contractility to 90 subjects.   
 
6.2.4.2 Reproducibility 
I re-reported each image set, for intra-observer variability. Each anonymised set of 
echocardiographic images was also reported by my colleague for inter-operator 
variability. The three features of the force-frequency relationship were documented for 
each dataset: the heart rate at which peak LV contractility occurred (the critical heart 
rate), peak LV contractility, and the slope of the force-frequency relationship. 
Reproducibility of echocardiographic measures between myself and a clinical scientist 
colleague were described by intraclass correlation coefficient (ICC). 
 
6.2.5 Statistical analysis  
Data analysis was undertaken using the Statistical Package for the Social Sciences 
(SPSS) version 21 (IBM Corp., Armonk, New York), R: A Language and Environment 
for Statistical Computing version 3.2.3 (R Development Core Team, Vienna, Austria), 




Normality for all continuous variables was tested using the Shapiro-Wilk test. Normally 
distributed continuous variables were reported as the mean and standard deviation, 
and non-normally distributed continuous variables were reported as the median and 
interquartile range. 
 
Groups were compared using either the analysis of variance test (ANOVA) and 
unpaired Student t test for normally distributed values, or the Kruskal-Wallis H test 
(one-way analysis of variance of ranks) for non-normally distributed data. Categorical 
variables were analysed using the chi-squared test for contingency tables. All 
statistical tests were two-sided, and any p value less than 0.05 was considered to be 
statistically significant.  
 
Reproducibility of echocardiographic measures were described by intraclass 
correlation coefficient (ICC) for both intra- and inter-observer variability. 
 
6.3 Results 
In total, 90 patients (mean age 73.5 ± 8.9 years) with chronic heart failure (mean LVEF 
33.3 ± 10.8%); and 15 control subjects (mean age 71.1 ± 16.0 years) with normal left 
ventricular function (mean LVEF, 55.6 ± 5.3%) were recruited. The baseline clinical, 
echocardiographic, and pacemaker variables are shown in the baseline characteristics 








Table 6.1: Baseline characteristics 
Demographic Control 
(n = 15) 
HFrEF patients 
(n = 90) 
P Valuea 
Male 14 (93) 79 (88) 0.53 
Age, years 71.1 ± 16.0 73.5 ± 8.9 0.39 
Ischaemic heart disease 2 (13) 54 (60) 0.0008 
Diabetes mellitus 4 (27) 28 (31) 0.73 
BSA, m2 1.9 ± 0.1 2.0 ± 0.2 0.07 
NYHA functional class 
     I 
     II 










Beta-blockers 3 (20) 82 (91) 0.0001 
ACE inhibitor/ARB 3 (20) 77 (86) 0.0001 
Furosemide dose, mg/day 0 47 (26)  
Digoxin 0 (0) 15 (17) 0.084 
Aldosterone antagonist 0 (0) 38 (42) 0.001 
Device (PPM/ICD/CRT) n/a 14/9/67 (16/10/74)  
Atrial fibrillation 3 (20) 25 (28) 0.51 
LV ejection fraction, % 55.6 ± 5.3 33.3 ± 10.8 0.0001 
Critical heart rate, beats/min 126 ± 15 103 ± 22 0.0002 
Peak contractility, SBP/LVESVi 9.8 ± 4.1 3.8 ± 3.7 0.0001 
Force-frequency relationshipb 0.054 ± 0.042 0.011 ± 0.028 <0.0001 
 
Key: Values are n (%) or mean ± SD. ap values are from unpaired Student t tests or chi-squared tests as appropriate. bfrom 
likelihood ratio test in linear mixed model.  
ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; BSA = body surface area; CRT = cardiac 
resynchronisation therapy; HFrEF = heart failure with reduced ejection fraction;  ICD = implantable cardioverter-defibrillator; 
LV = left ventricle; LVESVi = left ventricular end-systolic volume index; m = metre; mg = milligram; min = minute; n/a = not 
applicable; NYHA = New York Heart Association functional class; PPM = permanent pacemaker; SBP = systolic blood 





The three key variables of peak LV contractility, critical heart rate, and the slope of the 
relationship between heart rate and LV contractility were established in all participants.  
This demonstrated that patients with HFrEF had lower peak LV contractility (3.8 ± 3.7 
systolic blood pressure (SBP) divided by left ventricular end-systolic volume index 
(LVESVi) versus (vs) 9.8 ± 4.1 SBP/LVESVi; p = 0.0001), lower mean critical heart 
rate (103 ± 22 bpm vs 126 ± 15 bpm; p = 0.0002), and a lower slope of the relationship 
between heart rate and LV contractility below the critical heart rate (0.011 ± 0.028 vs 
0.054 ± 0.042; p = <0.0001) than controls (Table 6.1, Figure 6.1). 
 
 
Figure 6.1: Force-frequency relationship in patients and controls 
 
Separate models were required for each group, as compared with considering the data 
overall. We confirmed this by a likelihood ratio test for a saturated model compared 
with a simple additive model for heart rate, heart rate2, and patient group (chi-square 
test = 214.63; p < 10-15). We further examined the relationship in linear mixed effects 
Key: bpm = beats per minute; LVESVi = left ventricular end-systolic volume; SP = systolic pressure 
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models and showed that there was little evidence of a quadratic relationship in each 
group of patients: 
 
 Controls: 0.2915604 + 0.0844503 x heart rate - -0.00017 x heart rate2 
 HFrEF: 1.971 + 7.170e-03 + 2.510e-05 x heart rate2 
 
In the controls, the linear term was significant (p <0.05), and the quadratic term 
showed weak evidence of being required (p = 0.15). However, for HFrEF the linear 
term was not significant (p = 0.334), and the quadratic term was not significant (p = 
0.525). Thus, in controls, for every 10-bpm increase in heart rate there was a 0.8-unit 
increase in LV contractility; in HFrEF the relationship was significantly less, at <0.02. 
 
Using the Åstrand formula a higher peak heart rate was calculated than the measured 
critical heart rate for all except one HFrEF patient (mean heart rate 146 ± 9.0 bpm vs 
103 ± 22 bpm; p < 0.0001), and all except three control participants (149 ± 16 bpm vs 
126 ± 15 bpm; p = 0.002).  
 
No relationship was found between age and any of the measures of cardiac function, 
including LV contractility. Critical heart rate and resting LV function were also unrelated 
in both groups. However, there was a strong correlation between peak LV contractility 
and baseline LVEF (0.50; 95% confidence interval (CI), 0.33 to 0.64; p < 0.0001) in 







Figure 6.2: Peak contractility by levels of left ventricular dysfunction 
 
 
Echocardiographic outcome measures demonstrated strong intra-observer agreement 
for LVEF [ICC 0.980 (95%CI, 0.794 to 0.998)]; LV end-diastolic volume (LVEDV) [ICC 
0.996 (95%CI, 0.977 to 0.999)]; and LV end-systolic volume (LVESV) [ICC 0.991 
(95%CI, 0.935 to 0.999)]. Strong inter-observer agreement was also demonstrated for 
LVEF [ICC 0.971 (95%CI, 0.776 to 0.997)]; LVEDV [ICC 0.993 (95%CI, 0.954 to 
0.999)]; and LVESV [ICC 0.974 (95%CI, 0.754 to 0.997)]. 
 
6.4 Discussion 
This study demonstrates that patients with HFrEF have an impaired force-frequency 
relationship curve, compared to the controls, which can be assessed using a non-
Key: SP = systolic pressure 
LVESVi = left ventricular end-systolic volume index 
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invasive, reproducible echocardiographic method. Furthermore, peak LV contractility 
is related to the baseline cardiac function. This impairment of the force-frequency 
relationship is likely to contribute to the lower cardiac output during activity that is a 
recognised feature of HFrEF. 
 
Whilst LV contractility is seen to increase in both groups, the rate of change is very 
different. In the control group, LV contractility continues to increase until high heart 
rates are achieved, up to 140 bpm. However, in the patient group, the LV contractility 
response is slow, the peak LV contractility is lower, and the LV contractility declines at 
a lower heart rate, i.e. the critical heart rate is lower. Furthermore, increasing the heart 
rate beyond the critical heart rate in the patient group did not result in an increase in 
LV contractility. 
 
Many datasets exist that describe maximal heart rate changes with ageing (Robinson, 
1938; Cotes et al., 1973; Bassey, 1978; Robergs and Landwehr, 2002). However, the 
Åstrand formula (220 bpm minus age), an extrapolation of data from various sources, 
is the most frequently used dataset to describe maximal heart rate changes and age. 
All these datasets are based on experiments on healthy individuals exercising to 
physiological maximum.    
 
Consequently, it is possible that conventional pacemaker heart rate-response 
algorithms applied to HFrEF patients, increase the heart rate beyond the critical heart 
rate and onto the downward portion of the LV contractility curve, such that the cardiac 





This observational study contains biases that are common in studies of this type. A 
degree of patient selection bias is present since those patients with advanced heart 
failure or comorbidities may be less enthusiastic to participate in clinical research. 
 
The study necessarily restricts recruitment to those patients with a pacemaker device, 
although it is possible that they may have a different contractile response to increased 
heart rates from those without a pacemaker device. 
 
Image quality can be a limiting factor in obtaining accurate measurements using 
echocardiography. In this study, LV end-diastolic and end-systolic volumes were 
measured using the modified Simpson’s biplane method. This method, using 
echocardiography, is widely used, and accepted. The evaluation of end-systolic 
volume has a higher reproducibility than end-diastolic volume, using 
echocardiography, and only the former is used to build the force-frequency relationship 
(Bombardini, T. et al., 2005b). Furthermore, strong intra-observer and inter-observer 
agreement were found.   
 
6.6 Conclusion 
The force-frequency relationship can be reliably and non-invasively assessed in 
patients with HFrEF, and non-HFrEF participants, with a pacemaker device providing 
the heart rate increments. In control participants, higher heart rates resulted in greater 
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LV contractility, and greater potential for increased cardiac output in response to 
activity. However, the key findings from this observational study of a lower slope in 
response to heart rate increases, a lower peak LV contractility, and a lower critical 
heart rate in patients with HFrEF, confirm, non-invasively, the marked impairment of 
the force-frequency relationship in HFrEF, independent of cardiac loading or physical 
activity levels. Moreover, the data provide solid evidence that pacemaker heart rate 
programming should consider the underlying cardiac disease and not simply the age 







Chapter 7 : Does pacemaker programming tailored to the force-
frequency relationship improve exercise tolerance in patients 
with chronic heart failure? 
 
Hypothesis: Tailoring pacemaker settings based on a non-invasive assessment of 




Heart failure with reduced ejection fraction (HFrEF) is characterised by exercise 
intolerance and symptoms of breathlessness and fatigue. This limits patients’ ability to 
perform even minor levels of exercise, impacting on their daily activities of life, for 
example walking to the local amenities. Key features of HFrEF thought to contribute 
to exercise intolerance include impaired cardiac contractility and therefore cardiac 
output during activity. It is commonly perceived that these are compounded by reduced 
heart rate rise, and that this in turn is worsened by high dose beta-adrenoceptor 
antagonists (β-blocker).  
 
Optimal treatment for around one third of patients with HFrEF includes a 
resynchronisation pacemaker (cardiac resynchronisation therapy (CRT)). In addition 
to retuning the timing of cardiac contraction to increase cardiac efficiency, the device 
can also increase the heart rate during activity (rate-response pacing). The Åstrand 
formula of 220 beats per minute (bpm) minus age, is the only available guidance for 
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programming the rate-response setting. However, this formula, along with many 
published datasets describing heart rate changes with age, is based on data from 
experiments in healthy individuals exercising to physiological maximum. 
 
My data shown in chapter 6 demonstrated, using a non-invasive, reproducible method, 
that patients with HFrEF have a lower slope in response to heart rate increases, lower 
peak left ventricular (LV) contractility and a lower critical heart rate than controls. I also 
showed that by using this method, an ideal range for heart rate during activity could 
be determined in all patients. The optimal heart rate for most patients was between 90 
and 110 bpm. It is therefore possible that using conventional heart rate-response 
algorithms in HFrEF will increase the heart rate beyond the critical heart rate, so that 
LV contractility and cardiac output are decreasing whilst the heart rate is continuing to 
increase. 
 
The aim of this study, therefore, was to determine, whether maintaining heart rate 
during exercise on the upward slope of the force-frequency relationship curve, and 




7.2.1 Study design 
The design was a randomised, double-blind, placebo-controlled, cross-over study, to 
compare treadmill exercise time using conventional heart rate-response settings with 
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heart rate-response settings based on the data from a force-frequency relationship 
assessment.  
 
Ethical approval4 was granted by the Health Research Authority (National Research 
Ethics Service Committee: Yorkshire and the Humber Research Ethics Committee 
reference: 12/YH/0097). National Health Service (NHS) permission5 for this research 
was granted at Leeds Teaching Hospitals NHS Trust (LTHT) Research and 
Development Department (R&D) (LTHT R&D reference: CD12/10115). All participants 
provided informed written consent. 
 
7.2.2 Study population 
Patients with HFrEF, who had taken part in the observational study and who did not 
have peripheral vascular disease or non-cardiac conditions that could restrict walking 
on a treadmill, were invited to return for two additional visits, one week apart, at the 
Cardiovascular Clinical Research Facility (CVCRF) at LTHT. An unselected subgroup 
was invited to return for a third (blinded) exercise test, with the pacemaker device 
programmed to fixed rate pacing during exercise.  
 
7.2.3 Study procedures 
Before each test the pacemaker was interrogated. Patients were then randomly 
assigned to: conventional settings (heart rate-response on exercise to achieve age-
 
4 Ethical approval, see Appendix A 
5 NHS permission, see Appendix B 
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determined maximum), optimised heart rate-response on exercise, based on the 
individual’s force-frequency relationship assessment from the observational study 
(chapter 6) (limiting heart rate rise to below the critical heart rate), or, for patients 
consenting to perform a third test, fixed-rate pacing with rate-response settings 
programmed to ‘off’. Randomisation was achieved through a computer-generated 
random number method. 
 
The cardiopulmonary exercise test equipment was recalibrated prior to each test, 
using the manufacturer-recommended volume and gas calibration techniques. 
Participants performed a peak, symptom-limited exercise test, using the ramping 
treadmill protocol (Porszasz et al., 2003) at each visit, to measure exercise time. 
Expired air was collected, and metabolic gas exchange analysis was performed 
throughout the test (Ultima CardO2, Medical Graphics, St. Paul, Minnesota). Heart rate 
(bpm), oxygen consumption (VO2) (millilitres per kilogram per minute (ml/kg/min)), and 
carbon dioxide output (VCO2) (ml/kg/min), were recorded as 15-second averages. The 
V-slope method was used to calculate anaerobic threshold. Participants were asked 
to exercise to exhaustion, and no further motivation or instructions were given.  
 
To maintain blinding, neither I nor the participants were made aware of the pacemaker 
programming mode or the randomisation. Furthermore, the electrocardiogram (ECG) 
monitor was obscured throughout the test (baseline, exercise, and recovery) from the 
participants and me. An un-blinded clinical scientist monitored the ECG throughout, 
communicated with the other team members only if there were safety concerns, and 
reprogrammed the pacemaker to its pre-test settings after the cardiopulmonary 
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exercise test was completed. Participants’ pacing files were labelled to indicate that 
the patient was taking part in a research study, and that pacemaker settings should 
remain unchanged for the intervening week between research visits, unless 
symptomatic. For safety reasons, participants remained in the CVCRF for 30 minutes 
after completion of their test. All data were stored in a secure anonymised electronic 
database.  
 
7.2.3.1 Sample size calculation 
The primary endpoint of the study was change in exercise time. A key secondary 
endpoint was peak oxygen consumption. Using the guidelines for pilot studies 
(Lancaster et al., 2004; Julious, 2005), and a dropout rate of 20%, the aim was to 
recruit 28 patients to achieve 20 participants with complete data.  
 
7.3 Statistical analysis  
Data were analysed using the Statistical Package for the Social Sciences (SPSS) 
version 21 (IBM Corp., Armonk, New York), R: A Language and Environment for 
Statistical Computing version 3.2.3 (R Development Core Team, Vienna, Austria), and 
SAS version 9.4 (SAS Institute, Inc., Cary, North Carolina). 
 
The Shapiro-Wilk test was used to determine whether the participant demographics, 
cardiopulmonary exercise test and echocardiogram variables were normally 
distributed. Normally distributed variables were reported as mean and mean ± 
standard deviation (SD), and non-normally distributed continuous variables were 
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reported as median (interquartile range). Associations between groups or 
interventions and baseline characteristics were assessed using either analysis of 
variance and the 2-sample Student t test for normally distributed values, or the 
Kruskal-Wallis H test (one-way analysis of variance on ranks) for non-normally 
distributed data. Similar associations with categorical variables were analysed using 
the chi-squared test for contingency tables. 
 
Once a familiarisation test has been performed, a peak exercise test is not a training 
stimulus (Witte, K. K.  et al., 2003). However, to account for any carryover effects, we 
analysed the interventional crossover study using a linear mixed model with a random 
effect for subject. For each endpoint Yak (e.g., exercise time) under consideration in 
the study: 
Yak = µ + di + πj + in + αk + ink    
 
where, ink ~ N (0, σ2ε), αk ~ N (0, σ2α) and µ is the overall mean, τ is the treatment 
effect, π is the period effect, and λ is the carryover effect (which is mathematically 
identical to an interaction term between treatment and period). This model was 
estimated using PROC MIXED in SAS, and least squares means were estimated for 
each of these terms and their differences. 
 







In total, 52 patients (mean age 73.8 ± 9.6 years; mean left ventricular ejection fraction 
(LVEF) ± 11%) who had taken part in the observational cohort study (Chapter 6) were 
recruited to this subsequent interventional study. 
 
Table 7.1: Baseline characteristics 
Variable (n = 52) 
Male 44 (85) 
Age, years 73.8 ± 9.6 
Aetiology 
     Ischaemic heart disease 
 
33 (63) 
Diabetes mellitus 15 (29) 
BSA, m2 2.0 ± 0.2 
NYHA functional class 
     I 
     II 





Beta-blockers 47 (90) 
ACE inhibitor/ARB 47 (90) 
Furosemide dose, mg/day 43 ± 24 
Digoxin 6 (12) 
Aldosterone antagonist 21 (40) 
Device (CRT/ICD) 50/2 (96/4) 
Atrial fibrillation 15 (29) 
LV ejection fraction, % 32 ± 11 
Critical heart rate, beats/min 101 ± 19 
Peak contractility, SBP/LVESVi 3.4 ± 2.0 
Key: Values are n (%) or mean ± SD. 
ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; BSA = body surface area; CRT = cardiac 
resynchronisation therapy; ICD = implantable cardioverter-defibrillator; LV = left ventricle; LVESVi = left ventricular end-systolic 
volume index; m = metre; mg = milligram; min = minute; NYHA = New York Heart Association functional class; SBP = systolic 




The baseline clinical and echocardiographic variables (Table 7.1) were not different 
from those of patients in the observational cohort study. A sub-group of 12 patients 
underwent a third test with their device programmed to fixed-rate pacing. Exercise 
variables for conventional and heart rate-response tailored for LV contractility are 
shown in Table 7.2. 
 
Table 7.2: Exercise variables during conventional and optimised heart rate-
response programming 













(420.69 to 528.79) 
(370.84 to 478.94) 







(16.00 to 18.62) 
(15.25 to 17.87) 
0.75 (0.16 to 1.34) 0.0134 




(12.33 to 14.45) 
(9.13 to 11.25) 







(29.81 to 33.78) 
(31.70 to 35.67) 
-1.89 (-3.38 to -0.40) 0.0139 




(0.99 to 1.04) 
(0.99 to 1.05) 








(106.01 to 112.21) 
(108.87 to 167.12) 
-28.88 (-32.83 to 24.93) <0.0001 
Key: min = minute; ml/kg/min = millilitre/kilogram/minute; O2 = oxygen; RER = respiratory exchange ratio; s = second; VE/VCO2 slope = 
relationship between ventilation and carbon dioxide output; VO2 = oxygen consumption. 
 
 
Optimised settings (heart rate-response tailored to the force-frequency relationship) 
were associated with improved exercise time (475 ± 189 seconds (s) versus (vs) 425 
± 198 s; p = 0.003) (Figure 7.1A), peak oxygen consumption (17.3 ± 4.6 ml/kg/min vs 
16.6 ± 4.7 ml/kg/min; p = 0.01) (Figure 7.1B), oxygen pulse (13.39 (95% confidence 
interval (CI), 12.33 to 14.45) vs 10.19 (95%CI, 9.13 to 11.25); p <0.0001) (Figure 
7.1C), and lower slope of the relationship between ventilation and carbon dioxide 
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(VE/VCO2 slope) (31.80 (95%CI, 29.81 to 33.78) vs 33.69 (95%CI, 31.70 to 35.67); p 
= 0.014). Peak heart rate was also lower with optimised settings (109.11 (95%CI, 
106.01 to 112.21) vs 137.99 (95%CI, 108.87 to 167.12); p <0.0001) (Figure 7.1D). 
 
 
Figure 7.1: Results of the randomised, placebo-controlled double-blind 
crossover study of conventional versus optimised rate-adaptive pacing settings 
 
The sub-group of 12 unselected patients programmed to fixed-rate pacing (rate-
response function programmed ‘off’), for the duration of the cardiopulmonary exercise 























Table 7.3: Exercise variables in patients with diabetes mellitus during 
conventional and optimised heart rate programming 














(332.87 to 533.13) 











(13.89 to 18.08) 
(13.86 to 17.45) 
0.63 (-0.37 to 1.63) 0.1956 




(11.70 to 15.36) 
(8.27 to 11.93) 







(27.96 to 36.13) 
(30.10 to 38.27) 
-2.14 (-4.70 to 0.42) 0.0940 




(0.95 to 1.06) 
(0.95 to 1.06) 








(102.21 to 114.57) 





Values are means (SD) 
Key: min = minute; ml/kg/min = millilitre/kilogram/minute; O2 = oxygen; Peak VO2 = peak oxygen consumption; RER = 













Table 7.4: Exercise variables in patients with atrial fibrillation during 
conventional and optimised heart rate programming 













(336.01 to 559.19) 
(272.56 to 495.74) 







(12.79 to 17.47) 
(12.30 to 16.99) 
0.49 (-0.67 to 1.64) 0.3788 




(9.78 to 13.25) 
(6.78 to 10.25) 







(29.70 to 37.35) 
(30.51 to 38.51) 
-0.81 (-5.08 to 3.47) 0.6906 




(0.97 to 1.10) 
(0.94 to 1.08) 








(100.39 to 111.71) 
(131.89 to 143.21) 
-31.50 (-40.11 to -22.89) <0.0001 
Values are means (SD) 
Key: min = minute; ml/kg/min = millilitre/kilogram/minute; O2 = oxygen; Peak VO2 = peak oxygen consumption; RER = 




There was no significant difference in the benefits of tailored programming between 
those with and without diabetes mellitus (Table 7.3), those with and without atrial 








Table 7.5: Exercise variables in patients with ischaemic heart disease during 
conventional and optimised heart rate programming 














(392.22 to 511.35) 
(334.92 to 454.06) 







(14.91 to 18.27) 
(13.97 to 17.33) 
0.94 (0.20 to 1.69) 0.0150 




(11.85 to 14.54) 
(8.12 to 10.80) 







(29.78 to 34.42) 
(31.77 to 36.42) 
-1.99 (-3.99 to 0.00) 0.0505 




(0.99 to 1.06) 
(0.99 to 1.06) 








(102.67 to 109.85) 





Values are means (SD) 
Key: min = minute; ml/kg/min = millilitre/kilogram/minute; O2 = oxygen; Peak VO2 = peak oxygen consumption; RER = 




This study has demonstrated that by programming the heart rate-response algorithm 
in patients with HFrEF, so that heart rate during exercise remains below the critical 





A characteristic of HFrEF is exercise intolerance.  This is thought to be as a result of 
reduced cardiac output at rest because of myocardial contractile impairment, and 
impaired increase in cardiac output during exercise, leading to lower VO2, exercise 
intolerance, and fatigue. Cardiac output is dependent on both heart rate and stroke 
volume, which are interdependent because of the force-frequency relationship. The 
attenuation of the force-frequency relationship seen in HFrEF, such that LV 
contractility does not increase to the same degree or in the same manner as in the 
normal heart, raises the possibility that there may be a lower optimum heart rate range 
for cardiac contractility in patients with HFrEF than in non-HFrEF patients. 
 
Heart rate-response cardiac pacing was developed with the intention of optimising 
exercise tolerance in patients with chronotropic incompetence (Alt et al., 1995; 
McElroy et al., 1988). Pacemakers can be programmed to deliver either fixed-rate 
pacing or use a rate-response pacing algorithm, where the heart rate is altered in 
proportion to the level of activity as detected by internal device sensors. Rate-
response pacing in patients without HFrEF is associated with an increase in cardiac 
output during exercise (McMeekin et al., 1990), but inconsistent improvements in 
exercise capacity (Osswald et al., 1996; Galtes and Lamas, 2004), when compared to 
fixed rate pacing. However, it has been demonstrated that conventional rate-response 
pacing in patients with HFrEF does not improve exercise capacity compared with 
fixed-rate pacing (Ginzton et al., 1984), and that rate-response pacing may worsen 
prognosis and cardiac function (Thackray et al., 2006; Nägele, H et al., 2008). This 
might be because in HFrEF, conventional rate-response pacing algorithms do not 




Using the critical heart rate (calculated from the force-frequency assessment in 
chapter 6), the current randomised, double-blind, placebo-controlled, cross-over study 
of optimised rate-response programming versus conventional rate-response 
programming, aimed to optimise rate-response pacemaker programming in patients 
with HFrEF. The results have demonstrated that personalised, precise-approach rate-
response pacemaker programming can acutely improve treadmill exercise time and 
peak oxygen consumption. 
 
7.6 Limitations 
The study included only patients with a pacemaker device, who may present a different 
contractile response to increased heart rates from patients without a pacemaker 
device. 
 
Although the treadmill exercise modality and the ramping protocol may not have been 
ideal for all patients, it was used to allow comparison of exercise times, in addition to 
metabolic gas analysis data, and because treadmill-based activity is associated with 
greater upper body movement required for activation of the rate-response algorithms 
in pacemaker devices. Furthermore, the early, low workload at the beginning of the 
protocol, allowed those patients with the greatest limitation in exercise capacity to 







Optimising heart rate-response programming of the pacemaker device to maintain the 
heart rate below the critical heart rate during exercise, as determined by the 
individual’s force-frequency curve, is associated with an increase in exercise time.  
 
This raises the possibility that one might want to remove the term chronotropic 
incompetence and perhaps replace it with ‘chronotropic adaptation’ which in 
worsening HFrEF could be a cardio-protective mechanism to maximise contractile 




Chapter 8 : Can optimised heart rate settings lead to longer term 
benefits in exercise capacity? 
 
Hypothesis: Six months of tailored pacemaker heart rate settings based on a non-
invasive assessment of the force-frequency relationship in patients with HFrEF 
improves exercise capacity. 
 
8.1 Introduction 
Although a limitation in heart rate rise is a potential contributor to a lower cardiac 
output, heart rate lowering medication is not associated with impaired submaximal or 
peak exercise tolerance. Furthermore, increasing heart rate during exercise in patients 
with heart failure with reduced ejection fraction (HFrEF) and a pacemaker device, does 
not increase exercise capacity (Jamil et al., 2016). In health, higher heart rates lead to 
greater left ventricular (LV) contractility, and therefore greater potential for cardiac 
output to increase in response to increasing activity. However, in HFrEF the normally 
close relationship between heart rate, LV contractility, and stroke volume, known as 
the force-frequency relationship, is attenuated, such that LV contractility does not 
increase normally as the heart rate rises during activity. Indeed, in HFrEF, this 
physiological response is attenuated and is characterised by a decline in LV 
contractility above the critical heart rate (Cotton et al., 2001; Kayhan et al., 2002).  
 
In chapter 6, I described that the force-frequency relationship can be reliably assessed 
in patients with HFrEF who have a pacemaker device, in a non-invasive manner, using 
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echocardiography. I have also demonstrated that optimising heart rate-response 
pacing to keep heart rate below the critical heart rate during exercise, is associated 
with an acute increase in exercise time (chapter 7). The aim of the current study was 
to determine whether tailoring the rate-response pacing algorithm, using the 
physiology of the individual patient’s force-frequency relationship, leads to longer term 
improvements in exercise capacity and quality of life, compared with conventional age-
guided rate-response pacing, in patients with HFrEF and a pacemaker device, without 
compromising cardiac function. 
 
8.2  Methods 
8.2.1 Study design 
The study design was a randomised, controlled, double-blind, parallel-group trial 
comparing optimised rate-response programming with conventional rate-response 
settings, to determine whether the short-term improvements demonstrated in chapter 
7, translate into longer term benefits. 
 
Ethical approval6 was granted by the Health Research Authority of the United Kingdom 
(National Research Ethics Service Committee: East Midlands-Derby REC reference: 
17/EM/0004). National Health Service (NHS) permission7 for this research was 
granted at Leeds Teaching Hospitals NHS Trust (LTHT) Research and Development 
Department (R&D) (LTHT R&D reference: CD16/88879).  
 
6 Ethical approval, see Appendix C 
7 NHS permission, see Appendix D 
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8.2.1.1 Patient and public involvement and engagement 
The research question was prompted by patients with HFrEF and pacemakers 
attending outpatient clinics, with symptoms suggestive of HFrEF. The study was 
initially discussed with a well-established local patient and public involvement and 
engagement advisory group (PPIE-AG) consisting of people with cardiovascular 
disease and their families. The PPIE-AG advised on suitable follow-up periods, study 
procedures, information sheets and dissemination plans. Since reduced exercise 
capacity is a fundamental feature of HFrEF, members of the PPIE-AG were particularly 
interested in the potential for increased exercise capacity. 
 
8.2.2 Study population 
Patients attending the heart failure outpatient clinic, the pacemaker follow-up clinic, 
and previous participants in the acute crossover study (chapter 7) from 22 June 2017, 
were approached and given the participant information sheet. This was followed up 
with a telephone call to ensure that any remaining questions were answered. Those 
patients who agreed to take part were invited to the Cardiovascular Clinical Research 
Facility (CVCRF) at LTHT. 
 
8.2.3 Inclusion and exclusion criteria 
Patients with stable (for at least three months) symptomatic HFrEF, a cardiac 
pacemaker (for at least three months), taking optimal guideline-directed medical 
therapy, able to perform a symptom limited peak exercise test, willing and able to give 
written informed consent, were invited to take part. Those patients who had angina 
pectoris symptoms limiting exercise tolerance, unstable heart failure symptoms 
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(medical therapy alterations within the previous three months), poor 
echocardiographic image quality, or taking calcium channel blockers, were excluded 
from taking part in the study. 
 
8.2.4 Baseline study procedures 
A standard pacemaker device check was performed, along with a full baseline 
echocardiogram. Information was collected on comorbidities, past medical history, 
medication, pacemaker settings, and New York Heart Association (NYHA) functional 
class. The force-frequency relationship was assessed, to allow the critical heart rate 
and the optimal range of heart rate to be determined. This was achieved using 
echocardiography to non-invasively estimate cardiac contractility, and the pacemaker 
to increase the heart rate.  
 
8.2.4.1 Echocardiography 
Images were recorded in two- and four-chamber views (GE Vivid E95, GE Healthcare, 
Milwaukee, Wisconsin) at resting heart rate and at each 15 beats per minute (bpm) 
increase during an incremental pacing protocol. Images were stored anonymously in 
the EchoPAC digital imaging system (GE Healthcare) and analysed offline. Analysis 
included a calculation of LV end-diastolic volume (LVEDV), LV end-systolic volume 
(LVESV) and LV ejection fraction (LVEF), using the modified Simpson’s biplane 
method of discs, by tracing the endocardial border, excluding the papillary muscles 
(Wharton et al., 2015). The frame at the R-wave was taken as end-diastole, and the 
frame with the smallest LV cavity was taken as end-systole. A mean of three 
measurements (or five measurements if in atrial fibrillation (AF)) was used in the final 
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analysis. The LV end-systolic volume index (LVESVi) was calculated by dividing end-
systolic volume by body surface area, where body surface area was calculated using 
the Mosteller equation (Mosteller, 1987). To minimise observer bias, the analysis of 
the follow-up echocardiographic images was performed blinded to the images taken 
at baseline. 
 
8.2.4.2 Blood pressure measurement 
Dividing systolic blood pressure (measured manually) by LV end-systolic volume index 
gives a surrogate of LV contractility, which has been validated against invasive 
methods (Bombardini, T. et al., 2003; Bombardini, T. et al., 2005b). Blood pressure 
recordings, using a sphygmomanometer and a standard stethoscope, were taken at 
the same time as the echocardiographic images at each heart rate stage.  
 
8.2.4.3 Pacemaker programming protocol 
The first set of echocardiographic images was recorded at rest, with intrinsic atrial 
rhythm or a base rate of 40 bpm. Atrial pacing was then initiated at the lowest multiple 
of 10 bpm above baseline heart rate in the DDD mode8 (or VVI in patients with AF) for 
patients with a cardiac resynchronisation therapy (CRT) device, and AAI mode (or 
DDD with long atrioventricular delays to avoid right ventricular pacing, or VVI for those 
in AF) for patients without CRT. After four minutes of these programmed settings, 
another set of echocardiographic images was recorded. The pacing rate was 
subsequently increased in stepwise intervals of 15 bpm, along with echocardiographic 
 
8 Pacing modes, see Appendix E 
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images being recorded after every four-minute stage, until the maximum heart rate as 
predicted by the Åstrand equation (220 bpm minus age) was reached or patients 
became symptomatic of angina or breathlessness. Peak data were then collected 
before reprogramming the pacemaker device back to its pre-test settings. Patients 
then rested within the CVCRF for 30 minutes after this testing procedure. 
 
8.2.4.4 Force-frequency calculation 
Systolic blood pressure was divided by the end-systolic volume index to give a 
surrogate of LV contractility. Plotting LV contractility against each programmed heart 
rate allowed the critical heart rate, peak LV contractility, and the slope of the force-
frequency relationship, to be calculated for each patient. 
 
8.2.4.5 Exercise protocol 
The cardiopulmonary exercise test (CPET) equipment was recalibrated prior to each 
test, using the manufacturer-recommended volume and gas calibration techniques. 
Participants then performed a peak symptom-limited, CPET, using the ramping 
treadmill protocol (Porszasz et al., 2003), to measure exercise time. Expired air was 
collected, and metabolic gas exchange analysis was performed throughout the test 
(Ultima CardO2, Medical Graphics, St. Paul, Minnesota). Heart rate (bpm), oxygen 
uptake (VO2) (millilitres per kilogram per minute) (ml/kg/min), and carbon dioxide 
output (VCO2) (ml/kg/min), were recorded as 15-second averages. The V-slope 
method was used to calculate anaerobic threshold. Participants were asked to 




The effective delivery of biventricular stimulation in those patients with CRT, was 
confirmed from electrocardiographic (ECG) traces at peak exercise, at both time points 
(baseline and follow-up), by the absence of fusion or other QRS morphology changes.  
 
8.2.4.6 Quality of life 
Participants were also asked to complete three questionnaires: (Minnesota Living with 
Heart Failure (Figure 5.1), EuroQOL 5D-3L (EQ-5D) (Figure 5.2), and visual analogue 
score (Figure 5.3)), to assess their quality of life. 
 
8.2.5 Randomisation 
After the baseline data had been collected, participants were randomised on a 1:1 
basis to either optimised programming as predicted by their individual force-frequency 
curve assessment (to maintain heart rate during exercise below the critical heart rate), 
or to conventional settings whereby peak heart rate was determined by the Åstrand 
calculation of 220 bpm minus age. Randomisation was determined by a random 
number generator. Pacemaker programming was undertaken by an un-blinded clinical 
scientist, to maintain blinding. Atrioventricular delay programming was optimised to 
avoid fusion and to maintain consistent biventricular stimulation at higher heart rates 
in patients with CRT devices. Device-specific pacing avoidance algorithms were 
activated in patients in sinus rhythm without CRT devices. VVIR programming was 
used for patients in AF. Patients were blinded to their allocation. However, details were 






Each participant was telephoned one week after baseline testing and randomisation 
to check that they were tolerating any changes, and then invited back for follow-up 
testing after six months. Participants’ pacing files were labelled to indicate that the 
patient was taking part in a research study, and that unless the patient became 
symptomatic, the pacing settings should be left unchanged. 
 
A resting echocardiogram was performed to allow assessment of LV size and function. 
The cardiopulmonary exercise test was repeated to allow change in exercise time to 
be calculated.  To maintain blinding, the ECG monitor was positioned so that I could 
not see it. Only the un-blinded clinical scientist was aware of the pacemaker settings 
and the study arm. The effective delivery of biventricular stimulation in patients with 
CRT devices was confirmed from ECG traces at peak exercise by the absence of 
fusion or other QRS morphology changes. Participants were also asked to complete 
the quality of life assessments again. 
 
8.2.7 Sample size calculation 
The study was designed as a single-centre phase II trial, since there was an absence 
of data describing variability in outcomes to be able to robustly design a definitive trial. 
The aim was to make initial unbiased comparisons of groups and inform variability in 
outcomes in the target population of patients. Therefore, the target sample size was 
based on achieving a sample size appropriate to estimate the variability in the six-
month primary outcome measure. It is recommended that a pilot study such as the 
current one, has 70 measured subjects (35 per group) (Teare et al., 2014). The aim 
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for the current study was to have outcome data at six months for a minimum of 70 




Each echocardiographic image set was anonymised and re-reported by me, as the 
initial reporter, to check for intra-operator reproducibility. The anonymised image sets 
were also reported by a second clinical scientist, for inter-operator reproducibility. For 
each dataset, the critical heart rate, the peak LV contractility, and the force-frequency 
relationship slope were all documented. 
 
8.2.9 Statistical analysis 
Data were analysed using the Statistical Package for the Social Sciences (SPSS) 
(version 23; IBM Corporation, Armonk, New York, USA). As a pilot trial, the aim was 
to describe outcomes, and variability in outcomes, descriptively. Normality for all 
continuous variables was tested using the Shapiro-Wilk test. Normally distributed 
continuous variables were reported as mean and standard deviation (mean ± (SD)), 
and non-normally distributed continuous variables were reported as median and 
interquartile range (median ± IQR). Categorical variables were presented as count and 
percentages. Analysis of covariance (ANCOVA) was used to assess inter-group 
differences in outcome variables. All statistical tests were two-sided and presented as 




Reproducibility of echocardiographic measures were described by intraclass 
correlation coefficient (ICC) for both intra- and inter-observer variability. 
 
8.3 Results 
In total, 83 patients were recruited between 2 November 2017 and 16 January 2019. 
Of these, 38 were randomised to force-frequency relationship-guided rate-response 
programming, and 45 were randomised to conventional age-guided programming 






Figure 8.1: Consolidated Standards of Reporting Trials (CONSORT) diagram of 
patient enrolment, randomisation, and disposition during the study 
  
The six-month follow-up assessment was completed by 76 out of the 83 patients. Of 
the 76 patients, 35 were allocated to the force-frequency relationship-guided rate-
response programming group, and 45 were allocated to the conventional age-guided 
programming group. In total, 7 patients were lost to follow-up; there was one death 
and six patients declined to attend their six-month follow-up assessment. There were 
three patients in each group who did not tolerate the intervention; their pacemakers 




Not meeting inclusion criteria n=0 
Declined to participate n=138 




Allocated to tailored programming n=38 
 
Received tailored programming n=38 
 
Did not receive tailored programming n=0 
 
Discontinued tailored programming 
n=3 
(Intervention not tolerated) 
Lost to follow-up n=3, death=1, 
declined to attend=2 
Analysed n=32 
Excluded from analysis n=0 
(Intention to treat analysis) 
Allocated to conventional programming 
n=45 
Received conventional programming 
n=45 




(Intervention not tolerated) 




Excluded from analysis n=0 





were reprogrammed to their pre-study settings and the patients remained in the 
intention to treat analysis (Figure 8.1). 
 
The baseline characteristics of the two groups (force-frequency relationship-guided 
rate-response programming and conventional age-guided programming) were 
balanced, in particular including for force-frequency relationship variables of critical 
heart rate (106.7 ± 18.0 bpm versus (vs) 102.8 ± 17.7 bpm; p = 0.320) and peak LV 
contractility (4.6 ± 3.1 vs 4.2 ± 2.5; p = 0.574), and for exercise testing variables of 
resting heart rate (65.9 ± 9.4 bpm vs 66.4 ± 9.1 bpm; p = 0.787) and peak exercise 














Table 8.1: Patient demographic and baseline characteristics at randomisation: 
intention-to-treat population 


































Medication    
β-blocker 
Bisoprolol equivalent dose, mg/d* 
ACE inhibitor/ARB 





















Device allocation    
CRT with defibrillator 











Resting haemodynamics    
Resting heart rate, bpm 







Echocardiography and FFR data    
LV ejection fraction, % 
LV end-diastolic volume, ml 
LV end-systolic volume, ml 
Peak LV contractility 
















Exercise test results    
Treadmill walk time, s 
Peak VO2, ml/kg/min 
VE/VCO2 slope 
Peak exercise heart rate, bpm 
















Quality of life scores at baseline    
EQ-5D-5L 











Continuous variables expressed as mean±SD; categorical variables as n (%). *mean doses 
Key: ACE = angiotensin-converting enzyme; AF = atrial fibrillation; ARB = angiotensin receptor blocker; β-blocker = beta-adrenoceptor antagonist; bpm = beats per 
minute; CRT = cardiac resynchronisation therapy; EQ-5D-5L = 5-level EQ-5D; FFR = force-frequency relationship; ICD = implantable cardioverter-defibrillator; IHD = 
ischaemic heart disease; kg = kilogram; LV = left ventricular; mg = milligram; min = minute; ml = millilitres; MLWHF = Minnesota living with heart failure; mmHg = 
millimetres of mercury; µmol/l = micromole per litre; NYHA = New York Heart Association functional class; s = second; VE/VCO2 slope = slope relating ventilation and 




8.3.1 Primary outcome measure 
Treadmill walk time was the primary outcome measure. At the six-month visit, patients 
in the force-frequency relationship-guided rate-response programming group 
demonstrated a greater improvement in treadmill walk time, compared to the patients 
who were randomised to conventional age-guided programming. From baseline to six-
month follow-up, changes in treadmill walk time in the force-frequency relationship-
guided group versus (vs) the conventional age-guided group were respectively: 376 
to 483 seconds vs 402 to 415 seconds, with a mean difference between the groups of 
72 seconds (95% CI: 2 to 143; p = 0.044) in favour of force-frequency relationship-
guided programming (Figure 8.2). 
 
 
Figure 8.2: Change in treadmill walk time after six months of conventional 
versus force-frequency relationship-guided rate-adaptive pacing programming 
  
Key: FFR = force-frequency relationship; s = seconds 
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Table 8.2: Change in primary and secondary outcome variables after six months 
of tailored versus conventional pacemaker heart rate-response programming: 
intention-to-treat population 
End point Final value, mean (95% 
CI) 
Change after 6/12, 
mean (95%) 
ANCOVA, mean change 
(95%) 
p-value 
Primary outcome     
    Treadmill walk time, s    
          Tailored 
          
Conventional 
483.15 (431.10 to 
535.20) 
401.84 (363.62 to 
458.07) 
75.40 (23.35 to 
127.45) 
3.09 (-44.14 to 50.31) 
72.31 (1.94 to 142.67) 0.044 
Secondary 
outcomes 
    
     Left ventricular ejection fraction, %    
          Tailored 
          
Conventional 
35.79 (33.80 to 37.78) 
32.13 (30.28 to 33.00) 
-0.23 (-2.31 to 1.84) 
-3.69 (-5.62 to -1.76) 3.66 (0.94 to 6.38) 0.009 
     Left ventricular end-diastolic volume, ml    
          Tailored 
          
Conventional 
146.63 (135.87 to 
157.39) 
148.92 (138.91 to 
158.92) 
3.24 (7.52 to 14.00) 
5.52 (-4.48 to 15.53) 
-2.29 (-16.99 to 12.42) 0.757 
     Left ventricular end-systolic volume, ml    
          Tailored 
          
Conventional 
97.36 (89.36 to 105.35) 
105.61 (98.18 to 113.05) 
1.78 (-6.22 to 9.77) 
10.03 (2.60 to 17.47) -8.26 (-19.18 to 2.67) 0.136 
     Peak oxygen consumption, ml/kg/min    
          Tailored 
          
Conventional 
16.72 (15.81 to 17.64) 
15.59 (14.75 to 16.43) 
0.84 (-0.07 to 1.75) 
-0.30 (-1.14 to 0.54) 1.14 (-0.10 to 2.38) 0.071 
     Peak O2 pulse, ml/beat    
          Tailored 
          
Conventional 
13.84 (12.75 to 14.94) 
11.82 (10.82 to 12.83) 
2.74 (1.64 to 3.83) 
0.72 (-0.29 to 1.73) 2.02 (0.53 to 3.51) 0.009 
     VE/VCO2 slope     
          Tailored 
          
Conventional 
32.81 (30.30 to 35.32) 
32.31 (30.00 to 34.62) 
-0.73 (-3.24 to 1.78) 
-1.23 (-3.54 to 1.08) 0.50 (-2.91 to 3.91) 0.770 
     EQ-5D-5L     
          Tailored 
          
Conventional 
0.73 (0.68 to 0.78) 
0.66 (0.62 to 0.71) 
-0.02 (-0.07 to 0.04) 
-0.06 (-1.11 to -0.01) 0.06 (-0.01 to 0.14) 0.078 
     EQ-VAS     
          Tailored 
          
Conventional 
67.13 (62.18 to 72.07) 
62.84 (58.28 to 67.41) 
-1.16 (-6.72 to 4.40) 
-3.35 (-8.56 to 1.86) 4.28 (-2.46 to 11.02) 0.210 
     Minnesota Living With Heart Failure Questionnaire   
          Tailored 
          
Conventional 
31.68 (27.45 to 35.91) 
30.25 (26.34 to 34.15) 
-0.04 (-4.33 to 4.26) 
-0.63 (-4.65 to 3.40) 1.43 (-4.34 to 7.21) 0.622 
Key:    
Values are mean change (95% confidence intervals) 
EQ-5D-5L = Euro-quality of life score – 5 questions; kg = kilogram; min = minute; ml = millilitre; O2 = oxygen; pVO2; s = 
second; VAS = visual analogue score; VE/VCO2 slope = slope relating ventilation and carbon dioxide output. 
 
 
8.3.2 Secondary outcome measures 
There was no change to LVEF from baseline (35.3%) to six-month follow-up (35.9%) 
after six months of force-frequency relationship guided-guided rate-response pacing. 
However, in the conventional age-guided group, there was a reduction in LVEF from 
168 
 
baseline (35.1%) to six-month follow-up (32.1%), with a mean difference between 
groups of 3.7% (95% CI: 0.9 to 6.4; p = 0.009) in favour of force-frequency relationship-
guided programming (Table 8.2 and Figure 8.3). 
 
 
Figure 8.3: Change in LV ejection fraction after six months of conventional 
versus force-frequency relationship-guided rate-adaptive pacing programming 
 
 
No significant change in LVEDV was seen in either group. LVEDV in the force-
frequency relationship-guided group changed from 141 to 147 ml, and from 144 to 149 
ml in the conventional age-guided group, with a mean difference between groups of -
2.3 ml (95% CI: -17.0 to 12.4; p = 0.757). Change in LVESV in the force-frequency 
relationship-guided group from baseline to six-month follow-up was 96 to 97 ml. A 
larger change was seen in the conventional age-guided group of 96 to 106 ml. The 
mean difference between the groups was 8.26 ml (95% CI: -19.18 to 2.67; p = 0.136), 
Key: FFR = force-frequency relationship 
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trending towards favouring force-frequency relationship-guided programming Table 
8.2 and Figure 8.4A and B). 
 
 
Figure 8.4: Change in LV end-diastolic and end-systolic volumes 
Change in LV end-diastolic volume (A) and LV end-systolic volume (B) after six months of 
conventional versus force-frequency relationship-guided rate-adaptive pacing programming 
 
 
In terms of the cardiopulmonary exercise testing variables, there was a trend towards 
favourable changes in peak oxygen consumption in the force-frequency relationship-
guided group (15.1 to 16.7 ml/kg/min) compared to the conventional age-guided group 
(15.9 to 15.6 ml/kg/min), with a mean difference between groups of 1.14 ml/kg/min 
(95% CI: -0.1 to 2.4 ml/kg/min). Peak oxygen pulse increased in the force-frequency 
relationship-guided group from 10.46 to 13.84 ml/beat, and from 11.28 to 11.82 
ml/beat in the conventional age-guided group, with a mean difference between the 
groups of 2.02 ml/beat (95% CI: 0.5 to 3.5 ml/beat) in favour of force-frequency 
relationship-guided programming (Table 8.2). 
A B 




There was no difference in change in quality of life assessments from baseline to six-
month follow-up between the two groups. Mean change in the EQ-5D score from 
baseline to six-month follow-up in the force-frequency relationship-guided group was 
-0.02 (95% CI: -0.07 to 0.04) vs -0.06 (95% CI: -1.11 to -0.01) in the conventional age-
guided group. Mean change in the visual analogue scale score was -1.16 (95% CI: -
6.72 to 4.40) in the force-frequency relationship-guided group vs -3.35 (95% CI: -8.56 
to 1.86) for the conventional age-guided group. Mean change from baseline to six-
month follow-up for the Minnesota Living with Heart Failure questionnaire score was -
0.04 (95% CI: -4.33 to 4.26) for the force-frequency relationship-guided group vs 0.63 
(95% CI: -4.65 to 3.40) for the conventional age-guided group (Table 8.2).   
 
Echocardiographic outcome measures demonstrated strong intra-observer agreement 
for LVEF [ICC 0.988 (95%CI, 0.858 to 0.998)]; LVEDV [ICC 0.987 (95% CI, 0.824 to 
0.998)]; and LVESV [ICC 0.985 (95%CI, 0.903 to 0.998)]. Strong inter-observer 
agreement was also demonstrated for LVEF [ICC 0.970 (95%CI 0.778 to 0.996)]; 




The key findings in the current study are that in patients with HFrEF and a pacemaker, 
receiving optimal guideline-directed medical therapy, six months of tailored force-
frequency relationship-guided heart rate-response pacemaker programming leads to 
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improved exercise time, and furthermore prevents the decline in LVEF experienced by 
patients who were randomised to conventional age-guided programming. 
 
These findings are particularly relevant because although disease modifying 
treatments have significantly improved life expectancy for patients with HFrEF, they 
have had much less impact on exercise capacity. 
 
In the normal heart, cardiac output is positively coupled to the power of LV contractility 
by the force-frequency relationship, such that as heart rate rises, cardiac output and 
LV contractility increase. In adults with normal heart function, the heart rate rises 
steadily with increasing work, to a peak that is generally accepted to be inversely 
related to age. However, heart rate rise and peak heart rate during exercise are 
reduced in HFrEF (Colucci et al., 1989). Since cardiac output is a function of heart rate 
and stroke volume, it is possible that poor heart rate rise during exercise could 
contribute to the impaired exercise tolerance associated with HFrEF through adversely 
affecting cardiac output. However, the relationship between heart rate rise, cardiac 
output, and exercise capacity, and how their interaction changes with age, sex, fitness, 
and disease, is poorly understood. 
 
The relevance of heart rate rise has become particularly challenging in the context of 
heart rate limitation being a key target of HFrEF therapy. Observational and 
interventional data (Jamil et al., 2016; Chatterjee, N.A. and Heist, 2018) have 
challenged the belief that limited heart rate rise during exercise, known as chronotropic 




In around 30% of patients with HFrEF, optimal medical therapy includes implantation 
of a pacemaker device. One of the programmable functions is heart rate-response, or 
rate-adaptive, pacing, which was developed with the aim of optimising exercise 
tolerance in patients with chronotropic incompetence. The objective of heart rate-
response pacing is to simulate the physiological heart rate rise that occurs, in health, 
in response to increasing levels of activity. In people without HFrEF, rate-response 
pacing is associated with an increase in cardiac output during exercise (McMeekin et 
al., 1990) when compared with fixed rate programming (heart rate-response function 
programmed to ‘off’), but shows inconsistent improvements in exercise capacity 
(Osswald et al., 1996; Galtes and Lamas, 2004). 
 
However, heart rate-response pacing using an age-guided algorithm during exercise 
in patients with HFrEF, unreliably improves exercise capacity (Tse et al., 2005; Witte, 
K. K. and Clark, 2006), and furthermore, worsens outcomes and cardiac function 
(Thackray et al., 2006; Nägele, H et al., 2008).  
 
A key therapeutic aim in HFrEF is to limit the heart rate. Bradycardia at rest improves 
outcomes in HFrEF (Fox et al., 2008), but leads to a limitation of heart rate rise during 
exercise. Even without beta-adrenoceptor antagonists (β-blockers), patients with 
HFrEF often do not achieve their age-predicted maximal heart rate during exercise 
(Witte, K. K. and Clark, 2005; Witte, K. K. and Clark, 2009; Al-Najjar et al., 2012), 
which is commonly believed to contribute to reduced exercise tolerance in HFrEF 
(Colucci et al., 1989; White et al., 1995). This paradox, whereby heart rate limitation 
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using β-blockers is known to reduce hospitalisation and mortality (Maurer et al., 2009; 
McAlister et al., 2009) yet is proposed to worsen exercise intolerance, may contribute 
to poorly defined heart rate targets in guidelines (Ponikowski et al., 2016).  
 
During exercise the force-frequency relationship ensures that LV contractility, and thus 
stroke volume, increase with heart rate to compensate for the reduced filling time. In 
chapter 6, I demonstrated, using echocardiography, that this relationship is abnormal 
across the entire heart rate range in HFrEF, with a lower slope in response to heart 
rate increases, lower peak LV contractility, and a lower heart rate for peak LV 
contractility (the critical heart rate). Therefore, in HFrEF, maximal heart rate is not 
synonymous with optimal heart rate.  
 
Programming a pacemaker device to increase the heart rate during activity, up to the 
conventional age-guided maximal heart rate, does not improve exercise time. 
Furthermore, medications that limit the heart rate range response to exercise do not 
compromise exercise capacity (Jamil et al., 2016). This could be because conventional 
age-guided heart rate-response pacing algorithms do not consider the altered force-
frequency relationship in HFrEF.  
 
Using echocardiography, I have been able to determine an optimum heart rate range, 
tailored using the individual’s force-frequency relationship curve, throughout which LV 
contractility increased in patients with HFrEF. This current randomised, double-blind, 
controlled study, comparing six-months of tailored heart rate-response programming 
with six-months of conventional age-guided heart rate-response programming, found 
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that force-frequency relationship-guided programming is associated with improved 
exercise time and reduced progressive deterioration in LV function. 
 
An improvement in quality of life was not seen in this study. A longer follow-up period 
might be necessary to determine whether the intervention produces an improvement 
in quality of life. However, in a condition such as HFrEF, which is associated with a 
gradual decline in quality of life, the result of no deterioration might be a result of the 
intervention preventing further decline.  
 
8.5 Limitations 
The study was performed within a single centre in the United Kingdom, limiting 
generalisability. However, baseline demographic data indicate that the study 
population was representative of a pacemaker population with HFrEF. The study 
necessarily included only patients with a pacemaker device, who may present a 
different contractile response to increased heart rates from patients without a 
pacemaker device. 
 
It is possible that so-called ‘responders’ to CRT might have less to gain from tailored 
rate-response programming. However, the selection criteria were deliberately 
inclusive, and participants were approached consecutively, with no selection bias in 
terms of CRT response.   
 




Although the treadmill exercise modality and the ramping protocol may not have been 
ideal for all patients, it was used to allow comparison of exercise times, in addition to 
metabolic gas analysis data, also because treadmill-based activity is associated with 
greater upper body movement required for activation of the rate-response algorithms 
in pacemaker devices. Furthermore, the early, low workload, allowed those patients 
with the greatest limitation in exercise capacity to complete some exercise, reducing 
the bias towards less limited patients. 
 
8.6 Conclusion 
This novel, single-centre, randomised, double-blind, controlled trial, has demonstrated 
that after six-months of the heart rate-response pacing settings being programmed in 
accordance with the optimal heart rate range, defined by the individual’s non-invasive 
force-frequency relationship data, is associated with improved exercise time and 
reduced progressive deterioration in LV function in patients with HFrEF. Furthermore, 
conventional age-guided rate-response programming might be a suboptimal choice in 




Chapter 9 : Discussion 
 
Aristotle considered the heart to be the seat of intelligence and the centre of vitality in 
the body; the first organ to come to life, and the last to die. In almost all interactions 
between healthcare providers and their patients, heart rate is the primary assessment. 
Indeed, heart rate is a significant contributor to both the symptoms and progression of 




Heart failure has become epidemic in the developed world (Katz, A. and Konstam, 
2009). It is the end stage of all diseases of the heart and is a major cause of morbidity 
and mortality (Davis et al., 2000). Heart failure with reduced ejection fraction (HFrEF) 
is a common syndrome characterised by symptoms of breathlessness and fatigue in 
the presence of left ventricular systolic dysfunction (LVSD). A key feature of HFrEF is 
reduced exercise tolerance, which can have a significant impact on the daily activities 
of patients with HFrEF. 
 
The exercise intolerance associated with HFrEF is thought to be because of reduced 
cardiac output which leads to lower oxygen delivery to exercising skeletal muscle, 
exercise intolerance, and fatigue. Cardiac output is a function of heart rate and stroke 
volume, both of which are impaired in HFrEF. With normal cardiac function, during 
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activity the heart rate increases, leading to an increase in the force of contraction and 
cardiac output. This relationship, linking heart rate, left ventricular (LV) contractility and 
cardiac output, the force-frequency relationship, is impaired in patients with HFrEF, 
with a decrease in LV contractility over a certain heart rate (the critical heart rate). 
Increasing the heart rate beyond the critical heart rate may contribute to functional 
limitation and could potentially contribute to further progression of LVSD. 
 
Although improvements are reported in patient outcomes, due to advances in the 
treatment and management of HFrEF (Cleland et al., 2005; Hunt et al., 2009; Bristow, 
2011; Cubbon et al., 2011), the prognosis of this cohort of patients remains poor. The 
development of new therapeutic pathways for these patients, therefore, remains a 
priority.  
 
The literature highlights a conflict within the optimal therapies used for patients with 
HFrEF. Although chronotropic incompetence in HFrEF is associated with reduced 
functional capacity, correcting this with rate-response pacing in HFrEF patients does 
not lead to an improvement in oxygen consumption, symptoms, or exercise time. 
Moreover, the force-frequency relationship in HFrEF is attenuated, such that LV 
contractility does not increase normally with increases in heart rate. 
 
I have investigated the hypothesis that conventional rate-response algorithms do not 
consider the altered force-frequency relationship seen in HFrEF, and that there may 
be a lower optimal heart rate range for LV contractility in HFrEF. Rather than a one-




9.2 Observational study 
In an observational cohort study of 105 participants (90 with HFrEF; 15 non-HFrEF), I 
demonstrated that the force-frequency relationship can be reliably assessed non-
invasively, using transthoracic echocardiography, and a pacemaker device.  
 
I was able to show that patients with HFrEF had lower peak LV contractility, lower 
mean critical heart rate, and a lower slope of the relationship between heart rate and 
LV contractility below the critical heart rate, than controls. This confirms that in HFrEF, 
the force-frequency relationship is impaired, independent of cardiac loading or 
physical activity levels. Furthermore, in terms of optimal LV contractility, maximal heart 
rate is not synonymous with optimum heart rate. Therefore, pacemaker heart rate 
programming should consider the underlying cardiac disease of the individual patient. 
 
9.3 Interventional studies 
9.3.1 Tailoring rate-response programming to the force-frequency 
relationship (acute response) 
Conventional age-related heart response algorithms applied to patients with HFrEF 
could increase the heart rate beyond the critical heart rate, onto the downward portion 
of their LV contractility curve, such that, as heart rate increases, cardiac output 
decreases. This could be a contributing factor as to why HFrEF patients have reduced 
exercise capacity. Therefore, this investigation was designed to test whether 
programming the heart rate-response function to consider the patient’s force-




I applied the technique used in the observational study and performed a randomised, 
double-blind, placebo-controlled, cross-over study of 52 HFrEF patients who had 
participated in the observational study. This demonstrated that maintaining the rate-
response programmed heart rate below the critical heart rate (as calculated in the 
observational study) during exercise, was associated with improved treadmill exercise 
time. Therefore, personalised programming of the heart rate-response function, using 
the patient’s individual force-frequency relationship data, can improve exercise time. 
 
9.3.2 Tailoring rate-response programming to the force-frequency 
relationship (longer term response) 
A further randomised controlled trial was conducted in order to demonstrate whether 
the acute benefits described in the first interventional study could be translated into 
longer term benefits in terms of exercise time, cardiac function, and quality of life, in 
patients with HFrEF and a pacemaker device. 
 
A total of 83 patients were recruited into this interventional, double-blind, randomised, 
parallel-group trial. Patients were randomised on a 1:1 basis to either, tailored rate-
response programming based on individual force-frequency data, or to conventional 
age-guided rate-response programming, for a period of six months. I was able to 
demonstrate a greater improvement in treadmill exercise time in the tailored rate-
response group, than those randomised to conventional age-guided rate-response 
programming. Furthermore, there was reduced progressive LV dysfunction in the 




9.4 Clinical implications 
The novel findings reported here have clinical implications for the management of 
pacemaker devices in the context of HFrEF. I have demonstrated that a reproducible, 
non-invasive assessment of patients’ physiological response to increased heart rates, 
can be translated into clinical benefits by facilitating personalised heart rate-response 
pacemaker programming. Furthermore, this approach may provide a mechanism for 
the lack of benefit of conventional rate-response pacemaker programming in patients 
with HFrEF.  
 
The association of conventional settings, for a period of six months, with reduced 
progressive deterioration in LV function, could imply that the only available ‘age-
guided’ guidance for programming heart rate-response pacing might be a suboptimal 
choice in patients with HFrEF. 
 
The reduced heart rate increase associated with HFrEF corresponds to the heart rate 
range on the upslope of the LV contractility curve, raising the possibility that the 
‘chronotropic adaptation’ seen in HFrEF may be a cardio-protective measure, with the 
aim of maximising contractile response and exertional cardiac output. Furthermore, 
exercise capacity is not worsened by reducing the resting heart rate in patients with 
HFrEF. Consequently, pharmacological goals and pacemaker programming in 
patients with HFrEF should be different from that in those patients with normal LV 
function. A tailored, patient specific approach is necessary in interventions that may 




9.5 Future research 
Future work is now needed to explore the mechanisms of the findings within this thesis, 
to determine whether the greater increase in exercise time than peak oxygen 
consumption represents greater cardiac efficiency, and to determine whether the 
critical heart rate can be predicted from clinical variables. The findings should also be 
confirmed in a multicentre setting, and on longer-term clinical outcomes, including 
hospitalisation. 
 
Additionally, an investigation into whether patients with less severe LV systolic 
dysfunction and those with persistent symptoms but no existing indication for a 
pacemaker device might also benefit from this approach, would be valuable. 
 
9.6 Conclusion 
This work has shown that using a non-invasive assessment of the force-frequency 
relationship to determine a tailored optimal heart range to guide the personalisation of 
heart rate-response pacemaker programming in patients with HFrEF, can improve 
exercise capacity, by emulating the natural chronotropic adaptation evident in HFrEF, 
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